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Several neurodegenerative disorders, such as Parkinson’s disease (PD), are 
characterized by the deposition of misfolded and aggregated forms of a particular 
protein in different areas of the brain. Understanding the molecular mechanisms of 
neurodegenerative diseases are extremely important to prevent and stop such 
debilitate diseases.  
PD is a movement related disorder that primarily affects aged individuals, but 
mutations on alpha-Synuclein (aSyn) gene (SNCA) have been identified in an early- 
and juvenile-onset of the disease.  
aSyn is a small an intrinsically disorder protein, that binds to membrane and 
lipids. It is the major component of Lewy Bodies (LBs) and Lewy Neurites (LN) in 
the surviving neurons in parkinsonian brains. However, the molecular mechanisms 
that lead to the selective degeneration of dopaminergic neurons from the substantia 
nigra pars compacta are still unclear. aSyn aggregation is an important process for 
the pathology. In pathological conditions, aSyn aggregates, forming oligomeric 
species that can rapidly convert into amyloid fibrils. Amyloid fibrils made up of aSyn 
then deposit in LBs, along with several other proteins and lipids. A combination of in 
vitro, cell and animal models studies has been useful to investigate not only aSyn 
aggregation intermediates, but also the toxic mechanisms. 
Over the years, the number of models in the PD field increased significantly, 
but has not generated consensus with respect to the best models to use. Thus, it is 
important to choose the appropriate models to investigate a particular question of 
interest. Roughly, the PD models can be divided into two categories: those based on 
genetic alterations and those based on the effect of toxins. For the purpose of this 
thesis, I will focus on the genetic models. Due to our limited understanding of the 
molecular mechanisms underlying disease, cell-based models constitute a powerful 
tool to mimic important aspects of basic aSyn biology (such as aggregation and 
toxicity), and afford unique opportunities to test the effect of possible therapeutic 
strategies. A number of molecular dysfunctions have been associated with PD. These 
include defects in mitochondrial function, defects in degradation systems (ubiquitin–
proteasome and autophagy), increased production of reactive oxygen species, or 
impairment of intracellular trafficking. However, the lack of systematic comparisons 
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makes it difficult to interpret and reconcile the relevance of results obtained using 
different models. 
This study focuses mainly on the exploitation of two cell-based systems that 
try to model the oligomerization and aggregation of aSyn. The Bimolecular 
Fluorescence complementation assay enables us to visualize the dimerization and 
oligomerization of aSyn in living cells. To model aSyn aggregation, manipulations of 
the C-terminal region have been useful, as they promote the formation of LBs-like 
inclusions that can be readily detected by immunostaining. Thus, using these two 
models, we performed a systematic comparison to investigate the effects of genetic 
alterations on aSyn oligomerization and aggregation, and how these impacted on 
selected cellular functions. In addition, we investigated the effects of small molecules 
on the conformation and aggregation of aSyn, as this is thought to be a possible target 
for therapeutic intervention.  
Overall, our studies demonstrated the usefulness of the two cell-based models 
for studying specific aspects of aSyn aggregation and for the screening of drugs that 













1.1. Protein Folding and Misfolding 
Life relies on a series of fundamental biological processes like those 
governing the folding of biomolecules, such as proteins and nucleic acids. Depending 
on their primary amino acid (aa) sequences, proteins can be particularly unstable 
when they are formed, and the surrounding environment is critical to determine the 
proper folding of the polypeptide chain during and after translation. Different types of 
forces contribute to the folding process. These include hydrogen bonding (between 
amide and carbonyl groups), hydrophobic forces, electrostatic forces, and Van der 
Waals forces (Anfinsen 1973; Dobson 2003). The conjugation of the various forces 
according to the environment culminates with the folding of the protein, and the 
achievement of the functional native conformation, that is normally the most 
thermodynamically stable under physiological conditions.  
The ability of a polypeptide to fold to a specific structure has evolved since 
the beginning of life. Levinthal proposed that the folding of a protein can not be a 
random process but rather follow a particular “pathway” to shorten the time required 
to for the protein to reach the native state, otherwise the folding process would take 
longer than the age of the Universe (known as the Levinthal paradox) (Levinthal 
1968; Honig 1999). The nature of the folding reactions is determined by the potential 
energy surface, and by the thermodynamics laws. Proteins can cross a number of 
different energy landscapes, like in funnel-like shape, with the low-energy state 





Figure 1.1 The free energy landscape of protein folding (left) and aggregation (right).  Protein 
folding requires intramolecular connections that roughly resemble as a funnel in which non-native 
conformations occupy low energy levels. When proteins start to fold into amorphous structures, toxic 
oligomers or ordered amyloid fibrils will be produced with a lower free energy than the native state. 
Adapted from (Hartl et al. 2011). 
 
Despite tremendous progress in the field of structural biology, predicting the 
conformation of a specific polypeptide chain still a challenge, due to our limited 
understanding of the rules governing protein folding (Dobson 2003; Dobson 2001). In 
the cell, to avoid misfolding and proteotoxicity, molecular chaperones, folding 
catalysts, and other protein quality control systems (e.g. the ubiquitin proteasome 
system and autophagy-lysosomal pathway), act to either refold the unfolded or 
disordered regions of a protein, or to target them for destruction. When misfolded 
proteins escape these quality control systems, or when they establish 
undesired/aberrant interactions, problems and diseases can arise.  
Protein conformation, function, and localization can be modulated by internal 
and external signals, such as posttranslation modifications (PTMs), ligand binding, 




1.2. Cellular Quality Control Mechanisms 
Protein quality control mechanisms, highly conserved among all eukaryotes, 
ensure that each protein is properly folded or degraded to ensure the normal protein 
homeostasis (proteostasis) and the normal functioning of the cell. Thus, strategies 
aimed at maintaining or restoring homeostasis can be valuable for preventing disease. 
  
 
Figure 1.2 Deregulation of proteostasis due to protein misfolding. Proteins can acquire their native 
state or, upon environmental challenges and/or mutations, they may acquire a misfolded state. Here, 
proteins can be refolded with the aid of molecular chaperones, or degraded by cellular degradation 
mechanisms such as ERAD, proteasome, or autophagy. Alternatively, proteins can be redirected to the 
JUNQ compartment for ulterior refolding or degradation, or to the IPOD or aggresome, to be 
permanently sequestered.  
 
 When the cell is challenged or stressed, the stress response is proportional to 
the stress encountered, to enable a proper response to protein misfolding (Morimoto, 
2008). Heat, oxidative, osmotic, or pH stress are examples of types of stresses that 
can affect proteostasis (Morimoto, 2008). Aging can also affect proteostasis due to the 
progressive failure of cellular quality control systems, and can lead to the 




1.2.1. Molecular Chaperones 
The folding of a proteins in living cells is a great challenge due to the crowded 
macro-molecular environment of the cell, which favors protein misfolding and 
aggregation (Ellis 2001). To prevent illegitimate inter- and intramolecular 
interactions, and protect hydrophobic aa side chains, the folding process of some 
proteins is assisted by molecular chaperones. Molecular chaperones are proteins 
designed to effectively reduce the tendency of non-native proteins to aggregate, both 
in de novo synthesis or in stress conditions, to promote correct interactions within 
themselves and with other polypeptides (Frydman et al. 1996). In contrast to what 
happens in the process of protein assembly (the ordered association of several 
polypeptide chains), protein aggregation describes a disordered, non-specific 
association, which the cells need to prevent by all means (Walter et al. 2002). 
Chaperones can be regulated by various co-factors and some act in an energy 
dependent manner where ATPase activity works through cycles of binding and 
release of the substrate. Chaperones are found in all compartments of the cell where 
folding and other conformational adjustments need to occur (Walter et al. 2002). 
Heat Shock protein (HSPs), one type of molecular chaperones, play a critical 
role in the recovery of cells from heat stress, and in cytoprotection from subsequent 
insults (Nollen et al. 2002). For example, cells that have lost their ability to regulate 
cell growth, such as tumor cells, normally express high levels HSP proteins (Jaattela 
1999). This might indicate that chaperones can suppress or buffer the effect of 
mutations.  
In the process of de novo protein folding or refolding, the cooperative work 
between the Heat Shock protein 70 (Hsp70) system, small chaperones, chaperonins, 
and the Heat Shock protein 90 (Hsp90) system takes place (Sin et al. 2015). By 
binding to hydrophobic segments, Hsp70 can stabilize and prevent protein misfolding 
and aggregation, in an ATP-dependent manner. Then, the substrate can be transferred 
to other systems (such as chaperonins), where the folding takes place and the three-
dimensional (3D) structure is acquired (Sin et al. 2015). Hsp70 also assists membrane 
translocation of organellar and secretory proteins, and the activity of regulatory 
proteins (Mayer et al. 2005).  
Importantly, depletion of Hsp70 has been associated with PD. In vitro, Hsp70 
significantly increases the lag phase of aSyn aggregation (Roodveldt et al. 2009). The 
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inhibitory effect of Hsp70 depends on the ratio between Hsp70/aSyn, and on the 
relative levels of aSyn and ATP, or ADP (Roodveldt et al. 2009). One important 
aspect for the Hsp70-mediated inhibition of aSyn aggregation is the presence of the 
Hip co-chaperone (Roodveldt et al. 2009). Hip stabilizes the ADP-bound state of 
Hsp70 and assists Hsp70 in protein folding (Nollen et al. 2001). Alone, Hip can also 
bind to unfolded proteins and prevent their aggregation (Nollen et al. 2001). In vivo, 
in drosophila, Hsp70 was shown to reduce aSyn toxicity, but could not prevent the 
accumulation of amyloid-like aggregates (Auluck et al, 2002). 
  
 
1.2.2. Ubiquitin proteasome system (UPS) 
We still do not fully understand how misfolded proteins are discriminated 
from the correct folded counterparts. However, this is a crucial step in cellular 
homeostasis. Polypeptides that enter the secretory pathway are first received at the 
endoplasmic reticulum (ER) (Braakman et al. 2011). The ER is responsible for the 
addition of specific PTMs and, later, for targeting proteins to specific organelles or to 
the outside of the cell. So, it is no surprise, that the ER-associated degradation 
(ERAD) pathway cooperates tightly with the ubiquitin-proteasome system (UPS) to 
prevent the accumulation of misfolded proteins (Figure 1.2). This is a joint effort of 
selection, production, and transportation of misfolded proteins from the ER to the 
cytosol for degradation (Guerriero et al. 2012).  
The UPS is the major degradation pathways for short-lived proteins, such as 
those that regulate cell division, signal transduction, and gene expression (Kraft et al. 
2010). For that, there are two consecutive steps: ubiquitylation and proteasomal 
degradation (Hershko et al. 1998). Ubiquitylation is a common and reversible PTM 
where the small protein ubiquitin, a highly conserved protein of 76 aa, is ligated to a 
lysine residue in a substrate protein (Klein et al. 2016). After the recognition of 
eligible proteins, these can be mono- or poly-ubiquitinated (at least four ubiquitin 
molecules are added) (Weissman 2001), in an ATP-dependent process that starts with 
the attachment of ubiquitin to the polypeptide chain, in an ordered three-step process. 
The ubiquitin-activating enzyme (E1) transfers ubiquitin to an ubiquitin-carrier 
protein (E2) and, finally, the ubiquitin molecules are transferred to lysine residues in 
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the target substrate in a reaction catalyzed by the ubiquitin protein ligase (E3) 
(Ciechanover et al. 1980; Hershko et al. 1980).  
The ligation of multiple ubiquitin groups to a substrate protein leads to the 
formation of a polyubiquitin chain. This is a complex process in which at least seven 
different types of ubiquitin linkages can be established (K6, K11, K27, K29, K33, 
K48 or K63) (Kim et al. 2007; Ikeda et al. 2008). The exact conformation of the 
polyubiquitin chain will determine the fate of the substrate. For example, K48 chains 
generally target the substrate for degradation via the proteasome (Klein et al. 2016).  
However, ubiquitylation can have other roles besides proteasomal degradation. These 
include as cell-cycle control, differentiation, apoptosis, transcriptional regulation, and 
immune response. It has been reported that K63-linked ubiquitin chains do not act as 
a proteasome-targeting signal in vivo, as K48 (Nathan et al. 2013). Instead, these 
chains are implicated in macroautophagy (Kraft et al. 2010), and play an important 
role in signaling, endocytosis, and DNA repair (Ikeda et al. 2008). Also, K63-
polyubiquitinated proteins do not co-localize with proteasomes in cells (Newton et al. 
2008). 
The 26S proteasome complex is the most common form in cells, and is 
functionally and structurally divided into two parts: the 19S cap, and the core formed 
by the 20S proteasome (Inobe et al. 2014). The 19S subunit recognizes the substrates, 
unfolds the polypeptides and guides them through the channel to the proteolytic core 
(Inobe et al. 2014). The 20S core is responsible for the proteolytic activity and has 
three peptidase activities: chymotrypsin-like (Tyrosine or Phenylalanine at position 
1), trypsin-like (Arginine or Lysine at position 1), and caspase-like, that cleaves the 
substrate into short peptides (Bedford et al. 2010).  
 
1.2.3. Autophagy-Lysosome Pathway 
A second proteolytic system is commonly referred to as autophagy (“self-
eating” in Greek). This system eliminates cytosolic components, organelles, long-
lived proteins, and pathogens, via lysosomes. It is also involved in starvation and 
stress responses (Kraft et al. 2010). Autophagy can be divided in three categories: 
macroautophagy, microautophagy and chaperone-mediated autophagy (CMA). Both 
macro- and microautophagy involve dynamic membrane readjustments to engulf of 
the cytoplasm. In macroautophagy, commonly referred to as autophagy, the double 
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membrane forms a vesicle that engulfs the material- autophagosome. When the 
autophagosome fuses with an endosome or lysosome, it gives rise to the autolysosome 
where the hydrolytic enzymes will act (Figure 1.2) (Yang et al. 2009). 
In microautophagy, small particles from the cytosol are internalized by the 
lysosome through the invagination of its own membrane. CMA is particularly 
associated with lysosomal degradation. Unlike other degradation systems, it is based 
on the recognition of a specific aa sequence - KFERQ - which is present in around 
30% of cytoplasmic proteins (Dice 1990). HSP70 recognizes this aa sequence, and 
Hsc70 binds and delivers the proteins to the CMA receptor at the lysosome. 
If the capacities of the refolding machinery and 26S proteasome are 
overwhelmed and exceeded, misfolded proteins can accumulate in cellular inclusions. 
 
1.2.4. Protein compartmentalization 
When misfolded proteins exceed the degradation capacity of the quality 
control systems, proteins can have one of two fates: they can either accumulate, or be 
compartmentalized in the cell. Compartmentalization can be a cellular strategy, by 
spatially sequestering misfolded proteins into defined compartments, the deal with 
proteins that can then be either refolded or permanently sequestered (Figure 1.2). 
There are specific types of such compartments, evolutionary conserved from yeast to 
mammals, which accumulate proteins according to their solubility state the 
juxtanuclear quality control (JUNQ) and the insoluble protein deposit (IPOD) (Figure 
1.3) (Kaganovich et al. 2008; Weisberg et al. 2012).  
The JUNQ compartment sequesters mobile, misfolded polypeptides in a 





Figure 1.3 Schematic representation of a mammalian cell showing two misfolded proteins 
compartments. Proteins can be sorted into two different quality control compartments, the JUNQ or 
the IPOD, based on their ubiquitination state. 
 
The IPOD accumulates insoluble proteins at the periphery of the cells, 
typically adjacent to the pre-autophagosomal structure. Do to the insoluble material 
this compartment is immobile (Miller et al. 2015). Vimentin is an intermediate 
filament protein that establishes mitotic polarity in mitotic cells, by 
confining/encaging proteins in JUNQ, mediating asymmetric partitioning during 
(Figure 1.4) (Ogrodnik et al. 2014). This mechanism represents an important strategy 
for cellular rejuvenation. Asymmetric segregation in single-cell organisms (as 
Saccharomyces cerevisiae) potentiates the rejuvenation of the emerging generation by 
preventing the inheritance of damaged factors (Ogrodnik et al. 2014). The ability of 
mother cells to retain damaged factors such as DNA, lipids, and proteins, must be 
carefully regulated to isolate them or to filter several aging factors (Nystrom et al. 
2014; Lai et al. 2002; Aguilaniu et al. 2003; Lindner et al. 2008). In this fascinating 
process, the mother cell generates younger daughter cells where the clock of aging not 





Figure 1.4 Mitotic cells have asymmetric inheritance of JUNQ and IPOD. In mammalian the 
cytoskeleton, and intermediate filaments provide the scaffold for asymmetric inheritance of inclusions, 
in contrast to IPOD inclusions, which are not partitioned as effectively during mitosis. Adapted from 
(Ogrodnik et al. 2014). 
 
Another type of compartments are the aggresomes, localized at the 
microtubule organizing center (MTOC) (Figure 1.2) These periocentriolar 
cytoplasmic structures are typically formed when the proteasome can not clear 
misfolded proteins properly (Johnston et al. 1998), and transports them via 
dynein/dynactin complex to their final destination (Figure 1.2) (Johnston et al. 2002). 
Interestingly, the JUNQ shares several properties with the aggresomes, like the 
localization, the presence of ubiquitinated proteins and chaperones (Kaganovich et al. 
2008). However, neither the JUNQ nor the IPOD are localized in the spindle pole 
body (the microtubule organizing center in yeast cells, equivalent to the centrosome), 
unlike the aggresome, which co-localizes with MTOC (Johnston et al. 2002). 
However, the idea of protein sequestration as an alternative cellular defense 
was recently challenged. Instead, compartmentalization could be an early response to 
stress or to toxic misfolded species into transient and dynamic structures called “Q 
bodies” or cytosolic stress-induced aggregates (CytoQ) (Escusa-Toret et al. 2013). 
The recruitment of misfolded proteins into Q-bodies is an active process that relies on 
molecular chaperones (Escusa-Toret et al. 2013). However, these structures are not 
necessary targets for degradation but may improve cell fitness, using the same factors 
that promote folding (Escusa-Toret et al. 2013). The formation and the movement of 
the Q-bodies are independent of the cytoskeleton, but involve the cortical ER (tubular 
system analogous to the ER network in higher eukaryotes) and chaperones (Escusa-
Toret et al. 2013). 
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If all these systems fail, in mitotic cells, the asymmetric division known as 
replicative rejuvenation, can still be an option. Studies in bacteria and yeast showed 
that aging mother cells retain damaged proteins, where the daughter cells are freed of 
these proteins (Lindner et al. 2008; Liu et al. 2010; Coelho et al. 2013; Ogrodnik et al. 
2014).  
 
1.3. Protein Misfolding diseases 
Misfolded proteins compromise not only the integrity of the cellular proteome, 
but also cell viability. Despite a lack of similarity in aa sequence, there are 
approximately 50 disorders associated with misfolding of normally soluble, functional 
peptides and proteins, and their subsequent conversion into aggregates (Knowles et al. 
2014). 
The accumulation of aggregated proteins in the brain is a hallmark shared by 
several neurodegenerative diseases, like Parkinson’s (PD), Alzheimer’s (AD) and 
Huntington’s disease. Interestingly, these protein aggregates share common 
characteristics, like a fibrillar structure that shares similar morphology and size. They 
display a characteristic cross-beta structure X-ray diffraction pattern, revealing that 
the core structure is composed of β-sheets in which the β-strands run approximately 
perpendicular to the long fibril axis, and the inter-strand hydrogen bonds run 
approximately parallel to the long fibril axis (Sunde et al. 1998). Furthermore, fibrils 
exhibit yellow-green birefringence upon binding of the dye Congo red (Khurana et al. 
2001) and other specific optical properties upon binding to other dyes like Thioflavin 
T (ThioT) (Chiti et al. 2006) (Figure 1.5) These aggregates are also thermally stable, 
SDS- and protease-resistant. In vitro, amyloid fibrils are formed through a nucleation-




Figure 1.5 Different methods for amyloid protein characterization. (a) Amyloid proteins forms 
filaments composed of sheets of β-strands, that because of their arrangement it produces a distinctive 
cross-β X-ray diffraction pattern, reflecting the characteristic spacing between the β-sheets and the β-
strands. Using Congo red dye in combination with cross-polarizes light technique is possible to 
distinguish the presence of fibrils. (b) Amyloid formation initiates with a slow nucleation phase 
(formation of seeds), and the monomers and the oligomers can bond to the ends of the initial amyloid 
seed. The fibril can grow, and eventually break, producing more seeds. (d) In vitro, the nucleation 
phase can be shortened by the addition of pre-formed exogenous seeds. Adapted from (Jucker et al. 
2013) 
 
Typically, amyloid formation in mammals occurs with aging and is commonly 
associated with protein misfolding diseases (Selkoe 2003; Chiti et al. 2006).  
 
1.4. Parkinson’s Disease 
PD is the most common progressive motor disorder, and the second most 
prevalent neurodegenerative disorder, after AD, affecting around 1% of the 
worldwide population at the age of 60, and 4-5% of people over 85 (de Lau et al. 
2006). PD was first described in 1817 by the english physician James Parkinson, in 
his “An Essay on the Shaking Palsy”, as a movement-related disorder (Parkinson 
2002). PD is characterized by the progressive loss of dopaminergic neurons in 






                            
Figure 1.6 Afflicted region in PD patients. (a) Cut section, showing the localization of SN. (b) In PD 
patients there is a depletion of pigmented dopaminergic neurons localized in the SN.  
 
These neurons form the nigrostriatal dopaminergic pathway that primarily 
projects to the putamen, and are enriched with neuromelanin (Marsden 1983) and iron 
(Forno et al. 1974). The loss of these dopaminergic neurons leads to dopamine (DA) 
deficiency, responsible for the major cardinal symptoms in PD: muscle rigidity, 
bradykinesia, resting tremor, and postural instability. At the onset of symptoms, it is 
estimated that about 80% of putamental DA is depleted, and about 60% of SN 
dopaminergic neurons are lost (Dauer et al. 2003). In addition, about 30‐ 50% of 
non‐ DA cells are lost in the final stages of PD, including monoaminergic cells, 
cholinergic cells, and hypocretin cells, which are associated with cognitive deficits, 
gait problems and sleep disorders (Zarow et al. 2003; Hilker et al. 2005; Thannickal et 
al. 2007). Furthermore, other symptoms at the psychiatric level, such as anxiety and 
depression, dysautonomic symptoms (as hypotension and constipation), olfactory 
dysfunction, and seborrheic dermatitis can also arise (Checkoway et al. 1999). 
However, these symptoms precede the tremor or bradykinesia. 
The underlying causes for massive neuronal cell loss are still unknown, and 
the symptoms of PD can be, albeit transiently treated by replacement of DA (via 
levadopa), DA agonists, monoamine oxidase B or catechol-O-methyltransferase 
inhibitors, and N-methyl-D-aspartate receptor antagonists (Groiss et al. 2009; Litim et 
al. 2015). In some particular cases, deep brain stimulation is also a possibility 









1.4.1. Protein aggregation in PD 
The neuropathological hallmark of idiopathic PD is the presence of concentric 
hyaline cytoplasmic inclusions called Lewy bodies (LBs) and Lewy neurites (LN), 
first described in 1912 by Friedrich Lewy (Figure 1.7) (Goedert et al. 2013). This 
pathological hallmark can occur in the brainstem, basal forebrain, autonomic ganglia 
and, in higher concentrations, in the SN and locus coeruleus (Mezey et al. 1998). 
Nevertheless, LBs have also been observed in the brains of asymptomatic individuals 
(Nussbaum et al. 1997) and in 10-15% of healthy, aged individuals (Gibb et al. 1988; 
Conway et al. 2000). 
 
 
Figure 1.7 Lewy Bodies and Lewy Neurites in the SN of PD patients. Immunohistochemistry for 
aSyn and ubiquitin. Scale bar: 10 µm and 90 µm respectively. From (Spillantini et al. 1998). 
 
LBs are composed of a large number of molecules including synphilin-1 
(Sph1) (Wakabayashi et al. 2000), heat-shock proteins (Hsp90, Hsp70, Hsp40) 
(Auluck et al. 2002; McLean et al. 2002; Uryu et al. 2006)), p62 (Kuusisto et al. 
2003), sphingomyelin (den Jager 1969), tau (Ishizawa et al. 2003), ubiquitin (Lowe et 
al. 1988), and others. However, the most abundant protein component of LBs is 
alpha-Synuclein (aSyn) (Figure 1.7) (Spillantini et al. 1997). LBs are not exclusive in 
PD, and are also present in diseases such as Dementia with LBs (Spillantini et al. 
1998), sporadic AD, Down’s syndrome, Hallervorden-Spatz syndrome, and 
neurodegeneration with iron accumulation type 1 in the brain (Arawaka et al. 1998; 
Ebrahimi-Fakhari et al. 2011). Thus, these disorders are referred to as 





1.4.2. Etiology of PD 
The majority of PD cases are sporadic/idiopathic and most likely triggered by 
a combination of aging, genetic, and environmental factors. In fact, the exposure to 
certain pesticides like 1-methyl-4-phenyl-1, 2, 3, 6,-tetrahydropyridine (MPTP) or 
paraquat, results in the degeneration of dopaminergic neurons and in chronic 
parkinsonism (Di Monte et al. 2002). Interestingly, in monkeys treated with MPTP, it 
was observed that the depletion of striatal terminals precedes the death of 
dopaminergic neurons in the SN (Herkenham et al. 1991). 
Genetic predisposition also plays a role in the disease, and familial forms of 
PD can manifest in two ways: autosomal dominant or recessive. Initial studies on 
twins reveled that the concordance rate among monozygotic and dizygotic twins was 
similar overall. Nevertheless, in early-onset cases (before 50 years), the rate in 
monozygotic twins was significantly higher (100%) compared to dizygotic twins 
(17%) (Tanner et al. 1999).  
With the improvement of imaging methods, such as PET (positron-emission 
tomography), it became clear that striatal dopaminergic dysfunction was significantly 
higher in monozygotic than in dizygotic twin pairs (55%, 18%, respectively), even in 
pre-symptomatic cases (Burn et al. 1992; Piccini et al. 1999). Although, familial PD 
accounts for only a minority of all PD cases, the understanding of the underlying 
genetic alterations provides tremendous insight into the molecular pathogenesis of the 
disease (Thomas et al. 2007).  
Several genes have been linked to PD, and the list will potently continue to 




Locus  Gene  Description  Reference  
PARK 1/4  SNCA  Presynaptic/nuclear protein  
(Polymeropoulos et al. 
1997) 
PARK2  Parkin  Ubiquitin ligase  (Kitada et al. 1998) 
PARK3  SPR(?)  (Gasser et al. 1998) 
PARK5  UCH-L1  Ubiquitin protease  (Liu et al. 2002) 
PARK6  PINK1  Mitochondrial protein kinase  (Hatano et al. 2004) 
PARK7  DJ-1  Multifunctional protein  (Bonifati et al. 2003) 
PARK8  LRRK2  Leucine-rich repeat kinase 2 (Gasser 2009) 
PARK9  ATP13A2  Lysosomal ATPase  (Ramirez et al. 2006) 
PARK10  (?)  (Li et al. 2002) 
PARK11  GIGYF2  (Lautier et al. 2008) 
PARK12  (?)  (Pankratz et al. 2002) 
PARK13  Omi/HTRA2  Serine Protease  (Strauss et al. 2005) 
PARK14  PLA2G6  Phospholipase  (Paisan-Ruiz et al. 2009) 
PARK15  FBXO7  F-box protein  (Shojaee et al. 2008) 
PARK16  (?)  (Satake et al. 2009) 
PARK17  VPS35  Retromer Complex  (Wider et al. 2008) 
PARK18  EIF4G1  Translation Initiation Factor  
(Chartier-Harlin et al. 
2011) 
PARK19  DNAJC6  
DNAJ/HSP40 homolog, 
Subfamily C, Member 6  
(Edvardson et al. 2012) 
PARK20  SYNJ1  Synaptojanin 1  
(Krebs et al. 2013; 
Quadri et al. 2013) 
PARK21 DNAJC13 
DNAJ/Hsp40 Homolog, 
Subfamily C, Member 13 




helix domain containing 2 
(Funayama et al. 2015) 
PARK23 VPS13C 
Vacuolar protein sorting 13 
homolog C 
(Lesage et al. 2016) 
Table 1. Genes associated with PD.  
 
1.4.2.1. The synuclein family of proteins 
aSyn belongs to a family with three different gene products: a-, beta (b)- and 
gamma (g)-Syn. These proteins have been described in vertebrates, and seem to be 
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highly conserved among distantly related vertebrate species (Maroteaux et al. 1988; 
Jakes et al. 1994; George et al. 1995). Knockout of a-,b-, or gSyn in mice is not lethal, 
although some electrophysiological abnormalities have been described (Abeliovich et 
al. 2000; Chandra et al. 2004). aSyn and bSyn are predominantly expressed in the 
neocortex, hippocampus, striatum, thalamus, and cerebellum (Nakajo et al. 1993; Iwai 
et al. 1995). Additionally, aSyn can be found in fluids such as the cerebrospinal fluid, 
saliva, and blood plasma (El-Agnaf et al. 2003; Tokuda et al. 2006; Devic et al. 
2011). Recently, it was showed that the expression of human wild-type (WT) bSyn 
protein leads to the formation of proteinase K (PK) resistant aggregates, and loss of 
dopaminergic neurons in primary neuronal cultures and in rats, suggesting that bSyn 
may also play a role in the neurodegenerative process (Taschenberger et al. 2013). 
gSyn, is the least conserved and the smallest member of the synuclein family, and is 
expressed in the brain, in the ovary, testis, colon, and heart (Clayton et al. 1998). 
 
1.4.2.2. aSyn Structure  
aSyn is a small protein of 140 aa, highly negatively charged, thermally stable, 
and is usually functionally divided into three domains (Figure 1.8). 
aSyn was first discovered in the electric organ of Torpedo californica, and 
named synuclein for its cellular localization within synaptic nerve terminals and 
within the nuclear compartment (Maroteaux et al. 1988). However, aSyn was not 
consistently found in the nucleus in several subsequent studies, and this is still a 





Figure 1.8 Human aSyn. A. Schematic representation of the structure of human aSyn showing the 
three distinct domains (N- terminal, non-b-amyloid component (NAC), and C-terminal domain). Aa 
positions are indicated at the bottom. Green boxes represent the imperfect hexameric KTKEGV 
repeats. The lines show the familial mutations in PD context and the sites of aSyn phosphorylation. 
Adapted from (Gallegos et al. 2015)  
 
The N-terminal domain is a highly-conserved region with a series of imperfect 
hexameric (KTKEGV) repeats. This unstructured region adopts amphipathic α-helical 
structure in the presence of lipids or some detergents (Davidson et al. 1998; Eliezer et 
al. 2001; Mihajlovic et al. 2008). All the familial mutations described in aSyn are 
located in the N-terminal domain, suggesting that this region has an important cellular 
function (Fig. 1.8).  
The central hydrophobic domain of aSyn is also referred as the NAC region. 
This amyloidogenic region has the ability to change conformation from random coil 
to β-sheet structure (Sykes et al. 1990; Serpell et al. 2000), and to form A-like 
protofibrils and fibrils (Harper et al. 1997; Harper et al. 1999). The C-terminal region 
is the least conserved in the synuclein family, and is variable in size and sequence. 
This is a highly acidic domain composed of proline, glutamate, and aspartate residues 
(Amer et al. 2006), and has been proposed to confer chaperone-like activity to the 
protein (Kim et al. 2000; Souza et al. 2000; Park et al. 2002).  
 
1.4.2.3. aSyn aggregation and cytotoxic species 
Understanding the mechanisms involved in the aggregation process of aSyn is 
crucial to identify the toxic species that trigger diseases. A widely accepted 
hypothesis posits that aSyn oligomers and protofibrils are the cytotoxic species, and 
that the larger insoluble aggregates are cytoprotective (Caughey et al. 2003; Winner et 
al. 2011). As stated above, aSyn is a disordered protein in solution. This lack of 
defined secondary and tertiary structure allows aSyn to adopt multiple conformations. 
Thus, it is still not clear how native unfolded aSyn acquires a structure that is prone to 






Figure 1.9 Schematic model of the process of aSyn aggregation. When monomeric aSyn interacts 
with itself, in ways we do not fully understand, it starts to aggregate producing oligomers, and later 
amyloid fibrils, in a nucleation-dependent manner. The accumulation of aSyn in LBs is a primary 
hallmark of PD and other synucleinopathies. We still do not know precisely which of the various 
species of aSyn are responsible for cellular toxicity and neurodegeneration.  
 
The driving forces for these interactions are primarily due to the hydrophobic 
stretch in the middle of the aSyn sequence, constituted by 12 aa 
(VTGVTAVAQKTV) (Giasson et al. 2001). After these initial interactions, 
monomers start to aggregate, and form oligomeric species, which are soluble and non-
fibrillar. When oligomers reach a critical concentration, they are rapidly converted 
into protofilaments, protofibrils and, finally, into amyloid fibrils, of high molecular 
weight.  
The environment around aSyn can trigger its aggregation (Figure 1.9). 
Polyamines (like putrescine, spermidine, and spermine) (Antony et al. 2003), low pH 
(pH 4 or 5), and increasing salt concentrations (Hoyer et al. 2002), among others, are 
external known factors that accelerate the rate of aSyn fibrillation. The fibril 
elongation rate is correlated with protein concentration (Wood et al. 1999), which is 
in line with multiplication of SNCA. 
The C-terminus of aSyn stabilizes long-range interactions within the protein 
by shielding the central region and preventing aggregation (Bertoncini et al. 2005). 
When the C-terminus is truncated, the aggregation progresses faster (Hoyer et al. 
2004). However, two recent reports challenge this concept by suggesting that aSyn 
predominantly exists in a stable tetrameric state, with low propensity to aggregate. 
Furthermore, the dissociation of the tetramer into monomeric subunits would promote 




1.4.2.3.1. Mutations in aSyn 
The first gene linked to familial forms of PD was SNCA when, in 1997, a point 
mutation was identified in aSyn (the protein encoded by the SNCA gene), in an Italian 
family and in three unrelated Greek families with autosomal dominant inheritance of 
PD (Polymeropoulos et al. 1997). This mutation consists in the substitution of an 
alanine for a tyrosine at position 53 (A53T). In solution, A53T is more 
thermodynamically stable than WT aSyn, and has higher propensity to aggregate, due 
to an increase in β-sheet formation (Coskuner et al. 2013). Moreover, A53T mutant 
aSyn alters mitochondrial morphology, and the proteins involved in mitochondrial 
fission and fusion, in an age-dependent manner, in mice (Xie et al. 2012). 
One year later, another mutation was found in a German family, and consisted 
in the substitution of an alanine for a proline at position 30 (A30P) (Kruger et al. 
1998). In vitro, A30P reduces membrane and vesicle binding capacity, slows down 
fibrillation kinetics compared to the WT aSyn, and promotes protofibrillar and 
oligomeric accumulation (Conway et al. 2000; Jo et al. 2002). Also, overexpression 
A30P aSyn interferes with the process of tyrosine hydroxylase (TH) synthesis, and 
impairs neurite and axonal regeneration in damaged midbrain dopaminergic neurons 
(Kim et al. 2014; Tonges et al. 2014). 
The E46K mutation was identified in a Spanish family with autosomal 
dominant parkinsonism that showed dementia and visual hallucinations (Zarranz et al. 
2004). Recently, another case in a 60-year-old male, from Bolivia, with a familial 
history of autosomal dominant PD was reported (Pimentel et al. 2015). Thus, 
mutation was shown to increase rate of fibrillization, similar to A53T (Choi et al. 
2004; Greenbaum et al. 2005). In transgenic mice, it leads to intracytoplasmic 
neuronal inclusions in an age-dependent manner (Emmer et al. 2011). Furthermore, 
E46K can significantly enhanced phosphorylation on S129 in yeast, mammalian cells, 
and in the mouse brain (Mbefo et al. 2015). In addition, it increased the ability of 
aSyn to bind to negatively charged liposomes, in contrast to the A30P or A53T 




Figure 1.10 aSyn sequence. Examples of familial point mutations and their possible effects on aSyn 
conformation. From (Tosatto et al. 2015). 
 
 
In 2013, two studies reported another aSyn mutation - H50Q (Appel-Cresswell 
et al. 2013; Proukakis et al. 2013). H50Q mimics late-onset idiopathic PD with a 
positive response to levodopa (Kiely et al. 2015). It accelerates the aggregation 
(Ghosh et al. 2013; Khalaf et al. 2014; Rutherford et al. 2014), causes an increase of 
the flexibility of the C-terminal region, which indicates that H50Q can mediate long-
range interactions (Chi et al. 2014). In cell culture, H50Q increases aSyn secretion 
and cell death, and induces increased mitochondrial fragmentation in hippocampal 
neurons (Khalaf et al. 2014; Xiang et al. 2015). 
In the same year, the G51D nutation was found to associate with an unusual 
PD phenotype (Kiely et al. 2013; Lesage et al. 2013), with early disease onset. In 
vitro, G51D oligomerization occurs slowly and the fibrils are more toxic than those 
formed by WT aSyn (Lesage et al. 2013). G51D impairs membrane binding, and 
increases mitochondrial fragmentation (Fares et al. 2014). 
The most recent mutation (A53E) was discovered in a 36 years old Finish 
patient with atypical PD. The patient had a dense accumulation of SNCA inclusions in 
the striatum, and severe cortical pathology (Pasanen et al. 2014). In vitro, 
A53E attenuates aSyn aggregation and amyloid formation without altering the 
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secondary structure, and causes the accumulation of oligomers like the A30P 
mutation (Ghosh et al. 2014). This suggests that a negatively charged side chain from 
the glutamic acid may affect aSyn structure and, consequently, the fibrillation 
process. Furthermore, A53E reduces membrane-binding affinity compared to A53T 
and WT (Ghosh et al. 2014), and enhances toxicity in mitochondria (Rutherford et al. 
2015). 
In summary, the fact that all the reported PD-associated aSyn mutations are 
concentrated in the N-terminal region of the protein (Figure 1.8), suggests that this 
region is important in the process of aSyn aggregation and toxicity.  
In addition to point mutations, multiplications of the SNCA gene (duplications 
and triplications) appear to confer a functional gain of cytotoxicity to aSyn, clearly 
showing a dosage effect on disease progression (Singleton et al. 2003; Chartier-Harlin 
et al. 2004; Ibanez et al. 2004). Polymorphisms in the promoter region of SNCA, also 
play a role in PD by increasing aSyn expression (Holzmann et al. 2003). 
 
1.4.2.3.2. aSyn Posttranslational Modifications 
aSyn is known to undergo various types of PTMs. These include 
phosphorylation in S129 (Fujiwara et al. 2002), ubiquitination (Shimura et al. 2001), 
sumoylation (Dorval et al. 2006), C-terminal truncations (Li et al. 2005), or nitration 
(Giasson et al. 2000). However, it is not clear how these PTMs affect aSyn structure, 
folding, and how they modulate disease pathogenesis. Interestingly, most known sites 
of aSyn PTMs are localized in the C-terminal tail, including phosphorylation (Y125, 
S129, Y133 and Y136), truncation (D115, D119, P120, E130 and D135), 
ubiquitination (K96), and sumoylation (K96, K102) (Figure 1.11).  
 
Figure 1.11 Schematic representation of some of the known PTMs in aSyn. Adapted from (Schmid 




Phosphorylation at S129 (pS129) has been intensively studied since 
approximately 90% of aSyn in LBs is thought to be phosphorylated (Fujiwara et al. 
2002; Anderson et al. 2006). This suggests a close interaction between aSyn pS129 
and its aggregation.  Phosphorylated aSyn on tyrosine 39 (pY39) and 125 (pY125) 
has been also reported in human brains, although, no correlation was established 
among increased levels of phosphorylation and the pathological condition (Chen et al. 
2009; Mahul-Mellier et al. 2014). 
Several in vivo and in vitro studies attempted to clarify the consequences of 
aSyn phosphorylation by blocking (S129A) or mimic (S129D/E) phosphorylation. 
However, the conclusions turned out to be conflicting. In Drosophila, S129D aSyn 
was associated with pathology (Chen et al. 2005; Chen et al. 2009), but in yeast, rat, 
and Caenorhabditis elegans S129E had no effect. In addition, in budding yeast, 
S129A increases aSyn toxicity (Fiske et al. 2011; Sancenon et al. 2012). Moreover, in 
rats expressing aSyn in SN, S129A showed to be toxic, while S129D either was 
protective (Gorbatyuk et al. 2008) or had no effect (Azeredo da Silveira et al. 2009). 
Regarding the correlation between pS129 aSyn and aggregation is also not 
consensual. Most of the studies performed in cell lines reported an increase formation 
of soluble oligomers (Smith et al. 2005; Arawaka et al. 2006; Takahashi et al. 2007; 
Kragh et al. 2009; Wu et al. 2011), and in yeast, S129A is more toxic, and forms more 
inclusions and higher molecular oligomeric species than WT or S129E (Sancenon et 
al. 2012; Tenreiro et al. 2014). 
Tyrosine phosphorylation is known to be a very rapid process, difficult to 
evaluate in vivo. The only study in human brain tissue showed that the levels of 
pY125 decrease with age and PD pathology (Chen et al. 2009). However, a recent 
study did not observe any significant differences in the levels of pY125 between PD 
brains and controls (Mahul-Mellier et al. 2014). Nevertheless, tyrosine 
phosphorylation (Y125, Y133, and Y136) can suppress eosin-induced oligomerization 
(Negro et al. 2002).  
S87 (in addition to Y39) is the residue outside the C-terminal region that is 
phosphorylation (pS87) in rat, mice and human brains (Paleologou et al. 2010). In 
vitro studies demonstrated that pS87, inhibits aSyn fibrillization, and significant 
reduces aSyn binding to membranes, which is not the case of (Paleologou et al. 2010). 
However, depending on the model, the outcomes are different (Kim et al. 2006; 
Waxman et al. 2008; Paleologou et al. 2010). 
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Ubiquitin and the small ubiquitin-related modifier (SUMO) share structural 
similarities (Eckermann 2013). SUMO preferentially targets lysine residues at 96 and 
102 sites of aSyn. In vitro, aSyn aggregation and fibrillation can be delayed or even 
blocked by sumoylation (Krumova et al. 2011).  
 
1.4.2.3.3. Putative functions of aSyn 
Assessing the normal function of aSyn has been challenging, not only because 
it is an intrinsically disordered protein that shifts between conformations, but also 
because it is a promiscuous protein that interacts and interferes with a lot of 
biological/cellular processes. In addition, the model systems available only partially 
recapitulate the symptoms and molecular pathologies associated with the disease.  
Furthermore, these models generally rely on aSyn overexpression, which adds another 
layer of complexity (for example, compensatory mechanisms) to the interpretation of 
its pathogenic and physiological roles. 
The cellular localization of aSyn is thought to be regulated throughout brain 
development, during neuronal migration, maturation and synaptogenesis (Hsu et al. 
1998; Murphy et al. 2000). In animal models, like rodents, aSyn levels are low in 
early embryogenesis (prior to E15), but increases in later stages of neuronal 
development (E18) extending into the postnatal period (P7) (Hsu et al. 1998). Also, 
increase levels of aSyn in pre-synapses are involved in critical stages of development, 
such as learning and synaptic plasticity (Maroteaux et al. 1988; George et al. 1995; 
Clayton et al. 1998; Hsu et al. 1998; Murphy et al. 2000). A recent study performed 
with professional musicians reveled up-regulation of some genes after music 
performance. In the list, dopaminergic neurotransmission-related genes were 
consistently identified. Around 26% of the SNCA co-expression network, was found 
to be up-regulated along with SNCA, suggesting that music performance may 
modulate the biological pathways of aSyn (Kanduri et al. 2015).  
aSyn exists in a dynamic equilibrium between a soluble and a membrane-
bound state (Roy 2009). The interaction between aSyn and lipid surfaces is believed 
to be a key features both in physiological and pathological condition. The N-terminal 
region of aSyn can adopt α-helical secondary structure upon binding to detergent 
micelles, liposomes (Davidson et al. 1998) or to negatively charged lipids or 
membranes (Jao et al. 2004; Jao et al. 2008). The membrane binding likely occurs via 
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the 11-mer sequences, as truncation of this domain drastically reduces lipid binding 
(Bisaglia et al. 2006; Burre 2015). N-terminal acetylation of aSyn can also increase its 
helical folding propensity, membrane binding affinity, and resistance to aggregation 
(Fauvet et al. 2012; Kang et al. 2012; Maltsev et al. 2012). aSyn not only binds to 
membranes, but it can induce membrane curvature and membrane tubulation, similar 
to amphiphysin (curvature-inducing protein involved in endocytosis) (Figure 1.12) 
(Varkey et al. 2010). These membrane-curvature changes can have a significant 
impact on the fusogenic properties of synaptic vesicles. For example, vesicles that 
have a high curvature, favors fusion with flat target membranes (Auluck et al. 2010). 
Interestingly, aSyn can aggregate faster in the presence of brain membranes, than in 
the presence of cytosolic fractions (Lee et al. 2002). 
 
Figure 1.12 Model for aSyn-mediated membrane remodeling and curvature induction. (I) When 
aSyn binds to a single vesicle (II) the curvature strain causes initiation of a membrane tubule. The 
shape of the tube (V) is dependent of the concentration and orientation of the protein bound molecules 
on the membrane (III, IV) with higher concentrations favoring more curved structures. (V) Vesicular 
structures could originate from smaller membrane tubes or directly from large vesicles (II). B. 
Insertion of aSyn helical structure on intact vesicles occurs at the phosphate level. From (Varkey et al. 
2010) 
 
The mechanism by which membranes can be disrupted by aSyn is still 
intensely debated. Nevertheless, the formation of pore-like structures within the lipid 
bilayer (Lashuel et al. 2002), and the observation of donut-shaped complexes by 
atomic force and electron microcopy (Quist et al. 2005) have been reported. 
Mutations in aSyn also alter its phospholipid binding affinities. A30P and G51D 
decrease lipid affinity (Ysselstein et al. 2015).  
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Another role attributed to aSyn is its association with lipid metabolism. aSyn 
has been reported to bind to fatty acids (Sharon et al. 2001), to organize membrane 
components (Sharon et al. 2001), to regulate phospholipid composition (Adamczyk et 
al. 2007), and to inhibit  phospholipase D1 and D2 in vitro and in vivo (Ahn et al. 
2002; Outeiro et al. 2003). This implies that aSyn may be implicated in cleavage of 
membrane lipids and membrane biogenesis. 
aSyn can interfere with neuronal membrane trafficking, affecting both Ras 
analog in brain (Rab) GTPases and certain N-ethylmaleimide-sensitive factor 
attachment protein (SNAP) receptors (SNAREs) (Amaya et al. 2015). SNAREs are a 
family of proteins that act in membrane fusion (Bonifacino et al. 2004; Jahn et al. 
2006). aSyn directly promotes presynaptic SNARE-complex assembly via a 
nonclassical chaperone activity (Burre et al. 2010). aSyn is able to act as a SNARE 
chaperone when bound to the membrane, which can adopt α-helical conformation, 
and associates into multimers on the membrane surface. The multimers are the active 
forms that will promote SNARE complex assembly (Figure 1.13) (Burre et al. 2014). 
 
Figure 1.13 Schemating of a physiological folding pathway for aSyn. Native unstructured 
monomeric aSyn binds to synaptic vesicles during docking and priming of the vesicles. As a result of 
membrane binding, aSyn promotes SNARE complex assembly during docking and priming of synaptic 
vesicles. From (Burre et al. 2014) 
 
The loss of dopaminergic neurons in the SN in PD results in a deficiency of 
DA signaling. In this context, it was hypothesized that aSyn could be related with DA 
biosynthesis and metabolism. aSyn inhibits DA synthesis by downregulating tyrosine 
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hydroxylase (TH) (Gao et al. 2007), limiting the conversion of tyrosine conversion to 
L-3,4-dihydroxypheny-lalanine (L-DOPA) (Baptista et al. 2003). This likely occurs 
via reducing TH phosphorylation and activation, which would lead to the activation of 
protein phosphatase 2A (Peng et al. 2005; Liu et al. 2008). Furthermore, aSyn affects 
the vesicular DA transporter VMAT2. aSyn knockout mice showed increased density 
of VMAT2 molecules per vesicle, and altered DA release (Abeliovich et al. 2000).  
Expression of aSyn decreases the rate of DA release without changing DA 
levels or clearance/uptake mediated by dopamine transporter (Figure 1.14) (Yavich et 
al. 2005; Larsen et al. 2006). This shows that aSyn can acts as a negative regulator of 
DA release, by modulating vesicle function upon synaptic stimulation.  
 
 
Figure 1.14 Schematic model of the role of aSyn in regulating presynaptic vesicle cycling. (a) 
When the levels of aSyn are low, the availability of vesicles in the reserve pool decreases and more 
vesicles are become available to be released. This increases dopamine release. (b) Under physiological 
conditions aSyn is regulates the vesicle docking and fusion. (c) Elevated levels of aSyn (or E46K and 
A53T), aSyn reduces dopamine release. From (Venda et al. 2010) 
 
1.4.2.3.4. Prion-like spreading of aSyn pathology 
In the past few years, there was an increase of reports establish an analogy 
between the prion diseases with synucleinopathies, suggesting that aSyn can behave 
in a prion-like manner. The prion protein (PrP) can act both as normal and as 
infectious pathogenic agents, unlike conventional pathogenic organisms (as viruses, 
bacteria, or yeast) (Prusiner 1982). The non-viral pathogens can spread/transmit 
within and between species upon changes in protein conformation: the cellular form 
of PrP (PrPC) is rich in α-helices, and converts into the scrapie isoform (PrPSc) that is 
rich in β-sheet structure). Additionally, PrPSc will act as a template/seed and recruit 
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PrPc into aggregates, by triggering its conversion into PrPSc (Riek et al. 1996; Wille et 
al. 2009). However, in synucleinopathies, the prion-like terminology only indicates 
that aSyn might share some features with prions, albeit without having infectious 
properties.  
According to the “Braak hypothesis”, the topography of Lewy pathology is 
correlated with the extent and severity of PD symptoms. The chronological 
appearance of PD symptoms starts with a pre-symptomatic phase characterized by 
olfactory deficits, sleep disturbances, and constipation (LBs/LN are restricted to the 
peripheral enteric system, olfactory bulb, and the caudal brainstem), followed by the 
motor symptom phase (Lewy pathology appears in SN). The final phase is 
characterized by cognitive decline and psychiatric symptoms (LBs reach the 
neocortex) (Figure 1.15) (Braak et al. 2003). 
 
 
Figure 1.15 Spreading of aSyn. The Braak staging system hypothesizes that PD initiates in the 
olfactory bulb and the medulla oblongata and the dispersion of Lewy pathology into cortical regions 
(Doty 2012). 
 
Furthermore, grafts of embryonic mesencephalic neurons in PD patients were 
found to present LBs years after transplant (Kordower et al. 2008; Kordower et al. 
2008; Brundin et al. 2010), consistently with the proposed Braak hypothesis (Braak et 
al. 2006). The ability of fibrillar aSyn to self-propagate and spread, suggests that cell-
to-cell transmissions plays a role in disease progression (Braak et al. 2003; Angot et 
al. 2010). Intracerebral inoculation of aSyn preformed fibrils (PFFs) initiates a rapidly 
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progressive onset of neurological symptoms and death in A53T aSyn transgenic (tg) 
mice, by enhancing the conversion of endogenous aSyn into LBs (Luk et al. 2012). 
Also, single intrastriatal injection of misfolded aSyn seeds into mice was able to 
initiate a neurodegenerative cascade by the accumulation of intracellular LBs/LN, loss 
of SN DA neurons, and impaired motor coordination. Thus, aSyn is sufficient to 
induce the cardinal behavioral and pathological features of sporadic PD (Luk et al. 
2012). In line with Braak’s hypothesis, a recent study showed that in mice injected 
with aSyn PFFs in the olfactory bulb aSyn was able to spread gradually from the 
injected site to multiple olfactory and non-olfactory brain regions that are affected in 
PD (Rey et al. 2016). Another interesting study showed that intragastrical 
administration of rotenone (an inhibitor of complex I of the mitochondrial respiratory 
chain) induces a progressive accumulation of aSyn in the enteric nervous system, 
arising sequentially to the dorsal motor nucleus of the vagus, the spinal cord and the 
SN in mice (Pan-Montojo et al. 2010). These observations reinforce the idea that PD 
can start in the periphery and progress until it reaches the brain. 
Converging lines of evidence suggest that aSyn is released and taken up by 
neuronal cells. It is present in the cerebrospinal fluid, blood plasma, and saliva, in 
normal and affected patients (El-Agnaf et al. 2003; El-Agnaf et al. 2006; Al-Nimer et 
al. 2014). The mechanism by which aSyn is released is unclear. Thus, a better 
understanding of the mechanisms involved would be important for the potential 
identification of novel biomarkers and targets for therapeutic intervention. aSyn 
transfer has been proposed to occur via direct release, exosomes, endocytosis, and 




Figure 1.16 Proposed mechanisms for aSyn propagation. Several mechanisms have been proposed 
for the transfer of aSyn between neurons and induce disease to other brain regions. Once released to the 
extracellular environment, via exocytic pathway or via exosomes, these species can enter other neurons 
by direct penetration, or by endocytosis. The other two mechanisms possible ways involve a direct 
interaction between the host and the target cell and can occur by the formation of tunneling nanotubes 
or by trans-synaptic transmission. From (Wales et al. 2013) 
 
1.4.2.4. Synphilin-1: an aSyn-interacting protein  
aSyn binds to a number of ligands and proteins, which likely can alter its 
conformation. Sph1 belongs to this list of molecules, and was first identified as an 
aSyn-interacting protein in a yeast two-hybrid screen (Engelender et al. 1999). This 
was also confirmed by fluorescence resonance energy transfer (FRET) studies in 
mammalian cells (Kawamata et al. 2001), where co-expression of a domain of aSyn 
and Sph1 results in the formation of cytoplasmic inclusions that resemble LBs 
(Engelender et al. 1999). As a consequence, it was considered a candidate PD gene 
(since it binds to aSyn, potentiates aSyn aggregation, and is present in LBs). 
However, variability within the Sph1 locus is a rare cause of the disease. No coding 
change in the open reading frame has been found in the gene (Farrer et al. 2001), 
except for a point mutation (substitution of an arginine by a cysteine at position 621- 
R621C) in two sporadic PD patients (Marx et al. 2003). However, this connection has 
not been found in other synucleinopathies (Wakabayashi et al. 2000), and is even less 
consensual in AD (Wakabayashi et al. 2000; Iseki et al. 2002).  
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Sph1 is a protein with 919 amino acids, composed of different domains 
thought to form the basis of its function. It exists predominantly as a 90 kDa protein, 
but can also occur as a 120 kDa isoform.  Smaller fragments of Sph1 are also detected 
in the human brain, and may represent proteolytically processed forms, or alternately 
spliced species (Murray et al. 2003) (Figure 1.17).  
 
Figure 1.17 Schematic representation of the domains of Sph1 and Sph1A. Sph1 and Sph1A are 
structurally different in their exon and have different start codons.  
 
Sph1 is a neuronal protein, enriched in presynaptic nerve terminals (Ribeiro et 
al. 2002). It is present in cerebellar Purkinje, nigral and hippocampal pyramidal 
neurons, in the human brain (Engelender et al. 2000; Ribeiro et al. 2002; Murray et al. 
2003), and is also located within the central core of the LBs (while aSyn is in the 
periphery), and in glial cytoplasmic inclusions (Wakabayashi et al. 2000; Murray et 
al. 2003; Smith et al. 2010). This suggests that Sph1 deposition in LBs is not a 
secondary event, and may participate in their formation. Curiously, Sph1 does not 
seem to be present in LN, which may suggest heterogeneous composition and 
function (Wakabayashi et al. 2000). In terms of homology, human Sph1 sequence is 
86% similar to mouse, but this number increases to 96% if the comparison focuses in 
the central portion of the protein - the ankyrin-like repeats and the coiled-coil domain 
(so-called protein-protein interaction domain) (Kruger 2004) (Figure 1.17).  
Biochemical fractionation studies of human brain tissue revealed that Sph1 is 
predominantly soluble and is present in lipid bound fractions (Murray et al. 2003). At 
the ultrastructural level, Sph1 inclusions are membrane bound, and appear to include 
lipid-derived materials (den Jager 1969; O'Farrell et al. 2001), suggesting that the 
high lipid content facilitates protein incorporation into LBs, since it is known that 

















lipids are present in LBs (Gai et al. 2000), and that aSyn interacts with lipids and can 
associate with vesicular membranes (Davidson et al. 1998; Jensen et al. 1998).  
 
1.5. In vitro studies of aSyn 
Escherichia coli is routinely used to produce recombinant aSyn for in vitro 
studies that have been instrumental for our understanding of the structural properties 
and fibrillization of the protein. In vitro, unfolded monomeric aSyn tends to acquire 
transient structure that is prone to aggregate. After the initial lag phase, monomeric 
aSyn is converted to oligomeric species that then act as nuclei/seeds that rapidly 
assemble into protofilaments and protofibrils. Finally, the process reaches a plateau 
when amyloid fibrils are the majority of the polymers in solution. The kinetic 
properties of aSyn amyloid formation follow a sigmoidal curve and can be monitored 
using thioflavin T binding assay (Figure 1.5C) (Plotegher et al. 2014). 
Several other methods are used to characterize and identify amyloid fibrils. 
These include, but are not limited to, Fourier transform infrared (FTIR) spectroscopy, 
nuclear magnetic resonance (NMR), or transmission electron microscopy (TEM). 
FTIR provides evidence of the secondary structure distribution rather than 
precise structural details. Suspensions of aSyn fibrils display FTIR signal at 1630–
1635 cm−1 (vibrational frequencies of intramolecular parallel β-sheets) (Kaylor et al. 
2005; Qin et al. 2007). However, the resolution of FTIR analysis is low compared to 
NMR, since this powerful tool reports on atomic resolution (Jensen et al. 2014). 
The resolution of TEM resolution is limited not only by the electron 
wavelength but also by the staining procedure. Information regarding aSyn fibril 
length and periodicity can be estimated, but diameter measurements are strongly 
biased by the grains of uranyl acetate salt. Therefore, TEM experiments are typically 
used to qualitatively evaluate aggregate morphology (Heise et al. 2005; Plotegher et 
al. 2014). 
 The capacity to detect and monitor conformational changes in real time is 
essential to understand the relationship between structure and biological function. A 
well-established technique in physics and chemistry, called Second-Harmonic 
generation (SHG), offers a highly sensitive method for studying structure and 
conformational changes upon ligand binding (Salafsky 2006). SHG is a nonlinear 
optical technique in which two photons with equal energy (- the fundamental) 
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generate one photon with twice the energy (2- second harmonic) (Figure 1.18) 
(Salafsky 2006; Moree et al. 2015).  
 
 
Figure 1.18 SHG principal. Conventional phase-matching for SHG (k2ω = 2kω), where the 
fundamental and harmonic waves possess the same index of refraction and co-propagate along the 
same direction. Adapted from (Lan et al. 2015). 
 
When a ligand binds and alters the conformation of a protein, this causes a 
change in the time and space averaged orientation of the second-harmonic-active 
moiety, resulting in alteration of the light intensity. However, for this process to occur 
it is not allowed to use media with inversion symmetry, since it produces SHG 
(Salafsky 2006; Moree et al. 2015). Therefore, this technique can serve as a starting 
point for basic studies on protein folding and conformational change. In addition, 
SHG can also be useful for drug screening at the molecular level. 
 
1.6. Cell-based models of aSyn aggregation 
A big effort has been made over the years to link the in vitro aggregation 
properties of aSyn to its biological and pathological significance. aSyn aggregation is 
one of the hallmarks of synucleinopathies, so the study of this process is crucial to 
understand the pathological mechanisms underlying LBs formation (Figure 1.19). 
Several cellular models have been developed to aid in addressing this question. 
However, unlike many proteins prone to aggregate, aSyn does not readily aggregate 




Figure 1.19 Schematic model of aSyn aggregation. Summary of aSyn aggregation models. (a) 
Schematic model of aSyn aggregation. Propose mechanism of aSyn aggregation. (b) Schematic 
representation of Venus BiFC. This model allows in vivo visualization of aSyn complex. (c) 
Representation of humanized Gaussia luciferase (hGLuc) constructs. Non-bioluminescent halves 
of hGLuc are fused to aSyn. Upon aSyn interaction, luminescence can be measure either inter or 
extracellular.  
 
It is likely that the self-interaction of aSyn into dimers is the primary event 
underlying the formation of higher molecular weight species. The formation of those 
initial species is thought to be the rate-limiting step for aSyn aggregation (Krishnan et 
al. 2003; Roostaee et al. 2013). Therefore, mimicking the initial steps of aSyn 
aggregation in cells is of great interest. One approach to enable the visualization of 
protein dimers in living cells is the Bimolecular Fluorescence Complementation assay 
(BiFC) (Kerppola 2006). This system involves the association of two non-fluorescent 
fragments of a fluorescent protein, reconstituting the functional fluorophore. This 
method allows the direct visualization of protein-protein interactions in the context of 
a living cell, and therefore, their subcellular localization.  
The BiFC assay has been applied for the study of aSyn dimerization by fusing 
each of the fluorescent protein fragments to either to N- and/or C-terminus of aSyn 
(Figure 1.9b). When aSyn interacts, and forms dimers/oligomers, the two non-
fluorescent fragments can assemble, and generate fluorescence. aSyn dimers and 























































increase in cytotoxicity (Outeiro et al. 2008). aSyn dimerization was shown to be 
reversible, for example by the overexpression of Hsp70, that selectively impacts on 
high molecular weight species, and reducing cytotoxicity (Outeiro et al. 2008). 
A similar concept for the assessment of protein-protein interactions is the split 
luciferase assay. The principle is similar to that of the BiFC assay, but in this case the 
luciferase protein is split into N- and C-terminal fragments, that are then fused to the 
protein of interest. In this case, however, the readout is a luminescence, and not 
fluorescence (Figure 1.8c). The split luciferase assay has the advantage that it enables 
a more readily detection of protein dissociation (Remy et al. 2006). 
Another useful cell model in the study of aSyn aggregation consists on the co-
expression of aSyn linked with a truncated, non-fluorescent fragment of EGFP (SynT) 
together with Sph1 (Figure 1.20) (McLean et al. 2001).  
 
Figure 1.20 Schematic representation of the SynT structure. The initial 83 aa of EGFP are fused at 
the C-terminus of aSyn. This construction enables the visualization of aSyn cytoplasmatic inclusions 
that resemble LBs, upon immunostaining. 
 
Using this model, it was shown that alterations in the C-terminus of aSyn 
increase its potential to form intracellular inclusions, as this was not simply due to the 
EGFP fragment used. Fusion of the same 83 aa of EGFP with tubulin or 
synaptophysin did not induce the formation of protein inclusions (McLean et al. 
2001). 
All of these cell models have their limitations, since no cell-based assay is 
able to recapitulate the in vivo physiology of aSyn (Astashkina et al. 2012). However, 
these “living test tubes” facilitate the interpretation of the effect of single 
events/pathways, mutations, or drugs/small compounds, on aSyn aggregation and, 
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2. Aims of the study 
 
Synucleinopathies are a group of neurodegeneration disorders that share a 
common feature of misfolding and aggregation of aSyn. In order to achieve a better 
understanding of the molecular mechanisms underlying the disease, it is crucial to 
conduct systematic analyses of the cellular effects of aSyn. In this context, we decided 
to assess the effects of aSyn aggregation in cellular models of synucleinopathies. To 
achieve this, we focused on the systematic comparison of selected aSyn mutants 
described. 
The main goal of this project was to provide novel insight into the molecular 
determinants of aSyn aggregation in cultured human cells, and to investigate potential 
therapeutic approaches that modulate the process of aSyn aggregation. To this end, 
the specific aims of this thesis were to: 
 
Aim 1. Establish a base knowledge regarding the cellular effects of aSyn  
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Aggregation of alpha-synuclein (ASYN) in Lewy bodies and Lewy neurites is the typical pathological hallmark of Parkinson’s 
disease (PD) and other synucleinopathies. Furthermore, mutations in the gene encoding for ASYN are associated with familial and 
sporadic forms of PD, suggesting this protein plays a central role in the disease. However, the precise contribution of ASYN to 
neuronal dysfunction and death is unclear. There is intense debate about the nature of the toxic species of ASYN and little is 
known about the molecular determinants of oligomerization and aggregation of ASYN in the cell. In order to clarify the effects of 
different mutations on the propensity of ASYN to oligomerize and aggregate, we assembled a panel of 19 ASYN variants and 
compared their behaviour. We found that familial mutants linked to PD (A30P, E46K, H50Q, G51D and A53T) exhibited identical 
propensities to oligomerize in living cells, but had distinct abilities to form inclusions. While the A30P mutant reduced the 
percentage of cells with inclusions, the E46K mutant had the opposite effect. Interestingly, artificial proline mutants designed to 
interfere with the helical structure of the N-terminal domain, showed increased propensity to form oligomeric species rather than 
inclusions. Moreover, lysine substitution mutants increased oligomerization and altered the pattern of aggregation. Altogether, our 
data shed light into the molecular effects of ASYN mutations in a cellular context, and established a common ground for the study 
of genetic and pharmacological modulators of the aggregation process, opening new perspectives for therapeutic intervention in 
PD and other synucleinopathies. 
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Alpha-synuclein (ASYN) is an abundant neuronal protein whose 
normal function is still elusive, but seems to be related to SNARE-
complex assembly [1]. Misfolding and aggregation of ASYN in 
proteinaceous inclusions, known as Lewy bodies (LBs), are associated 
with Parkinson’s disease (PD) and other neurodegen-erative disorders 
known as synucleinopathies [2,3]. PD is the second most common 
neurodegenerative disease, affecting ap-proximately 1% of the population 
over 65 years of age [4], and is therefore a growing problem in the aging 
population. Both point mutations [5,6,7] and multiplications [8,9,10,11] of 
the SNCA gene, encoding for ASYN, have been linked to autosomal-
dominant forms of PD. More recently, GWAS studies identified the 
SNCA locus as a strong risk factor underlying PD [12,13], and
 
 
two additional familial mutations (G51D and H50Q) were recently 
identified [14,15,16]. The H50Q mutation is associated with late-onset 
parkinsonism, and the patients exhibit similar pathological features to 
those observed for patients carrying E46K or A53T mutations [17]. The 
G51D mutation is associated with early onset of disease [15].  
Over the years, numerous in vitro and in vivo studies confirmed the 
toxic potential of both wild type (WT) and PD-linked ASYN mutants 
[18,19]. In vitro, these ASYN mutations alter the aggregation process and 
interfere with oligomerization, fibril formation, and subcellular 
distribution [20,21,22]. Upon overex-pression, ASYN induces 
aggregation and cytotoxicity [23], disrupts vesicular transport [24,25], 
causes mitochondrial deficits, impairs autophagy [26], increases 
sensitivity to oxidative stress [27], impairs vesicle recycling, neuronal 
plasticity and synaptic 
 








The accumulation of aggregated proteins in the brain is 
common across several neurodegenerative disorders. In 
Parkinson’s disease (PD), the protein alpha-synuclein 
(ASYN) is the major component of aggregates known as 
Lewy bodies. It is currently unclear whether protein 
aggregates are protective or detrimental for neuronal 
function and survival. The present hypothesis is that 
smaller aggregated species, known as oligomers, might 
constitute the toxic forms of ASYN. Several mutations in 
ASYN cause familial forms of PD. In the laboratory, 
artificial mutations have been designed to enable the 
study of the aggregation process. However, different 
studies relied on the use of different model systems, 
compromising the interpretation of the effects of the 
mutations. Here, we addressed this by (i) assembling a 
panel of 19 ASYN variants and (ii) by performing a 
systematic comparison of the effects of the mutations in 
mammalian cell models. Interestingly, our study enabled 
us to correlate oligomerization and aggregation of ASYN 
in cells. Altogether, our data shed light into the molecular 
determinants of ASYN aggregation, opening novel ave-
nues for the identification of modulators of ASYN 
aggregation, which conceal great hopes towards the 
development of strategies for therapeutic intervention in 
PD and other synucleinopathies. 
 
 
integrity [28] as well as the folding/refolding of SNARE proteins [29]. 
Several animal models have also been generated based on the 
overexpression of either wild type or mutant ASYN, but the phenotypes 
reported are quite diverse [30,31,32]. 
 
Posttranslational modifications (PTM) in the context of PD are also 
controversial. The majority of ASYN in LBs isolated from PD patients is 
phosphorylated at serine-129 (S129) but whether this is a cause or a 
consequence of aggregation is unclear [33,34,35]. Other ASYN residues 
like serine-87 (S87) and tyrosines-125, -133 and -136 (Y125, Y133 and 
Y136) can be also phosphorylated [36]. SUMOylation, another type of 
PTM that modulates protein-protein interactions, affects subcellular 
localization, stability and solubility of target proteins [37,38]. Engineered 
mutants of ASYN to prevent SUMOylation enhanced the tendency to 
aggregate in cell-based assays and increase cytotoxicity in dopaminergic 
neurons of the substantia nigra (SN), in vivo [38]. 
 
Although aggregation of ASYN is recognized as a central process in 
synucleinopathies, it is still unclear whether inclusions are toxic or 
protective [39]. Actually, accumulating evidence suggests ASYN 
oligomers may constitute the toxic species, rather 
Effects of ASYN Mutations in Cells Models 
 
 
than mature aggregates [40,41]. To overcome these limitations, 
engineered mutation is a simple way to understand the putative effects 
impact of determine residues in the context of PD. Several artificial 
proline mutants of ASYN (A56P, A30P/A76P double mutant, and 
A30P/A56P/A76P triple mutant (TP) display impaired propensity to 
fibrilize [40]. A similar effect was reported for mutants disrupting the 
formation of salt bridges between b-strands of ASYN (E35K and E57K) 
[41], which increases the formation of oligomers when compared with 
WT ASYN. 
 
Nevertheless, conflicting results obtained in different cell and animal 
models, and the limited existence of systematic studies comparing the 
behaviour of WT and ASYN mutants in the same model systems, 
complicate our understanding of the molecular determinants of ASYN 
aggregation and toxicity. Here, we conducted a systematic comparison of 
the effects of PD-linked and engineered ASYN mutants in two established 
cell-based models of ASYN oligomerization [42] and aggregation [43]. 
Our findings establish the effects of the different mutants studied and pave 
the way for the identification of genetic and pharmacological modulators 
of the various processes studied, opening new perspectives for the design 





Design and generation of ASYN mutants 
 
To investigate the molecular determinants of ASYN oligomer-ization 
and aggregation in a cellular context, we used site-directed mutagenesis to 
generate a panel of 19 ASYN point mutants including five mutations 
associated with familial PD (A30P, E46K, H50Q, G51D and A53T) and 
others known to interfere with different aspects of ASYN biology (Fig. 1 
and Table S1). Then, we analysed the behaviour of each mutant in 
established paradigms of ASYN oligomerization (Fig. 2A) or aggregation 
(Fig. 3A). 
 
Effect of mutations on ASYN oligomerization 
 
In order to assess the effect of ASYN mutations on oligomer-ization, 
we used a variant of the Bimolecular Fluorescence Complementation 
(BiFC) assay we previously described [42], based on the reconstitution of 
functional Venus fluorescent protein promoted by the interaction between, 
at least, two ASYN molecules, that enables us to directly visualize the 
formation of ASYN dimeric/oligomeric species (hereforth referred to as 
oligomeric species for simplicity) in living cells (Fig. 2A) [42]. We have 
previously demonstrated that the efficiency of the ASYN BiFC assay is 
identical in different cell lines, including HEK cells [42]. Using 
epifluorescence microscopy we found that, as expected, all the ASYN 














Figure 1. Human ASYN. Scheme representing the structure of human ASYN with the three distinct domains (N-terminal, NAC and C-
terminal). Amino acid residues are indicated in the bottom. Brown bars inside protein domains represent the imperfect hexameric KTKEGV 
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Figure 2. Mutations effect on ASYN oligomerization. A. Schematic representation of Bimolecular Fluorescence Complementation assay (BiFC). ASYN BiFC 
constructs in anti-parallel orientation. B. Representative pictures of ASYN oligomerization. HEK-293 cells overexpressing VN-ASYN and ASYN-VC constructs. 
The green fluorescence results from the reconstitution of the Venus fluorophore, promoted by the interaction of the proteins of interest. Scale bar: 10 mm. C. 
Oligomerization efficiency. Mean fluorescence intensity of cells expressing different ASYN mutants was assessed 24 hours post-transfection, using a 
microcapillary system (GuavaeasyCyte HT system). For each sample 25,000 events were counted. D. Intracellular distribution of oligomeric ASYN. Nuclear and 
cytoplasmic venus fluorescence intensities in HEK-293 cells were quantified using ImageJ. The graph demonstrates an increase in nuclear fluorescence in cells 
expressing ASYN mutants. For each experiment.25 cells were analysed. E-F. Levels of ASYN. E. Representative immunoblot showing the expression levels of 
ASYN. F. Immunoblot analysis of the expression levels of VN-ASYN and ASYN-VC from all the mutations studied in HEK-293 cells. Student’s t test (*p,0.05, 
**p,0.01, ***p,0.001). n = 3. doi:10.1371/journal.pgen.1004741.g002 
 
 
(Fig. 2B and C). One striking observation was that the PD-linked mutant 
A53T promoted the strongest increase (,50%) in the accumulation of 
ASYN oligomers in the nucleus (Figure 2B and D). 
 
To compare the extent to which different ASYN variants promoted 
oligomerization we used flow cytometry to measure the fluorescence 
intensities of cells expressing the different mutants. We observed an 
increase in fluorescence intensity for proline and lysine mutants. This 
increase was around 16.3% for A56P mutant, and 16.5% for the TP 
mutant (Fig. 2C). In the case of A30P/A76P double mutant (DP) and 
single A76P mutant we observed a trend towards an increase in 
fluorescence intensity, but the increase was not statistically significant. 
Likewise, we found a 28.4% increase in oligomerization for the E35K 
mutant, and 28.1% for the E57K mutant. In contrast, we found that the 
S87E mutant, mimicking phosphorylation at S87, reduced oligomerization 
by,16%. To investigate whether these effects were explained by 
differences in the levels of ASYN, we performed immunoblot analysis. 
We found that the levels of VN-ASYN decreased for almost all mutants 
(statistically significant for G51D, S129D and S87A) and increased for 
H50Q, A30P/A76P and K96R/K102R (Fig. 2E, F). Interest-ingly, there 
was no correlation between the levels of the mutants and the fluorescence 
signal, suggesting the effects observed were intimately correlated with the 
effects of the mutations on oligomerization, and not due to differences in 
the levels of expression of the various ASYN mutants. 
 
Effect of mutations on ASYN aggregation 
 
In parallel, we asked whether the selected mutations altered ASYN 
inclusion formation. For this, we took advantage of an established 
paradigm of ASYN aggregation based on the co-expression of SynT and 
synphilin-1, an ASYN-interacting protein that is also present in LBs (Fig. 
3A) [43]. As previously established, human neuroglioma cells (H4) were 
co-transfected with plasmids encoding each of the SynT variants and 
synphilin-1 and inclusion formation was assessed 48 hours post-
transfection. Since the inclusion pattern was heterogeneous, we defined 
four categories (cells without inclusions, with ,5 inclusions, with more 
than 5 and less than 9 inclusions, or $10 inclusions) in order to obtain a 
more precise assessment of the effects of the mutations. For the PD-linked 
mutants, we found that A30P increased the percentage of cells without 
inclusions to ,70% when compared to WT ASYN. In contrast, the E46K 
and G51D mutations dramatically increased the percentage of cells with 
inclusions to ,90% and ,80%, respectively (Fig. 3B, C and Fig. S1). 
 
In the case of the proline mutants, we observed that all four mutants 
reduced the percentage of cells displaying inclusions (Fig. 3B, C and Fig. 
S1). 
 
For the E35K and E57K mutants, the number and the size of the 
inclusions varied. Both mutants promoted an increase to ,70– 80% of cells 
with inclusions (Fig. 3B, C and Fig. S1). While we predominantly 
observed the presence of small inclusions with the E57K mutant, we 




We also investigated the effect of phosphorylation on ASYN inclusion 
formation. For this, we screened mutants that block (S87A, Y125F, 
S129A and S129G) or mimic (S87E, Y125D and S129D) 
phosphorylation. We found that mimicking phosphoryla-tion on S87 
resulted in a marked decrease in the number of inclusions per cell, with 
,80% of the transfected cells displaying no inclusions (p,0.01 Fig. 3C, Fig. 
S1A). No significant effect was observed with the S87A mutant, 
suggesting the S87 may normally exist, at least in our cell model, mostly 
unphosphorylated. Also, no significant differences were observed for 
Y125D, S129A, S129G, or S129D mutants, when compared to WT SynT. 
However, we found the Y125F mutation and SUMOylation-deficient 
mutant (K96R/K102R) mutation induced an altered inclusion pattern, with 
the accumulation of inclusions of different sizes, similar to that observed 
with the lysine mutant. 
 
Immunoblot analysis showed that the levels of ASYN varied depending 
on the particular mutant being expressed, but we only found a significant 
increase in the levels of the S129G mutant (Fig. 3D and E). Interestingly, 
we found a trend towards a decrease in the levels of mutants that 
promoted accumulation of inclusions or changed the size of the inclusions 
(E46K, E57K and K96R/K102R). 
 
Based on the results obtained in the oligomerization and aggregation 
paradigms, we decided to focus on seven ASYN mutations (A30P, E46K, 
A53T, E35K, E57K, TP and Y125F) that had the most pronounced effects 
for subsequent analysis (Table S2 and Fig. 4). We examined these 
selected ASYN mutants using different assays, including toxicity 
measurements, biochem-ical analysis of ASYN, ASYN secretion, 
degradation pathways, and Golgi and ER stress (Fig. 4), in order to obtain 
detailed information on the cellular effects of specific types of ASYN 
accumulations. 
 
ASYN toxicity and aggregation in yeast 
 
We started by investigating the toxicity of the selected variants of 
ASYN by taking advantage of the budding yeast as a model of 
synucleinopathies, as previously described [23,44]. In conditions where 
the expression of ASYN was induced, using galactose-containing media, 
we found that almost all mutations induced toxicity similar to WT ASYN 
(Fig. 5A). In line with the observation in H4 cells, the TP mutant did not 
form inclusions and the A30P mutant strongly impaired inclusion 
formation (Fig. 3B-C and 5B-C). Neither of these mutants was toxic in 
yeast (Fig. 5A) [23,44]. Importantly, we found no significant differences 
in the levels of expression of all variants tested, ruling out the possibility 
that toxicity and/or inclusion formation were due to differences in the 
levels of expression of ASYN (Fig. 5D). 
 
Characterization of ASYN species 
 
To further assess the biochemical nature of the ASYN species 
visualized by the BiFC assay, we employed non-denaturing 
polyacrylamide gel electrophoresis (native-PAGE). Immunoblot analysis 
showed a smear, which is indicative of the accumulation of oligomeric 
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Figure 3. ASYN mutation effects in the inclusion formation. A. Constructs used in the aggregation model. This model consists of co-
expressing SynT together with synphilin-1. B. Inclusion pattern in H4 cells. Different SynT mutants resulted in the formation of distinct 
inclusion formation in human H4 cells. Scale bar: 10 mm. C. Inclusion quantification..50 cells were scored per experiment and classified in 
different groups according to the pattern of inclusions. Representative cells were drawn to show type of inclusions present in each 
categories. Lysine mutants (E35K, E57K) increase the percentage of cells with inclusions and the number of inclusions per cell, whereas 
A30P and proline mutants reduce percentage of cells with inclusions and also the number of inclusions per cell. D-E. Levels of ASYN. 
Immunoblot analysis of the expression levels of ASYN. Student’s t test (*p,0.05, **p,0.01, ***p,0.001). n = 3. 
doi:10.1371/journal.pgen.1004741.g003 
 
In order to characterize the structure of the ASYN inclusions formed in 
H4 cells, we used stimulated emission depletion (STED) super resolution 
microscopy (Fig. 6B). STED provided unprecedented access to the fine 
structure of the ASYN inclusions in the cytoplasm. We focused on 
selected mutants that displayed extreme patterns of aggregation (Fig. 3) 
and found that both smaller and larger inclusions are highly compact. For 
the TP mutant, only diffuse signal was detected, confirming the inability 
of this mutant to accumulate in inclusions that can be resolved by light 
microscopy techniques (Fig.6B). 
 
It is widely established that LBs are primarily composed of amyloid 
filaments of ASYN [2]. To determine whether the inclusions formed by 
the different ASYN mutants were composed of amyloid-like fibrils, we 
used thioflavin S (thioS), a dye that binds specifically to amyloid-like 
structures [26,45]. We verified that large inclusions formed by WT or 
mutant ASYN stained positive for thioS, whereas small inclusions did not 
(Fig. 6C). Also, thioS stained the inner part of the inclusions (marked with 
arrow head) (Fig. 6C), suggesting the accumulation of mature amyloid-
like structures in the inner part of the inclusions. To further characterize 
these different types of ASYN aggregates, we assessed the detergent 
solubility of the inclusions formed by the selected ASYN mutants. 
Interestingly, we observed that TP and E57K accumulated a smaller 
fraction of Triton X-100 insoluble ASYN species (Fig. 6D and E). 
 
Intra- and extracellular partitioning of ASYN oligomers 
 
To assess the effect of the selected mutations on the distribution of 
ASYN oligomers inside and outside cells, we used a previously described 
bioluminescent protein complementation assay (bPCA) that enables the 
detection of oligomeric species with great sensitivity [46]. In this assay, 
reconstitution of Gaussia princeps luciferase activity upon ASYN 
oligomerization was used as a readout [47] (Fig. 7A). Consistent with the 
results obtained with the Venus-based BiFC assay (Fig. 2A), we detected 
reconstitution of luciferase activity with all mutants tested. However, we 
observed a strong increase in intracellular (Fig. 7B) and extracellular (Fig. 
7C) luciferase activity with the TP and Y125F ASYN mutants when 
compared to WT ASYN. This indicates that not only these mutations are 
able to promote increased formation of oligomers inside cells, but also in 
the extracellular space. 
 
To determine if these mutants also promoted the release of oligomeric 
species we calculated the ratio of luciferase activity in the media 
compared to that in cells. Interestingly, we found that familiar mutants 
A30P and A53T showed an increased ratio of luciferase activity outside 
versus inside cells suggesting that these mutants also promote the 
secretion of ASYN oligomers (Fig. 7D). We confirmed these differences 
were not simply due to the accumulation of increased levels of mutant 






































PLOS Genetics | www.plosgenetics.org 6 November 2014 | Volume 10 | Issue 11 | e1004741 
 
  
































Figure 5. High-copy expression of a-synuclein-GFP variants in yeast. A. Yeast cells expressing GAL1-driven ASYN-GFP variants from 2 m 
plasmids were spotted in 10-fold dilutions on selection plates containing 2% glucose (control) or 2% galactose. After incubation for 3 days at 
30uC the plates were photographed. Expression of GFP from the same promoter was used as a control. B. Live-cell fluorescence 
microscopy of yeast cells expressing ASYN-GFP. Yeast cells, pre-grown to mid-log phase, were induced in galactose-containing medium 
and examined for aggregates at 6 hours of induction. GFP-expressing cells were used as control. Scale bar: 1 mM. C. Aggregate 
quantification of yeast cells, expressing ASYN-GFP. For each strain, the number of cells displaying cytoplasmic foci is presented as percent 
of the total number of cells counted. For quantification of aggregation at least 300 cells were counted per strain and per experiment. GFP-
expressing cells were used as a control. Student’s t test (*p,0.05, **p,0.01, ***p,0.001). D. Protein levels of ASYN-GFP variants. Expression 
of ASYN-GFP variants was induced for 6 hours in galactose-containing medium. Equal amounts of crude protein extracts were used for 
Western analysis with anti-ASYN antibody and anti-cdc28 antibody as a loading control. n = 2. 
doi:10.1371/journal.pgen.1004741.g005 
 
ASYN secretion is inversely correlated with toxicity 
 
ASYN is a cytosolic protein, but recent studies detected both 
monomeric and oligomeric forms of ASYN in human cerebrospi-nal fluid 
and plasma at low nanomolar concentrations, in both PD and control 
individuals [48,49]. 
 
To complement the observations with the bioluminescence 
complementation assay, we asked whether the selected ASYN mutants 
were differentially released from cells using the aggrega-tion paradigm 
described above (Fig. 3A). In this case, we measured the levels of ASYN 
in the culture medium using a highly sensitive electrochemiluminescence-
based immunoassay [50]. We detected extracellular ASYN with all 
variants tested (Fig 8A). 
 
Next, to demonstrate that the release of ASYN was not caused by 
membrane leakage from unhealthy or dying cells, we performed LDH 
toxicity measurements in the same media. In fact, in the aggregation 
paradigm, we observed an inverse correlation between ASYN release and 
cytotoxicity, where the TP and Y125F mutants appeared as the most toxic 
forms (Fig. 8B and C). 
 
Effect of ASYN mutants on lysosomal degradation 
 
Knowing that ASYN is predominantly degraded by lysosomal 
pathways and, therefore, requires intact lysosomal function, we used 
lysosomal associated membrane protein 1 (LAMP-1) as a
 
marker to establish the relationship with aggregation formation. We 
observed that LAMP-1 partially co-localized with ASYN inclusions (Fig. 
9A), suggesting that at least some types of inclusions might be degraded 
in lysosomes. Interestingly, we observed that some inclusions formed by 
two of the mutations that primarily accumulated thioS-negative inclusions 
(E57K and Y125F, Fig. 6B) stained positive for LAMP-1 at the periphery 
(Fig. 9B), reinforcing the idea that specific types of ASYN inclusions are 
degraded in lysosomes. 
 
Golgi fragmentation and ER stress 
 
Given that fragmentation of Golgi apparatus (GA) has been described 
in several neurodegenerative diseases [51,52,53], we next investigated the 
cellular consequences of the accumulation of ASYN oligomers or 
inclusions on this organelle. For this, we examined the morphological 
integrity of the GA using fluores-cence microscopy of cells 
immunostained for Giantin, an endogenous transmembrane protein of the 
cis and medial Golgi complex (Fig. 10). We defined three types of Golgi 
structures (non-fragmented, diffuse and fragmented). In general, we 
observed that in the ASYN oligomerization model there was an increased 
percentage of cells displaying fragmented Golgi, in comparison to what 
was observed in the aggregation model (Fig.10 A-B and Fig. S2). In 
particular, we found a statistically significant increase in the percentage of 
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Figure 6. ASYN biochemical state. A. Native Gels. Immunoblot analysis of native PAGE of cells transfected with the BiFC constructs in HEK 
293 cells. Smears indicate the presence of oligomeric species of ASYN with different sizes. n = 2. B. STED microscopy. Selected mutants 
were imaged in order to characterize the fine structure of the inclusions. C. Thioflavin S staining. H4 cells expressing selected SynT mutants 
were incubated with ThioS in order to reveal beta sheet-rich structures. Some of the inclusions display amyloid-like properties, with 
increased staining in the inner part of the inclusions, indicated with arrow heads (c). Scale bar: 10 mm. D-E. Triton X-100 solubility assay 
and quantification. H4 cells show that all mutants form detergent insoluble species. Student’s t test (*p,0.05, **p,0.01, ***p,0.001). n = 2. 
Quantification of insoluble fraction shows a decrease in TP and E57K mutants. 
doi:10.1371/journal.pgen.1004741.g006 
 
E35K and E57K mutants (Fig. 10A and Fig. S2A). In the ASYN 
aggregation paradigm, the GA displayed normal compact morphology 
near the nucleus (Fig. 10B and Fig. S2B). 
 
Recent studies showed that endoplasmic reticulum (ER) stress, together 
with deficient protein degradation, plays a crucial role in the death of 
dopaminergic cells [54]. Under ER stress conditions, BiP is upregulated 
and preferentially binds to misfolded proteins in the ER [55]. We 
observed that oligomeric forms of ASYN promoted an increase in the 
levels of BiP (E46K and A53T mutants)(Fig.10C and D) whereas no 
differences were detected in the aggregation paradigm (Fig.10 E). 
 
Taken together, these results suggest oligomeric forms of ASYN are 
more capable of promoting Golgi fragmentation and ER stress than 
aggregated forms. 
 
Effect of mutations on ASYN phosphorylation 
 
Accumulating evidence implicates phosphorylation on ASYN 
aggregation and toxicity [56]. However, it is unclear whether mutations in 
ASYN affect the typical pattern of phosphorylation. Using the 
oligomerization assay, we investigated whether ASYN was differentially 
phosphorylated on S129 (Fig. S3). Interestingly, we detected a significant 
increase in S129 phosphorylation in the E35K mutant, and only a trend 
towards an increase for the familial mutants and E57K (Fig. S3). The 
results shows that phosphorylation of ASYN on S129 is altered in the 





Given the central role of ASYN in PD and other synucleino-pathies, 
and the uncertainty about the precise molecular mechanisms leading to 
neurodegeneration, we sought to take advantage of various cellular 
systems in order to systematically compare a set of ASYN mutants 
according to their effects on different cell functions. 
 
Our systematic analysis enabled us to directly compare the effects of 
the selected mutations in terms of oligomerization and aggregation (Fig. 
11). We observed that all 19 mutations tested enabled the formation of 
ASYN oligomers, as assessed by the BiFC system and biochemical 
methods. Interestingly, we found the different mutants resulted in the 
accumulation of different types of inclusions. 
 
While we did not detect significant differences in the oligomer-ization 
induced by familial PD mutations, the A30P mutant displayed a reduced 
propensity to form inclusions, in contrast to the E46K and G51D mutants, 
which enhanced inclusion formation when compared with WT ASYN. 
The fact that we observed a decrease in the number of inclusions with the 
A30P might be related to the long-range contacts between the N and C-
termini, shielding the central domain, which is known to promote 
aggregation, and reducing the formation of the same types of inclusions 
observed with WT or other mutants. On the other hand, the robust 
increase of inclusion formation observed with the E46K mutant might be 
due to the location of the mutation within the KTKEGV repeats that are 
involved in alpha-helix formation [57]. The charge difference introduced 
by the mutation could 
 
enhance the destabilization of the protein structure, leading to an 
increased propensity to aggregate, as reported previously [57]. Recent 
studies showed that the G51D mutation attenuates aSyn aggregation in 
vitro [58,59]. However, we observed a different trend in our cell models, 
where G51D increased the number of aSyn inclusions per cell, as 
observed with the E46K mutant. This might be explained by differences 
in the cellular environment in the different models, but might also be due 
to the presence of synphilin-1 in the particular model we used for aSyn 
aggregation. The same might apply to the H50Q mutant since, in contrast 
to other studies, we did not observe any difference in comparison to WT 
aSyn [59]. For the A53T mutant we found increased presence of 
oligomeric species in the nucleus, but no differences in terms of the 
aggregation pattern. Thus, additional studies on the effect of ASYN in the 
nucleus will be important. 
 
The use of engineered mutants enables the exploration of the structural 
determinants of ASYN physiology in the cell. Artificial proline mutations 
were designed to impair fibrillization in vitro and promote the formation 
of soluble oligomers [40]. Indeed, in our cell models, the proline mutants 
resulted in increased oligomerization (Fig. 2B and C) and lowered the 
propensity to form inclusions. In particular, the TP mutant increased 
oligomer-ization as assessed by BiFC and bPCA, and reduced inclusion 
formation. These observations were also confirmed in yeast cells, where 
the A30P formed fewer inclusions, and the TP mutant completely blocked 
inclusion formation. However, in contrast to what was observed in 
primary neurons, worms, and in flies [40], the proline mutants failed to 
promote increased cytotoxicity in yeast cells. One possibility is that yeast 
process the species formed by the proline mutants in a distinct manner, 
explaining the lower levels of toxicity. 
 
The lysine mutants (E35K and E57K) were designed to disrupt salt 
bridges between the b-strands of ASYN and to interfere with its binding 
to lipid membranes [41]. We found both mutants increased ASYN 
oligomerization and promoted distinct inclusion patterns. The lack of 
thioS staining suggests the inclusions may represent either off-pathway or 
immature species that cannot proceed towards the formation of mature 
amyloid-like inclusions. Interestingly, in cells where we could detect 
inclusions formed by the E57K mutant, these appeared surrounded by 
LAMP1, suggesting they were targeted to lysosomal degradation. 
 
Post-translational modifications (PTMs) are important modula-tors of 
the structural and functional properties of proteins in health and 
pathological conditions. Several lines of evidence suggest that 
phosphorylation of ASYN may play an important role in regulating its 
aggregation, fibrillogenesis, Lewy body formation, and neurotoxicity in 
vivo. In addition, it appears that, in vivo, less than 5% of ASYN is 
normally phosphorylated [60] and that this occurs predominantly in the C-
terminus (S129 and Y125) but also in the NAC domain (S87). However, 
there is still no consensus on the effects of phosphorylation due to existing 
contradictory results [56,61,62,63]. S87 is located in the NAC region, 
which is crucial for ASYN aggregation and fibrillogenesis [64] and is also 
the region involved in interactions with other proteins [62]. Our study 
supports the importance the NAC domain in the formation of ASYN 
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Figure 7. ASYN bPCA. A. Schematic representation of the ASYN bPCA constructs. Non-bioluminescent halves of humanized Gaussia 
luciferase (hGLuc) were fused to ASYN monomers. B-C. Intact cells (intracellular) and medium (extracellular) from H4 cells co-transfected 
with S1 and S2 were assayed for luciferase activity 48 hours post-transfection. Intracellular (B) and extracellular (C) TP displayed a 3-fold 
increase in luciferase activity compared to WT. n = 12. Student’s t test (*p,0.05, **p,0.01, ***p,0.001) D. Ratio of luciferase activity in media 
compared to cells was expressed. n = 12, Student’s t test (*p,0.05, **p,0.01, ***p,0.001) E-F. Levels of ASYN. Immunoblot analysis of the 
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Figure 8. ASYN secretion is inversely correlated with toxicity. A. Secretion of ASYN. B. Toxicity measurements. Medium from H4 cells were 
collected to determine the secretion and the percentage cytotoxicity for each mutant. To measure the release of ASYN, an ELISA assay 
was performed. Using the same media we also measured the release of lactate dehydrogenase as a measure of cytotoxicity. We observed 
that these values were inversely correlated with those obtained in the release/secretion experiments. A decrease trend particularly for TP 
and Y125F detected in terms of secretion, was higher in toxicity. n = 3. C. Correlation between Secretion and Toxicity. The graph shows the 
inverse trend in secretion and toxicity. 
doi:10.1371/journal.pgen.1004741.g008 
 
different effects than those observed with the S87A mutant (Fig. 3B and 
C). This is in line with in vitro experiments where the S87E mutant 
inhibits ASYN aggregation [62]. Again, this effect on the formation of 
cytoplasmic inclusions might be attributed to changes in the conformation 
when binding to membranes, as other studies suggested [63]. Moreover, a 
recent study showed that S87E ASYN reduces aggregation and is less 
toxic [62]. 
 
Detecting significant levels of Y125-P in ASYN in human brain tissues 
has proven difficult [65]. Our results indicate, in the context of living 
cells, Y125-P ASYN exhibits similar aggregation properties to WT 
ASYN, in accordance with what was observed in other systems [65]. We 
also observed the accumulation of small inclusions for the Y125F mutant 
that were similar to those formed by the lysine mutants. 
 
Recently, it was shown that when SUMO acceptor sites in ASYN 
(K96R/K102R) are modified, SUMOylation is strongly impaired, leading 
to increased inclusion formation and toxicity [38]. In our study, we 
observed only a 10% increase in the percentage of cells displaying 
inclusions and, interestingly, we observed the accumu-lation of smaller 
inclusions. These small inclusions promoted by several mutants tested 
(E35K, E57K, Y125F and SUMOylation mutants, Fig.3B) might 
represent intermediate species in the aggregation process of ASYN that 
fail to mature and may, therefore, lead to proteasomal impairment. To 
gain insight into the cellular consequences of different types of ASYN 
accumulations, we selected representative mutations for additional 
studies. 
 
ASYN overexpression and/or aggregation can affect the secretory 
pathway. One of the consequences observed is the
 
disruption of the Golgi and impairment ER-to-Golgi trafficking. 
Fragmentation of this organelle has been reported in neurode-generative 
disorders [51,52], including PD [53], and it was shown that it occurs in 
the cells accumulating prefibrillar ASYN aggregates [66]. Indeed, we 
observed the same trend in our study, where increased Golgi 
fragmentation was observed in the oligomerization model, particularly 
with E35K and E57K ASYN. Furthermore, we observed increased levels 
of BiP with familial mutants of ASYN in the oligomerization model. This 
was not detected in the aggregation model, further supporting the concept 
that oligomers are detrimental and disturb proteostasis by affecting the 
normal intracellular trafficking. 
 
Autophagy is a catabolic process that is involved in the control of 
cellular damage in response to genetic perturbations, aging, and/or 
environmental toxins. Our study also underscores the interplay between 
ASYN inclusion formation and autophagy since we found the lysosomal 
marker LAMP-1 surrounding and concealing mature inclusions, as judged 
by thioS staining (Fig. 9B). Again, this reinforces the idea that aggregates 
per se might not be directly harmful to cells but, instead, might constitute 
an effort for cells to remove abnormal proteins from the cytoplasm. 
 
Altogether, the systematic assessment of the effects of different ASYN 
mutations on its oligomerization and aggregation in cellular models 
allowed us to address, for the first time, the effect of the selected 
mutations on a panel of readouts that reflect important aspects of the 
biology/pathobiology of the protein. While additional studies using 
alternative models will be important to further dissect 
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Figure 9. ASYN partially co-localizes with endosomes/lysosomes. A. Immunocytochemistry analysis of H4 cells expressing selected ASYN 
mutants. Partial co-localization of ASYN and LAMP1 suggests interplay between lysosomal degradation and ASYN inclusion formation. B. 
E57K and Y125F inclusions co-localize with lysosomal marker LAMP-1. We detected the presence of endosomes/lysosomes surrounding 
the aggregates in E57K and Y125F. This indicates that, maybe this could be the preferential via for degradation for these mutations. Scale 
bar: 10 mm. doi:10.1371/journal.pgen.1004741.g009 
 
 
the effects of mutations, our study establishes the foundation for testing 
hypotheses that may open novel opportunities for the development of 
therapeutic strategies for synucleinopathies. 
 




The primers were designed according to the manufacturer’s 
instructions using the QuickChange Primer Design Program and the web-
based program Primer X (Table S1). 
 
Generation of the mutant ASYN constructs 
 
Site-directed mutagenesis using QuickChange II Site-Directed 
Mutagenesis Kit (Agilent Technologies, SC, USA) was performed 
following the manufacturer’s instructions. Mutagenesis were performed in 
the plasmids encoding the ASYN-Venus BiFC 
 
 
system [42] or SynT [43] and confirmed by DNA sequencing. Also, 
fusion constructs ASYN-hGLuc1 (S1) and ASYN-hGLuc2 (S2) were 
generated as described previously [42]. 
 
Yeast plasmids expressing GFP (pME3759), human wild-type ASYN-
GFP (pME3763), A30P-GFP (pME3764), A53T-GFP (pME3765) and 
TP-GFP (pME3942) from galactose-inducible promoter (GAL1) were 
described previously [67]. Plasmids harboring E46K-GFP (pME4085), 
E35K-GFP (pME4086), E57K-GFP (pME4087) and Y125F-GFP 
(pME4088) were gener-ated by site-directed mutagenesis using the same 
primers as above. Plasmid pME3763 was used as a template for 




Human neuroglioma cells (H4) were maintained in Opti-MEM I 
Reduced Serum Medium (Life Technologies- Gibco, Carlsbad, 
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Figure 10. A-B morphology analysis of Golgi apparatus. The morphology of the Golgi apparatus in.50 cells was analysed and quantified. We 
observed that, in the BiFC assay, E35K and E57K mutants displayed increased Golgi fragmentation (A). In the aggregation model, Golgi 
morphology appeared normal, displaying a compact appearance near the nucleus (B). Levels of BiP in the oligomerization assay (C) and in 




CA, USA) and Human Embryonic Kidney 293 (HEK) cells were grown in 
Dulbecco’s Modified Eagle Medium (DMEM, Life Technologies- 
Invitrogen, Carlsbad, CA, USA). Both media were supplemented with 
10% Fetal Bovine Serum Gold (FBS) (PAA, Co¨lbe, Germany) and 1% 
Penicillin-Streptomycin (PAN, Aiden-bach, Germany). The cells were 




HEK cells. The cells were plated in 24-well plates (Costar, Corning, 
New York, USA) the day before. Thirty minutes before the transfection 
the cells were incubated in Opti-MEM (Life Technologies-Invitrogen, 
Carlsbad, CA, USA) and subsequently transfected with equimolar 
amounts of the plasmids using Metafectene (Biotex, Munich, Germany) 
according to the manufacturer’s instructions. Five hours after transfection, 
the medium was replaced. Twenty-four hours after transfection the cells 
were collected or stained for further analysis. 
 
H4 cells. Twenty-four hours prior to transfection, the cells were plated 
in 35 cm dish (Ibidi, Munich, Germany) or in 12-well plates (Costar, 
Corning, New York, USA). Equal amount of the plasmids encoding 
ASYN and synphilin-1 were transfected using FuGENE6 Transfection 
Reagent (Promega, Madison, USA) in a ration of 1:3 according to the 
manufacturer’s instructions. Forty-eight hours after the transfection, the 
media were collected and frozen for further experiments. Additional, cells 
were subjected to immunocytochemistry, for studying ASYN inclusions. 
 
Gaussia luciferase protein-fragment complementation 
assay 
 
For the bioluminescence complementation assay with ASYN-hGLuc1 
(S1) and ASYN-hGLuc2 (S2) constructs, the cells were transfected as 
described above and conditioned media was collected 48 hours post-
transfection and centrifuged for 5 minutes at 3000 g to eliminate floating 
cells before being used. 
 
Forty-eight hours after transfection, culture media was trans-ferred to a 
new 96 well plate (Costar, Corning, NY, USA). Cells were washed with 
PBS and replaced with serum- and phenol-red free media. Luciferase 
activity from protein complementation was measured for conditioned 
media and live cells in an automated plate reader at 480 nm with a signal 
integration time of 2 seconds following the injection of the cell permeable 
substrate, Coelenter-azine (20 mM) (PJK, Kleinblittersdorf, Germany). 
 
Yeast cell culture conditions  
Yeast strain W303-1a (MATa; ura3-1; trp1D 2; leu2-3,112; his3-
11,15; ade2-1; can1-100) was used for transformation performed by 
standard lithium acetate protocol. All strains were grown in Synthetic 
Complete medium lacking uracil (SC-Ura), supplemented with 2% 
raffinose or 2% galactose. ASYN expression was induced by shifting 
yeast cells cultured overnight in raffinose to galactose medium (OD600 = 
0.1). 
 
Overnight cultures of yeast strains were grown in SC-Ura medium 
containing 2% raffinose. For induction of the GAL1 promoter, cells were 




























Figure 11. Correlation between the effects of ASYN mutations on oligomerization and inclusion formation. The graph depicts how mutations 
affect oligomerization and inclusion formation, enabling the selection of mutants with different effects. Values were attributed to ASYN 










galactose to an OD600 = 0.1 and incubated for 6 h. Cell extracts were 
prepared and the protein concentrations were determined with a Bradford 
assay. Immunoblotting was performed following standard procedures 
using anti-ASYN monoclonal antibody (AnaSpec, CA, USA) or Cdc28 
polyclonal antibody (Santa Cruz Biotechnologies, Santa Cruz, CA, USA) 




To analyse cell growth on solid media, cultures were grown to mid-log 
phase in SC-Ura medium containing raffinose. Cells were normalized to 
equal densities, serially diluted 10-fold starting with an OD600 of 0.1, and 
spotted on SC-Ura plates containing either 2% glucose or 2% galactose. 
After 3 days incubation at 30uC the plates were photographed. 
 
Fluorescence microscopy and quantifications of yeast 
cells 
 
Yeast cell cultures were grown in SC-Ura medium containing 2% 
raffinose until mid-log phase and transferred to SC-Ura medium 
supplemented with 2% galactose. Expression was induced for 6 h and 
fluorescent images were obtained with Zeiss Observer. Z1 microscope 
equipped with CSU-X1 A1 confocal scanner unit (YOKOGAWA), 
QuantEM:512SC (Photometrics) digital camera and SlideBook 5.0 
software package (Intelligent Imaging Innova-tions). For quantification of 
aggregation at least 300 cells were counted per strain and per experiment. 
For each strain, the number of cells displaying cytoplasmic foci was 
reported to the total number of cells counted and displayed as percentage 




Twenty-four or forty-eight hours after transfection, cells (HEK or H4) 
were washed with PBS and fixed with 4% paraformal-dehyde (PFA) for 
10 minutes at room temperature (RT), followed by a permeabilization step 
with 0.5% Triton X-100 (Sigma-Aldrich, St. Louis, MO, USA) for 20 
minutes at RT. After blocking in 1.5% normal goat serum (PAA, Co¨lbe, 
Germany)/ DPBS for 1 hour, cells were incubated with primary antibody. 
Primary antibodies used were: mouse anti-ASYN (1:1000, BD 
Transduction Laboratory, New Jersey, USA) or rabbit anti-ASYN 
(1:1000, Abcam, Boston, USA), rabbit anti-LAMP-1 (1:1000, Abcam, 
Boston, USA), anti-Giantin (1:1000, Abcam, Boston, USA) for 3 hours or 
overnight and secondary antibody (Alexa Fluor 488 donkey anti-mouse 
IgG and/or Alexa Fluor 555 goat anti rabbit IgG, (Life Technologies- 
Invitrogen, Carlsbad, CA, USA) for 2 hours at RT. Finally, cells were 
stained with Hoechst 33258 (Life Technologies- Invitrogen, Carlsbad, 





For STED microscopy, H4 cells were plated in 15 mm coverslips. 
Forty-eight hours after transfection, the cells were washed with PBS and 
fixed with 4% PFA for 30 minutes at RT. The cells were rinse with 
quenching buffer (PBS +100 mM of Ammonium Chloride (Sigma-
Aldrich, St. Louis, MO, USA)) for 15 minutes. After washing, the cells 
were permeabilized and blocked (2% BSA and 0.1% Triton X-100, in 
PBS) for 20 minutes. Cells were then incubated with primary antibodies 
against ASYN (1:2000, BD Transduction Laboratory, New Jersey, USA) 
in the permeabilization-blocking solution diluted 1:2 with PBS for 1 hour 
at RT. Finally, we incubated the cells with a secondary goat anti-mouse 
antibody labeled with Atto 
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647N (5 mg/mL; Sigma-Aldrich, St. Louis, MO, USA). STED images 
were taken with a Leica TCS STED system (Leica Microsystems) with a 
100X oil objective (1.4 numerical aperture, NA, 1003 HCX PL APO CS 
oil; Leica Microsystems). For excitation, we used a 635 nm diode laser, 
and for the depletion donut (130 mW with the 1003 objective) we used a 
Spectra-Physics MaiTai multiphoton laser at 750 nm (Newport Spec- tra-
Physics). Scans were performed at 1,000 Hz and the final images 
represent an average of 96 scans (STED) (average performed line-by-line) 
with the pinhole set at 47 mm. STED images were obtained at 
20.20620.20 nm pixels. 
 
Thioflavin S staining 
 
After staining with secondary antibody, cells were incubated with 
freshly prepared 0.05% Thioflavin S (Sigma-Aldrich, St. Louis, MO, 
USA) for 5 minutes. Cells were then washed with 80% EtOH for 5 
minutes and, finally, stained with Hoechst 33258, washed and maintained 
in PBS for fluorescence microscopy. 
 
Quantification of nuclear and cytoplasmic fluorescence 
intensities 
 
Nuclear and cytoplasmic fluorescence intensities were quanti-fied 
using ImageJ software (http://rsbweb.nih.gov/ij/). Using the freehand tool 
the nucleus and cytosol were selected and the respective intensities were 
measured. The results reflect the counting of 25 cells per experiment. 
 
Quantification of ASYN inclusions 
 
Transfected cells were detected and scored based on the ASYN 
inclusions pattern and classified into four groups: cells without inclusions, 
less than five inclusions (,5 inclusions), between five to nine inclusions 
($5–9 inclusions) and more than ten inclusions ($ 10 inclusions). Results 
were expressed as the percentage of the total number of transfected cells 
obtained from three independent experiments for each mutation. 
 
Quantification of Golgi fragmentation 
 
Transfected HEK and H4 cells were scored based on the morphology 
of the Golgi apparatus and classified into three groups: non-fragmented, 
diffused and fragmented. Results were expressed as the percentage of the 
total number of transfected cells. Three independent experiments were 
performed. 
 
Western blot analyses 
 
HEK and H4 cells were lysed with Radio-Immunoprecipitation Assay 
(RIPA) lysis buffer (50 mM Tris pH 8.0, 0.15 M NaCl, 0.1% SDS, 1% 
NP40, 0.5% Na-Deoxycholate), 2 mM EDTA and a Protease Inhibitor 
Cocktail (1 tablet/10 mL) (Roche Diagnostics, Mannheim, Germany). To 
detect phosphorylated-ASYN was added Phosphatase Inhibitor Cocktail 
(1 tablets/10 mL) (Roche Diagnostics, Mannheim, Germany). Protein 
concentration was determined using the Bradford assay (BioRad 
Laboratories, Hercules, CA, USA) and the gels were loaded with 40 mg 
protein after denaturation for 10 minutes at 100uC in protein sample 
buffer (125 mM of 1 M Tris HCl pH 6.8, 4% SDS 0,5% Bromphenol 
blue, 4 mM EDTA 20% Glycerol 10% b-Mercapto ethanol). 
 
The samples were separated on 12% SDS-polyacrylamide gels (SDS-
PAGE) with a constant voltage of 110 V using Tris-Glycine SDS 0.5% 
running buffer (250 mM Tris, 200 mM Glycin, 1% SDS, pH 8.3) for 60 
minutes. 
 
The transfer was carried out to nitrocellulose membrane (Protran, 
Schleicher and Schuell, Whatman GmbH, Dassel, 
 






Germany) for 90 minutes with constant current at 0.3 A using Tris-
Glycine transfer buffer. 
 
Membranes were blocked with 5% (w/v) skim milk (Fluka, Sigma-
Aldrich, St. Louis, MO, USA) in 1xTBS-Tween (50 mM Tris, 150 mM 
NaCl, 0.05% Tween, pH 7.5) for 60 minutes at RT. 
 
Membranes were further incubated with the primary antibody, either 
mouse anti-ASYN (1:1000, BD Biosciences, San Jose, CA, USA) or 
rabbit anti-ASYN (1:1000, Santa Cruz Biotechnologies, Santa Cruz, CA, 
US), anti-BiP (BD Biosciences, San Jose, CA, USA) and 1:1000 mouse 
anti-b-actin (Sigma-Aldrich, St. Louis, MO, USA) in 3% Albumin Bovine 
Fraction V (BSA)/TBS-Tween (NZYTech, Lisbon, Portugal), at RT for 3 
hours or overnight at 4uC. 
 
After washing three times in TBS-Tween for five minutes, the 
membranes were incubated for 1 hour with secondary antibody, anti-
mouse IgG, or anti-rabbit IgG, horseradish peroxidase labeled secondary 
antibody (GE Healthcare, Bucks, UK) at 1:10000 in 3% milk/TBS-
Tween. 
 
Detection was done using Luminol Reagent and Peroxide Solution 
(Millipore, Billerica, MA, USA) and applied to the membrane 1 minute 
before scanning with in AlphaImager FluoroChem software 
(AlphaInnotech). 
 
Protein levels were quantified using ImageJ and normalized to the b-
actin levels. 
 
H4 cells transfected with ASYN-hGLuc constructs were washed with 
cold PBS to remove excess cell culture media. Cell lysis buffer (20 mM 
NaCl, 0,6% Deoxycholate, 0,6% Igepal, 25 mM Tris pH 8.0, Protease 
Inhibitor Cocktail tablet, 1 tablet/10 mL) was added on human H4 cells in 
60 mm dishes and incubated on ice for 10 minutes. After cell scraping 
samples were centrifuged for 10 minutes at 13,000 g. Lysates were 
resolved by electrophoresis on a 4–12% Bis-Tris gradient gel (NuPAGE 
Novex Bis-Tris Gel, Life Technologies, Darmstadt, Germany) according 
to manufacturer’s instructions using NuPAGE MOPS buffer. After 
transfer to nitrocellulose membrane (Protran, Schleicher and Schuell, 
What-man GmbH, Dassel, Germany) membranes were blocked in 1x Roti 
Block (Roth, Carlsbad, Germany) for 1 hour at RT. The forward steps 
were similar as describe above. 
 
Assessment of ASYN phosphorylation 
 
The blots were directly removed from the blotting chamber and fixed in 
0.4% PFA in PBS for 30 minutes. The membranes were briefly boiled in 
PBS, washed very short in TBS-Tween with phosphatase inhibitor (25 
mM B-Glycerolphosphat, 5 mM NaF, 1 mM Na3VO4), and then were 
blocked in 5% BSA/TBS-Tween with phosphatase inhibitor for at least 1 
hour (in the cold room). Anti-S129 phosphorylation ASYN 1:1000, 
WAKO, Richmond, Virginia, USA) was prepared in 5% BSA/TBS-
Tween with phosphatase inhibitor and incubated overnight in the cold 
room. After washing tree times with TBS-Tween with phosphatase 
inhibitor for 10 minutes, the membranes were incubated with secondary 
antibody (anti-mouse IgG) for 1,5 hours at RT. Finally they were washed 




For native PAGE, samples were lysed with detergent-free lysis buffer 
(50 mM Tris HCl pH 7.4, 175 mM NaCl, 5 mM EDTA pH 8.0 and 
Protease Inhibitor Cocktail tablet, 1 tablet/10 mL). Native-PAGE was run 
with detergent-free Tris-Glycine running buffer (250 mM Tris and 200 
mM Glycin) and in protein sample buffer (1 M Tris HCl pH 6.8, Glycerol 
100%, 0,4% Bromophenol blue). 
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Detergent solubility experiments 
 
The H4 cells were plated and transfected as previously describe. Using 
80 mL lysing buffer 1 (25 mM Tris pH 7.5, 150 mM NaCl, 1 mM EDTA, 
1% Triton X-100, K tablet of EDTA Protease Inhibitor) the cells were 
harvested and centrifuged at 100.000 g for 30 minutes at 4uC. 
Supernatants were collected (soluble fraction) and the pellets (insoluble 
fraction) were washed with cold PBS and transferred to new tubes. 
 
Once again, the samples were centrifuged at 14.000 rpm for 10 minutes 
at 4uC and the pellets were resuspended in 50 mL lysing buffer 2 (75 mM 
Tris pH 6.8, 3% SDS, 15% Glycerin, 3.75 mM EDTA pH 7.4). Finally, 
the samples were sonicated (10 pulse/ second) and a western blot was run 
as previously described.  
The insoluble fraction was calculated as: 
insoluble fraction 





HEK cells were plated and imaged after twenty-four hours, as 
described above. Then, cells were trypsinized, neutralized with growth 
medium, centrifuged (1500 g at 5uC) and the pellet was reconstituted in 7-
aminoactinomycin D (7-AAD, Life Technolo-gies- Invitrogen, Carlsbad, 
CA, USA) prepared 1:1000 in PBS. The fluorescence was measured using 
a microcapillary system (GuavaeasyCyte HT system, Millipore). 25000 
events were counted per sample. 
 
ASYN levels in the culture medium 
 
A detailed description of the assay procedure has been published before 
[50]. [50]96-well Multi-Array standard plates (Meso Scale Discovery, 
Gaithersburg, MD, USA) were coated with 30 ml of MJF1 clone 12.1 
(kindly provided by Liyu Wu, Epitomics, Burlingame, CA, USA) as 
capture antibodies at 3 mg/ ml dissolved in PBS buffer and incubated 
overnight at 4uC without shaking. All washing steps were done three 
times with 150 ml PBS-T (PBS supplemented with 0.05% Tween-20). 
After washing away the capture antibodies plates were blocked with 1% 
BSA/PBS-T for 1 h at RT with shaking at 300 rpm. Standards and 
biosamples collected from H4 cells were diluted in 1% BSA/PBS-T and 
applied in 25 ml volumes. Incubation was done for 1 h (RT, 700 rpm). 
Plates were washed again and 25 ml Sulfo-TAG labelled ASYN (BD 
Biosciences, Heidelberg, Germany) were applied at 1 mg/ml. After a final 
washing 150 ml 2x Read Buffer T (MSD) were applied to the wells and 
plates were read in a Sector Imager 6000 (MSD). 
 
Toxicity assays – LDH release 
 
For lactate dehydrogenase (LDH) cytotoxicity assay (Roche 
Diagnostics, Mannheim, Germany) the reaction mixture were prepared 
according to the manufacturer. The growth media from H4 cells were 
plated in triplicates in a 96 well plate, in a ratio 1:1 with the reaction 
mixture. The absorbance measurements were performed in a TECAN 
Infinite 200 Pro plate reader at 490 nm. To determine the percentage 
cytotoxicity, the average absorbance values were subtracted with the 
average absorbance value obtained in the background control. The 




Data were analysed using GraphPad Prism 5 (San Diego California, 
USA) software and were expressed as the mean 6 SEM of at least three 

















ASYN mutations from flow cytometry were normalized to WT ASYN 
and mean values for each experiment were determined. Statistical 
differences from WT ASYN were calculated using unpaired Student t-
test. Significance was assessed for p#0.05, where * corresponds to p#0.05, 
** corresponds to p#0.01 and ***  




Table S1 Primers used in the site directed mutagenesis. Primer used to 
performed site-directed mutagenesis and generated all the mutants 
versions of ASYN used in this study.  
(PDF) 
 
Table S2 Summary of the effects of the mutations on ASYN 
oligomerization and aggregation. The table resume the effects that each 
mutation had in the two systems analyze regarding the WT. In grey it is 




Figure S1 Statistical analysis of ASYN inclusion formation. A. Cells 
without inclusions. B. Cells with less than five inclusions. C. Cells with 
more than 5 and less than 10 inclusions. D. Cells with 
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more than ten inclusions. Student’s t test (*p,0.05, **p,0.01,  
***p,0.001). n = 3. 
(PDF) 
 
Figure S2 Morphological analysis of Golgi apparatus. A. Oligomerization 
paradigm B. Aggregation model paradigm. Student’s t test (*p,0.05, 
**p,0.01, ***p,0.001). n = 3.  
(PDF) 
 
Figure S3 Phosphorylation state of ASYN on S129. A-B Phosphorylation 
of ASYN in the BiFC assay. E35K and E57K showed an increase of S129 
ASYN phosphorylation. Student’s t test (*p,0.05, **p,0.01, ***p,0.001). n 





Conceived and designed the experiments: TFO KMD. Performed the 
experiments: DFL EFR RL HS KK BP NK TR. Analyzed the data: DFL 
EFR KK BP NK KMD TFO. Contributed reagents/materials/analysis 
tools: EG PG SOR BM GHB MDP TFO. Wrote the paper: DFL KMD  




1. Burre J, Sharma M, Tsetsenis T, Buchman V, Etherton MR, et al. (2010) 
Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. 
Science 329: 1663–1667. 
2. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, et al. 
(1997) Alpha-synuclein in Lewy bodies. Nature 388: 839–840. 
 
3. Goedert M, Spillantini MG, Del Tredici K, Braak H (2013) 100 years of 
Lewy pathology. Nat Rev Neurol 9: 13–24. 
 
4. de Rijk MC, Tzourio C, Breteler MM, Dartigues JF, Amaducci L, et al. 
(1997) Prevalence of parkinsonism and Parkinson’s disease in Europe: the 
EURO-PARKINSON Collaborative Study. European Community Concerted 
Action on the Epidemiology of Parkinson’s disease. J Neurol Neurosurg 
Psychiatry 62: 10–15. 
 
5. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, et al. (1997) 
Mutation in the alpha-synuclein gene identified in families with Parkinson’s 
disease. Science 276: 2045–2047.  
6. Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, et al. (1998) Ala30Pro 
mutation in the gene encoding alpha-synuclein in Parkinson’s disease. Nat 
Genet 18: 106–108. 
 
7. Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, et al. (2004) The 
new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body 
dementia. Ann Neurol 55: 164–173. 
 
8. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, et al. (2003) 
alpha-Synuclein locus triplication causes Parkinson’s disease. Science 302: 
841. 
 
9. Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, et al. 
(2004) Alpha-synuclein locus duplication as a cause of familial Parkinson’s 
disease. Lancet 364: 1167–1169. 
 
10. Ibanez P, Bonnet AM, Debarges B, Lohmann E, Tison F, et al. (2004) Causal 
relation between alpha-synuclein gene duplication and familial Parkinson’s 
disease. Lancet 364: 1169–1171. 
 
11. Farrer M, Kachergus J, Forno L, Lincoln S, Wang DS, et al. (2004) 
Comparison of kindreds with parkinsonism and alpha-synuclein genomic 
multiplications. Ann Neurol 55: 174–179. 
 
12. Simon-Sanchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, et al. (2009) 
Genome-wide association study reveals genetic risk underlying Parkinson’s 
disease. Nat Genet 41: 1308–1312. 
 
13. Nalls MA, Plagnol V, Hernandez DG, Sharma M, Sheerin UM, et al. (2011) 
Imputation of sequence variants for identification of genetic risks for 
Parkinson’s disease: a meta-analysis of genome-wide association studies. 
Lancet 377: 641– 649.  
14. Kiely AP, Asi YT, Kara E, Limousin P, Ling H, et al. (2013) alpha-
Synucleinopathy associated with G51D SNCA mutation: a link between 
Parkinson’s disease and multiple system atrophy? Acta Neuropathol 125: 
753– 769.  
15. Lesage S, Anheim M, Letournel F, Bousset L, Honore A, et al. (2013) G51D 
alpha-synuclein mutation causes a novel parkinsonian-pyramidal syndrome. 
Ann Neurol 73: 459–471.  
16. Proukakis C, Dudzik CG, Brier T, MacKay DS, Cooper JM, et al. (2013) A 




17. Khalaf O, Fauvet B, Oueslati A, Dikiy I, Mahul-Mellier AL, et al. (2014) The 
H50Q mutation enhances alpha-synuclein aggregation, secretion and toxicity. J 
Biol Chem 289: 21856–21876. 
 
18. Marques O, Outeiro TF (2012) Alpha-synuclein: from secretion to dysfunction 
and death. Cell Death Dis 3: e350. 
 
19. Lashuel HA, Overk CR, Oueslati A, Masliah E (2013) The many faces of alpha-
synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci  
14: 38–48.  
20. Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE, et al. (2000) Acceleration 
of oligomerization, not fibrillization, is a shared property of both alpha-synuclein 
mutations linked to early-onset Parkinson’s disease: implications for pathogenesis and 
therapy. Proc Natl Acad Sci U S A 97: 571–576. 
 
21. Fredenburg RA, Rospigliosi C, Meray RK, Kessler JC, Lashuel HA, et al. 
(2007) The impact of the E46K mutation on the properties of alpha-synuclein in 
its monomeric and oligomeric states. Biochemistry 46: 7107–7118. 
 
22. Goncalves S, Outeiro TF (2013) Assessing the Subcellular Dynamics of Alpha-
synuclein Using Photoactivation Microscopy. Mol Neurobiol 47: 1081–1092. 
 
23. Outeiro TF, Lindquist S (2003) Yeast cells provide insight into alpha-synuclein 
biology and pathobiology. Science 302: 1772–1775. 
 
24. Cai H, Reinisch K, Ferro-Novick S (2007) Coats, tethers, Rabs, and SNAREs 
work together to mediate the intracellular destination of a transport vesicle. Dev 
Cell 12: 671–682. 
 
25. Murphy DD, Rueter SM, Trojanowski JQ, Lee VM (2000) Synucleins are 
developmentally expressed, and alpha-synuclein regulates the size of the 
presynaptic vesicular pool in primary hippocampal neurons. J Neurosci 20: 
3214–3220.  
26. Klucken J, Poehler AM, Ebrahimi-Fakhari D, Schneider J, Nuber S, et al. 
(2012) Alpha-synuclein aggregation involves a bafilomycin A 1-sensitive 
autophagy pathway. Autophagy 8: 754–766.  
27. Hernandez-Vargas R, Fonseca-Ornelas L, Lopez-Gonzalez I, Riesgo-Escovar J, 
Zurita M, et al. (2011) Synphilin suppresses alpha-synuclein neurotoxicity in a 
Parkinson’s disease Drosophila model. Genesis 49: 392–402. 
 
28. Bonini NM, Giasson BI (2005) Snaring the function of alpha-synuclein. Cell 
123: 359–361. 
 
29. Vekrellis K, Xilouri M, Emmanouilidou E, Rideout HJ, Stefanis L (2011) 
Pathological roles of alpha-synuclein in neurological disorders. Lancet Neurol  
10: 1015–1025. 
 
30. McDowell K, Chesselet MF (2012) Animal models of the non-motor features of 
Parkinson’s disease. Neurobiol Dis 46: 597–606.  
31. Low K, Aebischer P (2012) Use of viral vectors to create animal models for 
Parkinson’s disease. Neurobiol Dis 48: 189–201. 
 
32. Bezard E, Przedborski S (2011) A tale on animal models of Parkinson’s 
disease. Mov Disord 26: 993–1002. 
 
33. Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, et al. (2002) 
alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 4: 
160–164. 
 
34. Okochi M, Walter J, Koyama A, Nakajo S, Baba M, et al. (2000) Constitutive 
phosphorylation of the Parkinson’s disease associated alpha-synuclein. J Biol 
Chem 275: 390–397. 
 
 






35. Paleologou KE, Schmid AW, Rospigliosi CC, Kim HY, Lamberto GR, et al. 
(2008) Phosphorylation at Ser-129 but not the phosphomimics S129E/D 
inhibits the fibrillation of alpha-synuclein. J Biol Chem 283: 16895–16905.  
36. Taschenberger G, Garrido M, Tereshchenko Y, Bahr M, Zweckstetter M, et al. (2012) 
Aggregation of alphaSynuclein promotes progressive in vivo neurotoxicity in adult rat 
dopaminergic neurons. Acta Neuropathol 123: 671–683.  
37. Dorval V, Fraser PE (2006) Small ubiquitin-like modifier (SUMO) 
modification of natively unfolded proteins tau and alpha-synuclein. J Biol 
Chem 281: 9919– 9924.  
38. Krumova P, Meulmeester E, Garrido M, Tirard M, Hsiao HH, et al. (2011) 
Sumoylation inhibits alpha-synuclein aggregation and toxicity. J Cell Biol 194: 
49–60.  
39. Shults CW (2006) Lewy bodies. Proc Natl Acad Sci U S A 103: 1661–1668.  
40. Karpinar DP, Balija MB, Kugler S, Opazo F, Rezaei-Ghaleh N, et al. (2009) 
Pre-fibrillar alpha-synuclein variants with impaired beta-structure increase 
neurotoxicity in Parkinson’s disease models. EMBO J 28: 3256–3268.  
41. Winner B, Jappelli R, Maji SK, Desplats PA, Boyer L, et al. (2011) In vivo  
demonstration that alpha-synuclein oligomers are toxic. Proc Natl Acad Sci U S A 
108: 4194–4199.  
42. Outeiro TF, Putcha P, Tetzlaff JE, Spoelgen R, Koker M, et al. (2008) Formation of 
toxic oligomeric alpha-synuclein species in living cells. PLoS ONE  
3: e1867.  
43. McLean PJ, Kawamata H, Hyman BT (2001) Alpha-synuclein-enhanced green 
fluorescent protein fusion proteins form proteasome sensitive inclusions in 
primary neurons. Neuroscience 104: 901–912.  
44. Tenreiro S, Munder MC, Alberti S, Outeiro TF (2013) Harnessing the power of 
yeast to unravel the molecular basis of neurodegeneration. J Neurochem 127: 
438–452.  
45. Lee HJ, Lee SJ (2002) Characterization of cytoplasmic alpha-synuclein 
aggregates. Fibril formation is tightly linked to the inclusion-forming process in 
cells. J Biol Chem 277: 48976–48983.  
46. Danzer KM, Ruf WP, Putcha P, Joyner D, Hashimoto T, et al. (2011) Heat-
shock protein 70 modulates toxic extracellular alpha-synuclein oligomers and 
rescues trans-synaptic toxicity. FASEB J 25: 326–336.  
47. Remy I, Michnick SW (2006) A highly sensitive protein-protein interaction 
assay based on Gaussia luciferase. Nat Methods 3: 977–979.  
48. Borghi R, Marchese R, Negro A, Marinelli L, Forloni G, et al. (2000) Full 
length alpha-synuclein is present in cerebrospinal fluid from Parkinson’s 
disease and normal subjects. Neurosci Lett 287: 65–67.  
49. El-Agnaf OM, Salem SA, Paleologou KE, Cooper LJ, Fullwood NJ, et al. (2003) 
Alpha-synuclein implicated in Parkinson’s disease is present in extracellular 
biological fluids, including human plasma. FASEB J 17: 1945–1947. 
 
50. Kruse N, Schulz-Schaeffer WJ, Schlossmacher MG, Mollenhauer B (2012) 
Development of electrochemiluminescence-based singleplex and multiplex 
assays for the quantification of alpha-synuclein and other proteins in 
cerebrospinal fluid. Methods 56: 514–518.  
51. Gonatas NK, Stieber A, Gonatas JO (2006) Fragmentation of the Golgi apparatus in 
neurodegenerative diseases and cell death. J Neurol Sci 246: 21–30.  
52. Fan J, Hu Z, Zeng L, Lu W, Tang X, et al. (2008) Golgi apparatus and 
neurodegenerative diseases. Int J Dev Neurosci 26: 523–534. 
Effects of ASYN Mutations in Cells Models 
 
 
53. Fujita Y, Ohama E, Takatama M, Al-Sarraj S, Okamoto K (2006) 
Fragmentation of Golgi apparatus of nigral neurons with alpha-synuclein-
positive inclusions in patients with Parkinson’s disease. Acta Neuropathol 112: 
261–265. 
 
54. Holtz WA, O’Malley KL (2003) Parkinsonian mimetics induce aspects of 
unfolded protein response in death of dopaminergic neurons. J Biol Chem 278: 
19367–19377. 
 
55. Hetz C (2012) The unfolded protein response: controlling cell fate decisions 
under ER stress and beyond. Nat Rev Mol Cell Biol 13: 89–102.  
56. Chen L, Feany MB (2005) Alpha-synuclein phosphorylation controls neurotox-
icity and inclusion formation in a Drosophila model of Parkinson disease. Nat 
Neurosci 8: 657–663. 
 
57. Pandey N, Schmidt RE, Galvin JE (2006) The alpha-synuclein mutation E46K 
promotes aggregation in cultured cells. Exp Neurol 197: 515–520.  
58. Fares MB, Ait-Bouziad N, Dikiy I, Mbefo MK, Jovicic A, et al. (2014) The 
novel Parkinson’s disease linked mutation G51D attenuates in vitro aggregation 
and membrane binding of alpha-synuclein, and enhances its secretion and 
nuclear localization in cells. Hum Mol Genet 23: 4491–4509.  
59. Rutherford NJ, Moore BD, Golde TE, Giasson BI (2014) Divergent effects of 
the H50Q and G51D SNCA mutations on the aggregation of alpha-synuclein. J 
Neurochem. E-pub ahead of print. doi:10.1111/jnc.12806  
60. Trexler AJ, Rhoades E (2010) Single molecule characterization of alpha-
synuclein in aggregation-prone states. Biophys J 99: 3048–3055. 
 
61. Chen L, Periquet M, Wang X, Negro A, McLean PJ, et al. (2009) Tyrosine and 
serine phosphorylation of alpha-synuclein have opposing effects on 
neurotoxicity and soluble oligomer formation. J Clin Invest 119: 3257–3265. 
 
62. Oueslati A, Paleologou KE, Schneider BL, Aebischer P, Lashuel HA (2012) 
Mimicking phosphorylation at serine 87 inhibits the aggregation of human 
alpha-synuclein and protects against its toxicity in a rat model of Parkinson’s 
disease. J Neurosci 32: 1536–1544.  
63. Paleologou KE, Oueslati A, Shakked G, Rospigliosi CC, Kim HY, et al. (2010)  
Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-
synuclein oligomerization, and influences synuclein-membrane interactions. J 
Neurosci 30: 3184–3198.  
64. El-Agnaf OM, Jakes R, Curran MD, Middleton D, Ingenito R, et al. (1998) 
Aggregates from mutant and wild-type alpha-synuclein proteins and NAC 
peptide induce apoptotic cell death in human neuroblastoma cells by formation 
of beta-sheet and amyloid-like filaments. FEBS Lett 440: 71–75.  
65. Hejjaoui M, Butterfield S, Fauvet B, Vercruysse F, Cui J, et al. (2012) 
Elucidating the role of C-terminal post-translational modifications using protein 
semisynthesis strategies: alpha-synuclein phosphorylation at tyrosine 125. J Am 
Chem Soc 134: 5196–5210. 
 
66. Gosavi N, Lee HJ, Lee JS, Patel S, Lee SJ (2002) Golgi fragmentation occurs in 
the cells with prefibrillar alpha-synuclein aggregates and precedes the formation 
of fibrillar inclusion. J Biol Chem 277: 48984–48992. 
 
67. Petroi D, Popova B, Taheri-Talesh N, Irniger S, Shahpasandzadeh H, et al. 
(2012) Aggregate clearance of alpha-synuclein in S. cerevisiae depends more 








































3.2. Small Molecules Detected by Second-Hamonic Generation 
Modulate the Conformation of Monomeric a-Synuclein and 
Reduce Its Aggregation in Cells 
 
Ben Moree#, Guowei Yin#, Diana F. Lázaro#, Francesca Munari, Timo Strohaker§, 




Experiments Done by 
Analysis of BIOD303 inhibition on a-synuclein inclusion 
formation in an H4 neuronal cell model, in Figure 7. 
Diana F. Lázaro 
Analysis of proteasome activity in H4 cells, in Figure 8 Diana F. Lázaro 
Analysis of insoluble a-synuclein levels with BIOD303 in H4 
cells, in Figure9 
Diana F. Lázaro 
All other experiment were performed by the other authors 










THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 290, NO. 46, pp. 27582–27593, November 13, 2015 
© 2015 by The American Society for Biochemistry and Molecular Biology, Inc.   Published in the U.S.A. 
 
 
Small Molecules Detected by Second-Harmonic Generation 
Modulate the Conformation of Monomeric a-Synuclein and 
Reduce Its Aggregation in Cells
* 
Received for publication, September 2, 2015  Published, JBC Papers in Press, September 22, 2015, DOI 10.1074/jbc.M114.636027  
Ben Moree‡1, Guowei Yin§1, Diana F. Lázaro¶ 1, Francesca Munari§**, Timo Strohaker§, Karin Giller§, 
Stefan Becker§, Tiago F. Outeiro¶ 2, Markus Zweckstetter§**2, and Joshua Salafsky‡3  
From ‡Biodesy, Inc., South San Francisco, California 94080, the §Max Planck Institute for Biophysical Chemistry, Am Fassberg 11, 
37077 Go¨ttingen, Germany, the ¶Center for Nanoscale Microscopy and Molecular Physiology of the Brain, University Medical Center, 
37075 Go¨ttingen, Germany, the Department of Neurodegeneration and Restorative Research, University Medical Center Go¨ttingen, 
37073 Go¨ttingen, Germany, and the **German Center for Neurodegenerative Diseases (DZNE), 
37077 Go¨ttingen, Germany 
 
Background: a-Synuclein aggregation is associated with Parkinson disease.  
Results: Small molecules were identified by second-harmonic generation (SHG) that change a-synuclein conformation in 
vitro and reduce the aggregation of protein in cells.  
Conclusion: Conformation plays a role in a-synuclein aggregation in cells.  
Significance: Small molecules that modulate the conformation of a-synuclein and reduce its aggregation could be developed 

































Proteins are structurally dynamic molecules that perform 
specialized functions through unique conformational changes 
accessible in physiological environments. An ability to specifically 
and selectively control protein function via conformational 
modulation is an important goal for development of novel ther-
apeutics and studies of protein mechanism in biological networks and 
disease. Here we applied a second-harmonic generation-based 
technique for studying protein conformation in solution and in real 
time to the intrinsically disordered, Parkinson disease related protein 
a-synuclein. From a fragment library, we identified small molecule 
modulators that bind to monomeric -synuclein in vitro and 
significantly reduce a-synuclein aggregation in a neuronal cell 
culture model. Our results indicate that the conformation of -
synuclein is linked to the aggregation of protein in cells. They also 
provide support for a therapeutic strategy of targeting specific 




The regulation of protein activity and function through changes in 
protein conformation is a central theme in biology. Diverse biological 
processes such as enzyme catalysis, allostery, and protein-protein 
interactions are all governed by conforma-tional changes (1–3). 
Classical biochemical experiments on 
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enzyme catalysis led to the development of the structure-function 
paradigm, whereby the structure of a protein determines its function 
(4, 5). However, this paradigm has been challenged by the discovery 
of intrinsically disordered proteins (IDPs)4 (6, 7).  
IDPs exist as a highly dynamic ensemble of conformations and 
thus do not populate a dominant and stable three-dimensional 
structure. IDPs as a class are estimated to comprise 15– 45% of all 
eukaryotic proteins and include both proteins that lack a folded 
structure as well as those that have disordered regions, such as loops 
and linkers, of greater than 30 amino acids in length (8). Although 
they are natively unstructured, IDPs may adopt secondary and tertiary 
structures upon binding ligands or other proteins (9).  
The protein a-synuclein is a 140-residue IDP that is highly 
enriched in the brain (10). Although the precise cellular function of 
a-synuclein is not completely understood, it is thought to promote 
SNARE complex assembly and play a role in regulating synaptic 
vesicle levels and dopamine release at the pre-synaptic terminal (11–
13). The aggregation and accumulation of a-synuclein in neurons is 
associated with a number of neurodegenerative diseases known as 
synucleinopathies. One such example is Parkinson disease (PD), 
which is a characterized by the progressive loss of dopaminergic 
neurons in the substantia nigra of the midbrain and by the presence 
of Lewy bodies, which are comprised mainly of aggregated a-
synuclein fibrils (14). Mutations in a-synuclein have also been linked 
to both sporadic and rare forms of early onset PD, providing further 




2 The abbreviations used are: IDP, intrinsically disordered protein; SHG, 
second-harmonic generation; PcTS, phthalocyanine tetrasulfonate; Ro3, 
rule of three; PD, Parkinson disease; PRE, paramagnetic relaxation 
enhancement; MTSL, oxy-2,2,5,5-tetramethyl-D-pyrroline-3-methyl)-
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FIGURE 1. Schematic of second-harmonic generation. Incident laser 
light strikes the surface and through total internal reflection creates an 
evanescent wave that decays away from the surface. Labeled protein is 
bound to the surface and the SHG signal magnitude depends on the 
orientation of the dye label relative to the surface normal (z axis). A 
conformational change that re-orients the average, net orientation of the 
label toward or away from the normal results in a signal change. 
 
the disease (15–18). In vitro, a-synuclein adopts a wide range of 
conformations from compact to fully extended (19 –21). Inter-actions 
between the N and C termini appear to stabilize the protein 
predominantly in a compact, monomeric conformation that is non-
toxic (19). The process by which the protein proceeds from monomer 
to oligomers and fibrillar aggregates is currently the subject of 
intense scrutiny (22–24). Growing evidence suggests that oligomers 
of a-synuclein, formed prior to the larger aggregates found in the 
brains of patients with the disease, may be neurotoxic in vivo (20, 
22). Irrespective of the toxic species, monomeric a-synuclein is an 
attractive therapeutic target for small molecules that modulate a-
synuclein conformation as it is the most upstream form of the protein 
in the aggregation process. However, the intrinsic disorder of the pro-
tein makes it difficult to screen by conventional techniques and few 
molecules are known to bind specifically to the protein (25–32).  
To overcome the challenges associated with traditional small 
molecule screening of a-synuclein, we developed a novel sec-ond-
harmonic generation (SHG)-based screen to identify com-pounds that 
directly modulate the conformation of monomeric a-synuclein. SHG 
is a nonlinear optical technique (33, 34) in which two photons of 
equal energy are combined by a nonlinear material or molecule to 
generate one photon with twice the energy. Because the intensity of 
the SHG signal is highly sensitive to the angular orientation of 
second-harmonic active molecules tethered to a surface, the 
technique can be applied to study structure and conformational 
changes. (35–38). Although biological molecules are not usually 
second-harmonic active, they can be rendered so through the 
incorporation of a second-harmonic active dye molecule (39). Once 
tethered to a surface, a labeled second-harmonic active protein 
irradiated by a fundamental light beam produces an SHG signal 
whose intensity depends sensitively on the tilt angle of the dye with 
respect to the surface (Fig. 1). The SHG intensity is the coherent 
superposition of scattered second-harmonic light orientationally 
averaged across the molecules in the irradiated ensemble. When the 
protein molecules undergo a conformational change upon ligand 
binding, this causes a change in the orientational distribution of the 
second-harmonic active moiety, leading to a change in the intensity 
of light. Changes in SHG intensity therefore correspond with high 
orientational sensitivity to conformational changes at the attachment 
site of the second-harmonic active probe. In addition, conformational 
 
changes can be classified by their response in both magnitude and 
direction relative to baseline (for a more detailed explanation of the 
theoretical background for SHG, please see the “Experimental 
Procedures”).  
In the study presented here, we used an SHG-based fragment 
screen to identify novel conformational modulators of a-synuclein. 
We subsequently used these modulators, which include a compound 
we named BIOD303 and its analogs, to probe the biological 
chemistry of monomeric a-synuclein. We demonstrate that these 
molecules bind to the protein by both SHG and NMR spectroscopy 
and by paramagnetic relaxation enhancement (PRE). We also show 
definitively by SHG that these molecules induce a conformational 
change in a-sy-nuclein. Finally, we demonstrate that these 
modulators reduce a-synuclein aggregation in a human neuronal cell 
model. Taken together, our results demonstrate that modulation of a-
synuclein conformation by small molecules can significantly reduce 
the aggregation of the protein in cells. In addition, our results 
demonstrate that SHG can sensitively study the biolog-ical 
mechanism of ligand-protein interactions and enable the 
identification of novel ligands for drug discovery and basic research. 
 
 
Experimental Procedures  
a-Synuclein Purification and Labeling—A single-site cysteine 
mutant (A90C) of a-synuclein was constructed and labeled with the 
second-harmonic active dye SHG2-maleimide (thiol-reactive, 
available from Biodesy), and conjugated to the protein according to 
the manufacturer’s instructions. The incorporation of a single label at 
A90C was confirmed by mass spectrometry.  
SHG Instrumentation and Measurements—Our instrument 
comprises a mode-locked Ti:Sapphire oscillator, which pro-vides the 
fundamental beam necessary to generate the second-harmonic signal 
(high peak power). For these experiments, we used a Mira 900 
Ti:Sapphire ultrafast oscillator (Coherent Inc., Santa Clara, CA) 
pumped by a Millenia V DPSS laser (Spectra-Physics Corp., Santa 
Clara, CA). The fundamental was passed through a half-wave plate to 
select p-polarization (used for all the experiments described here), 
and focused into a Dove prism for total internal reflection at a spot 
size of 100 mm. The second-harmonic light was collected by a lens, 
separated from the fundamental using a dichroic mirror and 
wavelength filters, and directed into a PMT module with a built-in 
pre-amplifier for photon counting (Hamamatsu, Bridgewater, NJ). A 
custom electronics board was used to digitize the signal and the data 
were sent to a computer running customized control and data 
collection software (Labview, National Instruments Corp., Austin, 
TX). For these experiments, a microscope slide with protein was 
coupled to a prism using BK7 index matching fluid (Cargille, Cedar 
Grove, NJ) and the prism itself was secured onto a one-dimensional 
translation stage capable of 1-mm randomly addressable precision 
(Renishaw, Parker-Hannifin Corp., Rohnert Park, CA). A silicone 
template defined 16 wells on each slide. Each of the 16 wells is read 
in sequence by translating the stage via the control software. The 
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Tecan Systems, Inc., San Jose, CA) that delivered a liquid bolus (in 
the screening experiments, spermine).  
a-Synuclein Assay Slide Preparation—A custom 2-mm thick 
silicone template with adhesive backing (Arrowleaf Research, Bend, 
OR) was applied to commercially available aldehyde derivatized 
glass microscope slides (Xenobind, Xenopore, Hawthorne, NJ). Each 
silicone template defined 16 wells whose spacing and diameter 
equals those of a standard 384-well plate format. Stock solutions of 
second-harmonic active dye-labeled a-synuclein were diluted to 5 
mM final concentration (below the threshold for oligomer formation 
(40)) in PBS and allowed to adsorb to the glass surface in each well 
by incubating at room temperature for 30 min. After allowing the 
protein to adsorb, the slide was placed on the instrument and each 
well was scanned via SHG to determine the amount of signal in each 
well. Unbound protein was then removed by washing five times with 
20 ml of PBS. A post-wash well scan was then performed. 
 
Maybridge Library Screening—The Maybridge Rule of Three 
(Ro3) fragment library contains 1,000 pharmacophores of $95% 
purity that conform to the rule of three standard (molec-ular mass 300 
Da, ClogP 3, and the number of hydrogen bond donor and acceptors 
3) (41). Each compound has a stated solubility of up to 1 mM in PBS. 
Because fragments typically possess lower potency than larger 
compounds, they were screened at 1 mM final concentration. For 
screening experiments, each compound from the library was 
solubilized at 50 mM in DMSO and diluted in PBS to produce a final 
concentration of 2 mM (4% DMSO). Each compound (2 mM) was 
then injected into a well containing an equal volume of buffer to 
produce a final concentration of 1 mM compound in the well. To 
ensure that a buffer mismatch did not occur, the buffer used during 
screening was PBS 4% DMSO. The slide was then loaded onto the 
instrument stage, baseline signal was measured in real time, and 
spermine was injected at 5 mM while reading the SHG signal. In 
these experiments, baseline signals were monitored for 8 s, followed 
by spermine injection, and the SHG signal was recorded for an 
additional 8 s. For the screen, each well was loaded with 5 mM a-
synuclein, washed out after binding to the surface, and preincubated 
with one compound from the Maybridge Ro3 library for 30 min at 1 
mM. Spermine was then added to each well at 5 mM and the 
resulting change in SHG signal was measured. Compounds that 
inhibited the spermine-induced conformational change as measured 
by SHG were re-tested. A similar procedure was used to test the 
BIOD303 analogs.  
Dose-response Curves—To measure the dose-response curves of 
spermine (Sigma) and BIOD303, serial dilutions of each con-
centrated stock compound were prepared. Each compound was added 
to a well to produce the indicated final concentration. For spermine, 
the range of concentrations tested was 10 mM, 30 mM, 100 mM, 300 
mM, 1 mM, 3 mM, and 10 mM. For BIOD303 the concentration 
range was 5 mM, 32.5 mM, 62.5 mM, 125 mM, 250 mM, 500 mM, 
and 1 mM. Concentrations were then converted to logarithmic scale 
and the percent change at each concentration was plotted in Prism 
(GraphPad Software, La Jolla, CA) using a non-linear regression fit 
for log (agonist) versus normalized response. The data were 
normalized so that the values for the lowest concentration and the 
highest concentration were set to 
 
0 and 100%, respectively. EC50 values were calculated empirically 
using the software.  
Compound Injections—BIOD303, spermine, spermidine, and 
phthalocyanine tetrasulfonate (PcTS, Sigma) were all freshly 
prepared as stock solutions at the indicated concentrations in PBS. 
Compounds from the Maybridge library were also pre-pared in PBS 
at the indicated concentrations. To determine the change in SHG 
signal that a given compound produced, the baseline signal of a-
synuclein was measured for 10 s followed by compound injection. 
The change in SHG intensity was recorded for 90 s after compound 
addition. Where appropriate, the buffer was supplemented with 
DMSO to prevent buffer mismatch.  
Quantifying Changes in SHG Intensity—Control experiments were 
performed on each compound to empirically determine the time 
required for each compound to produce a maximal response (tmax). 
For all experiments except those using PcTS the maximal response 
measured by SHG occurred within 30 s after compound addition. For 
the PcTS experiments, the maximal response occurred 45 s after 
compound addition. To calculate the percent change in SHG intensity 
(% SH), the sec-ond-harmonic intensity measured just prior to 
injection (It0) was subtracted from the second-harmonic intensity at 
tmax (Itmax) and then divided by the initial second-harmonic inten-sity 
(It0) according to Equation 1. 
 
%∆ SH =(It,max - It0)/It0 (Eq. 1) 
 
All experiments included a control buffer injection that was used 
to determine the threshold for SHG intensity change, which was 
calculated in a similar manner. The net SHG intensity change for 
each compound was then reported by subtracting the buffer threshold 
value from the SHG intensity value produced by compound addition. 
The resulting value was reported as the percent change in SHG 
intensity resulting from compound addition.  
NMR Spectroscopy—NMR spectra were acquired at 15 °C on a 
Bruker Avance 600 NMR spectrometer using a triple-resonance 
cryoprobe equipped with z axis self-shielded gradient coils. a-
Synuclein and BIOD303 or the analog compounds were dissolved in 
50 mM HEPES, 100 mM NaCl buffer containing 2% DMSO. Low 
temperature (15 °C) inhibits the rate of aggregation of a-synuclein 
and ensures the species under study is in the monomeric form. a-
Synuclein-ligand binding was measured using two-dimensional 1H- 
15N heteronuclear single quantum coherence experiments. Chemical 
shift perturbations s1H15N were calculated according to [(∆𝜎2H)2 + 
(0.2 ∆𝜎15N)2]0.5, where ∆𝜎1H and ∆𝜎15N are the observed changes in 
the 1H and 15N dimensions. PRE was measured using spin-labeled 
A90C a-synuclein. Spin labeling with oxy-2,2,5,5-tetramethyl-D- 
pyrroline -3-methyl)- methanethio-sulfonate (MTSL, Toronto 
Research Chemicals, Toronto) was carried out as described (42). PRE 
effects were measured from the peak intensity ratios between two 1H-
15N heteronuclear single quantum coherence spectra in the absence 
and presence of a 10-fold excess (compared with protein) of DTT. To 
exclude contributions from DMSO, the chemical shifts and PREs in 
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addition of the same amount of DMSO without ligand. Data 
processing was performed using the software packages 
NMRPipe/NMRDraw (43), Topspin (Bruker), and Sparky (62). 
 
Cell Culture—Human neuroglioma cells (H4) were maintained in 
Opti-MEM I Reduced Serum Medium (Life Technologies-Gibco) 
supplemented with 10% fetal bovine serum Gold (FBS) (PAA, 
Colbe, Germany) at 37 °C in an atmosphere of 5% 
CO2.  
Cell Transfection—H4 Cells were plated in 12-well plates (Costar, 
Corning, New York) 1 day prior to transfection. On the subsequent 
day, cells were transfected with FuGENE 6 Transfection Reagent 
(Promega, Madison, WI) according to the manufacturer’s instructions 
with equal amounts of plasmids encoding a C terminally modified a-
synuclein (SynT construct) and synphilin-1 as previously described 
(44 – 46). Twenty-four hours after the transfections, the cells were 
treated with different compounds at different concentrations (0, 10, 
100, or 500 mM). DMSO was used as the vehicle. Twenty-four hours 
later the cells were subjected to immunocytochemistry to examine a-
synuclein inclusion formation. 
 
Immunocytochemistry—After transfection, cells were washed with 
PBS and fixed with 4% paraformaldehyde for 10 min at room 
temperature. Cells were then permeabilized with 0.5% Triton X-100 
(Sigma) for 20 min at room temperature and blocked in 1.5% normal 
goat serum (PAA)/PBS for 1 h. Cells were then incubated for 3 h 
with mouse anti-ASYN primary antibody (1:1000, BD Transduction 
Laboratories, NJ), and afterward with a secondary antibody (Alexa 
Fluor 488 donkey anti-mouse IgG) for 2 h at room temperature. 
Finally, cells were stained with Hoechst 33258 (Life Technologies-
Invitrogen) (1:5000 in PBS) for 5 min and maintained in PBS for 
epifluorescence microscopy.  
Quantification of a-Synuclein Inclusions—Experiments were 
performed as previously described (44). Briefly, transfected cells 
were detected and scored based on the a-synuclein inclusions pattern 
and classified as presented. Results were ex-pressed as the percentage 
of the total number of transfected cells. A minimum of 50 cells were 
counted per condition.  
Immunoblotting—Twenty-four hours after H4 cells co-ex-pressing 
a-synuclein (SynT) and synphilin-1 were treated with BIOD303, the 
cells were lysed with radioimmunoprecipitation assay (RIPA) lysis 
buffer (50 mM Tris, pH 8.0, 0.15 M NaCl, 0.1% SDS, 1% Nonidet P-
40, 0.5% sodium deoxycholate), 2 mM EDTA and a protease 
inhibitor mixture (1 tablet/10 ml, Roche Diagnostics, Mannheim, 
Germany). Using the Bradford assay (Bio-Rad Laboratories), the 
protein concentration was deter-mined and the gels were loaded with 
30 mg of protein. The samples were denatured for 5 min at 99 °C in 
protein sample buffer (125 mM Tris-HCl, pH 6.8, 4% SDS 0.5% 
bromphenol blue, 4 mM EDTA, 20% glycerol, 10% b-
mercaptoethanol). 
 
The samples were separated on 12% SDS-PAGE with a constant 
voltage of 110 V using Tris glycine, SDS 0.5% running buffer (250 
mM Tris, 200 mM glycine, 1% SDS, pH 8.3) for 90 min and 
transferred to a nitrocellulose membrane (Protran, Schleicher and 
Schuell, Whatman GmbH, Dassel, Germany) for 120 min with 
constant current at 0.3 A using Tris glycine transfer buffer. 
 
Membranes were blocked with 5% (w/v) skim milk (Fluka, Sigma) 
in 1 TBS-Tween (50 mM Tris, 150 mM NaCl, 0.05% Tween, pH 7.5) 
for 60 min at room temperature. Afterward, membranes were 
incubated with the primary antibody, mouse anti-ASYN (1:1000, BD 
Biosciences, San Jose, CA), and 1:5000 mouse anti-GAPDH (Cell 
Signaling, Danvers, MA) in 3% albumin bovine fraction V/TBS 
(NZYTech, Lisbon, Portugal) overnight at 4 °C. After washing three 
times in TBS-Tween, the membranes were incubated for 2 h with 
secondary antibody, either anti-mouse IgG-or anti-rabbit IgG-
horseradish peroxidase (GE Healthcare, Bucks, United Kingdom) at 
1:10,000 in 3% milk/TBS-Tween. Detection was performed using 
Luminol Reagent and peroxide solution (Millipore, Billerica, MA). 
Protein levels were quantified using ImageJ and normalized to the 
GAPDH levels.  
Proteasome Activity Reporter Assay— H4 cells expressing SynT 
synphilin were transfected with a plasmid encoding GFP-u, a reporter 
of proteasome activity (47). After 24 h, cells were treated with 
different concentrations of BIOD303. Cells were imaged using an 
Olympus IX81-ZDC microscope system (Olympus Germany, 
Hamburg, Germany) and analyzed using the Olympus Scan∧R Image 
Analysis Software.  
Triton X-100 Solubility Assay—Experiments were performed as 
previously described (44). Briefly, H4 cells transiently co-transfected 
with a-synuclein (SynT) and synphilin-1 were treated with vehicle 
(DMSO) or BIOD303 (10, 100, or 500 mM). After 24 h, cells were 
washed with cold PBS and lysed in lysis buffer (PBS supplemented 
with protease and phosphatase inhibitor mixture tablets, Roche 
Applied Science). Samples were sonicated three times for 30 s and 
incubated on ice for 1 min between each sonication step. Total 
protein concentration was measured and 1% of Triton X-100 was 
added to 150 mg of the protein extracts. Samples were incubated at 4 
°C for 30 min and the Triton X-100-insoluble (InsoI) fraction was 
separated from the soluble (Sol) fraction by centrifugation at 100,000 
g for 1 h at 4 °C. The insoluble fraction was resuspended in 40 ml of 
lysis buffer containing 2% SDS and sonicated twice for 30 s with 1-
min incubation on ice between each sonication step. Both fractions 
were run on an SDS-PAGE for immunoblotting analysis. A 
representative membrane is shown (n 3). 
 
Theoretical Background of SHG—The intensity of SHG light 
generated from a population of SHG molecules under irradiation by a 
fundamental beam, for a given polarization combina-tion of the input 
and output beams, is given as: 
 
ISH = G (𝜒 (2)) 2I2   (Eq. 2) 
 
where ISH is the measured second-harmonic intensity, G is a function 
that depends on the experimental geometry, polariza-tion of the 
fundamental and second-harmonic beams, refractive indices, angle of 
incidence, optical wavelengths, and the symmetry-allowed elements 
of the tensor nonlinear susceptibility x(2), and I is the intensity of the 
fundamental light. x(2) connects the microscopic properties of the 
second-harmonic active molecules to the observed second-harmonic 
intensity as, 
 
x 2  = Ns <a (2) >       (Eq. 3) 
 
where Ns is the surface density of the second-harmonic active 























































































FIGURE 2. SHG results of the -synuclein assay and Maybridge Ro3 fragment library screen. A, left, the SHG response for a-synuclein upon addition of 5 mM spermine. 
Middle, the SHG response of a-synuclein upon addition of 5 mM spermine after preincubation with 1 mM BIOD303. Right, the SHG response of a-synuclein upon addition of 1 mM 
BIOD303. The arrows denote compound addition. Each interval on the time axis is 10 s. B, quantification of the mean percent change in SHG intensity for 5 mM spermine, 5 mM 
spermine addition after preincubation with 1 mM BIOD303, and 1 mM BIOD303. The change in SHG intensity is plotted as the percent change normalized to preinjection levels. C, 



























FIGURE 3. BIOD303 induces a distinct conformation in -synuclein compared with spermine. A, dose-response curves of spermine; and B, BIOD303 on a-synuclein 
conformation as measured by SHG. C, a representative trace showing the SHG response from a competition experiment in which 5 mM spermine is injected onto a-synuclein prior 
to BIOD303 addition. Left, the SHG response for a-synuclein upon addition of buffer. Middle, the SHG response upon addition of 5 mM spermine onto a-synuclein. Right, the SHG 
response of a-synuclein upon addition of 1 mM BIOD303 after injecting 5 mM spermine. The arrows denote compound addition. The dotted lines on the graph represent the 
baseline level for normalization of the percent change in SHG intensity. Only the portion of the kinetic trace up to the SHG intensity plateau is shown. D, quantification of the mean 
percent change in SHG intensity for 5 mM spermine, 1 mM BIOD303 addition after preincubation with 5 mM spermine, and the total percent change for the original SHG baseline 
signal after both injections. Change in SHG intensity plotted as percent change normalized to preinjection levels. For all figures error bars S.E. n 5. 
 
age over a(2), the molecular nonlinear polarizability, a property two photons of the fundamental beam. In solution phase with  
of the second-harmonic active molecule that determines the isotropic molecular orientation, SHG vanishes, as seen from  
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FIGURE 4. BIOD303 is a highly specific inhibitor of the spermine-induced 
conformational change in -synuclein. A, chemical structures of the top five 
scoring BIOD303 analogs from the Maybridge Ro3 library as determined by the 
program SimFinder. B, quantification of the conformational change of a-synuclein 
upon exposure to the top five scoring chemical analogs of BIOD303. Each analog 
was added at 1 mM final concentration and the change in SHG intensity was 
measured. Representative data indicating the typical SHG response for 1 mM 
BIOD303 addition is included for comparison pur-poses. Changes in SHG 
intensity are plotted as the percent change normal-ized to pre-injection levels. C, 
quantification of conformational change in the analog-spermine competition 
assay. The indicated BIOD303 analog was pre-incubated with 1 mM a-synuclein 
and the change in SHG intensity upon expo-sure to 5 mM spermine was 
measured. Representative data indicating the typical SHG response from the 
BIOD303 5 mM spermine competition assay is included for comparison purposes. 
Changes in SHG intensity are plotted as a percent change. For all experiments 
error bars S.E. n 3. 
 
a net orientation and allowing SHG. The requirements for gen-erating 
second-harmonic light are thus as follows: the mole-cules must 
possess second-harmonic activity (a non-zero a(2)) and a net, average 
orientation. Non-centrosymmetric mole-cules with a large difference 
dipole moment between the ground and excited states often possess 
second-harmonic activity. Equation 3 can be expressed further as, 
 
𝜒𝑠,𝑖𝑗𝑘
(2) = 𝑁2 < 𝑇𝑖𝑖′𝑇𝑗𝑗′𝑇𝑘𝑘′ > 𝛼
(2)
𝑖′𝑗′𝑘′ (Eq. 4) 
 
where a(2)i j k is the molecular nonlinear polarizability mea-sured in 
the cartesian coordinate frame of the molecule. It is common for 
planar second-harmonic active molecules, such as dye molecules 
with aromatic heterocycles, to exhibit nonlinear polarizability in a 
single plane, such as x z , and mirror symme-try perpendicular to the 
x axis of the molecule. If molecular orientation is also isotropic in the 
plane of the surface, as is commonly the case, by symmetry only 
three terms of xs,ijk(2) contribute to the observed SHG, xppp(2) xpss(2) 
xsps(2). Furthermore, the nonlinear polarizability is often dominated by 
a single element, i.e. 𝛼′𝑍′𝑍′𝑍′
 (2). Then x(2) is given by, 
 






TABLE 1  
Quantification of BIOD303 analog data  
Compound 
  % Change  
 Compound only Competition assay 
BIOD303  31.7   4.3% 1.4   1.1% 
Analog 1 6.0   0.8% 14.5   1.9% 
Analog 2  8.3   0.4% 15.8   5.1% 
Analog 3  6.5   0.3% 9.2   1.7% 
Analog 4  7.4   0.8% 12.3   1.9% 
Analog 5  11.2   2.7% 14.1   4.8% 
 
where p and s denote the polarizations parallel and perpendicular to 
the plane of incidence and u is the angle between the molecular z axis 
and the surface normal (48). The observed SHG intensity of the 
labeled protein from Equation 2 is thus directly related to the 
orientationally averaged tilt angle u of the second-harmonic active 
moiety in the laboratory frame. For example, SHG is often measured 
using total internal reflection geometry. Under total internal 
reflection excitation at the critical angle, under p-polarized excitation 
and detection, and with a population of oriented molecules that have 
a single dominant element in nonlinear polarizability 𝛼𝑍′𝑍′𝑍′  and a 
narrow orientational distribution, the SHG intensity ISH≈cos6𝜃. With 
this sensitivity to tilt angle, at a mean tilt angle of 45°, for example, 
and a population of oriented molecules, conformational changes of 1° 
or less could be resolved with typical experimental noise of ~1%. For 
a dye of 1-nm length, this corresponds to a conformational arc of sub-




Ligand-induced a-Synuclein Conformational Change Analysis—
We began by examining the conformational change of a-synuclein 
upon addition of the tool compound spermine, which has previously 
been shown to bind to the C-terminal domain of a-synuclein and 
induce a change in the conforma-tion of the protein from a closed to 
an open form (19, 40). Addition of 5 mM spermine to labeled a-
synuclein resulted in an instantaneous increase in the SHG signal 
intensity (Fig. 2A, left trace). We measured the change in the SHG 
intensity at 5 mM spermine to be 36.3 5.0% (Fig. 2B). We also tested 
two other known binders, spermidine and PcTS (25, 40, 49), and 
confirmed they also induced conformational change upon binding a-
synuclein (3 mM spermidine 19.9±2.4%; 10 𝜇 M PcTS= -79.5± 
6.2%, data not shown). Next, we tested each compound from the 
Maybridge Ro3 fragment library for an ability to inhibit the a-
synuclein conformational change upon spermine addition. A hit was 
defined as complete abolishment of the spermine-induced signal 
change following preincubation of the test compound. One 
compound from the library, BIOD303, completely prevented 
spermine-induced conforma-tional change at a concentration of 1 
mM as measured by SHG (-1.4±1.1%; Fig. 2A, middle trace; Fig. 
2B).  
We next sought to determine by SHG if BIOD303 could induce a 
conformational change in a-synuclein on its own. As shown in Fig. 
2A (right trace), addition of 1 mM BIOD303 to a-synuclein changed 
the SHG baseline signal immediately. We measured the change in 
SHG intensity to be 31.7±4.3% and classified the response of the 




































































  (Eq.6) 
 
 




































FIGURE 5. Addition of a 5-fold excess of BIOD303 to -synuclein does not alter its monomeric conformation in solution. A, elution profile of a-synuclein (100 
mM) in the absence (blue) and presence (green) of 5-fold excess of BIOD303 (500 mM) shows comparable retention behavior and elution at a volume of 14 ml on a 
Superdex 200 10/300 GL size exclusion column. B, different elution fractions of size exclusion chromatography and the column loads were analyzed by reducing SDS-
PAGE and compared with an a-synuclein standard. C, 1H NMR spectra of a-synuclein (30 mM) in the absence (blue) and presence (green) of 5-fold excess of 
















































relative to baseline, magnitude, and kinetics, to be similar to that of 
spermine (Fig. 2B). Although different conformational changes 
generally produce different changes in SHG magnitude, direction, or 
kinetics, they can lead to a similar change, as observed when 
BIOD303 and spermine bind to the protein. Only a single site (A90C) 
is labeled, so the angular change at this particular site may be similar 
although the overall conformations are distinct. Moreover, spermine 
and BIOD303 are not chemically similar (Fig. 2C). 
To better understand the relationship between spermine and 
BIOD303, we determined the EC50 of both compounds for a-
synuclein conformational modulation using SHG. We obtained a 
dose-response curve (Fig. 3A) for spermine and determined its EC50 
to be 787 𝜇M (log EC50 −3.13), in agree-ment with previous values 
(40). We also measured the dose response of BIOD303 by SHG (Fig. 
3B) and determined its EC50 to be 105 mM (log EC50 −3.98). Thus, 
BIOD303 has a ~ 7.5-fold higher affinity for a-synuclein than 
spermine, which suggests that BIOD303 can potentially outcompete 
spermine in binding to a-synuclein.  
To determine whether BIOD303 was competing with sperm-ine 
for binding to a-synuclein, we repeated our original com-petition 
experiments except that we reversed the order of com-pound 
addition. In this experiment, if both ligands at a 
 
saturating dose bind to and produce the same conformation of a-
synuclein, addition of BIOD303 subsequent to spermine would not be 
expected to change the SHG signal. As seen in Fig. 3C, addition of 5 
mM spermine to a-synuclein resulted in a 39.8±4.1% increase in 
SHG signal of a-synuclein, similar to previous results. Interestingly, 
subsequent addition of 1 mM BIOD303 to the same sample resulted 
in a further 40.7±6.7% increase in the SHG intensity of a-synuclein 
suggesting that BIOD303 causes a different conformational change 
upon bind-ing a-synuclein than spermine. If the time scale for protein 
and dye re-orientation back to the original apo state is slower than 
BIOD303 binding, i.e. the reaction is not at equilibrium, this would 
account for the additional change observed when BIOD303 is 
introduced after spermine. Thus the data suggests the lack of 
response in the original competition experiment from the screen is 
due to direct inhibition of spermine by BIOD303 and not because the 
sensitivity of the assay has reached a maximal response.  
Next, we wanted to determine whether fragments chemically 
similar to BIOD303 could also modulate the conformation of a-
synuclein. We used the ranking program SimFinder (50) to select the 
five most closely related chemical analogs of BIOD303 from the Ro3 
library (Fig. 4A). The addition of each individual analog at 1 mM 
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FIGURE 6. BIOD303 binds to the C-terminal domain of -synuclein and 
attenuates intramolecular long-range contacts. A, detail of the superposi-tion 
of 1H-15N NMR spectra of 100 𝜇 M a-synuclein in the absence (black) and 
presence (red) of BIOD303. B, chemical shift perturbation analysis of 1H-15N 
resonances of a-synuclein in the presence of BIOD303 at a 1:10 molar ratio. C, 
profile of PRE of amide protons in MTSL-labeled A90C a-synuclein (100 mM) in 
the absence (black) and presence (red) of BIOD303 (3 mM). D–F, chemical shift 
perturbation analysis of 1H-15N resonances of a-synuclein in the presence of 
analogs 1 (D), 2 (E), and 5 (F), at a molar ratio of 1:80. 
 
intensity than BIOD303, indicating modulation of a-synuclein 
conformation (Fig. 4B, Table 1), but they did not fully block 
spermine binding in the competition assay (Fig. 4C, Table 1). These 
data support the exclusion of the analogs as hits in the original screen 
and suggest that the magnitude and direction of SHG responses can 
be used to distinguish structure-activity relationships, by measuring 
the degree to which ligands induce or prevent conformational change. 
In addition, these results demonstrate that BIOD303 is the most 
specific and potent inhibitor of spermine-induced conformational 
change from this series of compounds.  
NMR Analysis of the Ligand-induced a-Synuclein Conformational 
Changes—To obtain further insight into the a-synuclein-BIOD303 
interaction, we used NMR spectroscopy. NMR resonances are 
sensitive probes of protein-protein and protein-ligand interactions and 
can provide a description of interaction interfaces and binding 
affinities (51). First, the influence of BIOD303 on the aggregation 
state of a-synuclein was tested. To this end, we compared the elution 
profile of a-synuclein on a Superdex 200 10/300 GL in the absence 
and presence of a 5-fold excess of BIOD303 (Fig. 5, A and B). The 
presence of BIOD303 did not change the retention time, indicating 
that a-synuclein remains predominantly monomeric. Consistent with 
this hypothesis, the overall signal intensity in a one-dimensional 
NMR spectrum of a-synuclein was not attenuated upon addition of a 
5-fold molar excess of BIOD303 (Fig. 5C). Next,
 
BIOD303 was exposed to 15N-labeled a-synuclein and changes in 
chemical shifts were followed by two-dimensional 1H-15N correlation 
spectra of a-synuclein (Fig. 6A). Significant changes in NMR signals 
( ~0.01%) were observed for residues Gly-111 to Ala-140 of a-
synuclein (Fig. 6, A and B) at a 10:1 compound: protein molar ratio. 
A similar perturbation profile had been observed upon addition of 
spermine to a-synuclein (40), indicating that both BIOD303 and 
spermine bind to the C-terminal domain of a-synuclein. 
We also tested analogs 1, 2, and 5 for binding to a-synuclein. The 
analysis of chemical shift differences suggest that analogs 1 and 2 
bind a-synuclein more weakly than BIOD303 at 12-fold molar excess 
to a-synuclein (data not shown). No chemical shift was detected for 
analog 5 at 12-fold molar excess to a-synuclein, although chemical 
shift perturbation at the C terminus was observed at 80-fold molar 
ratio. The residual binding of analogs 1 and 2 at the a-synuclein C 
terminus was also emphasized at 80-fold molar ratio of 
compound:protein (Fig. 6, D–F). These data further corroborate our 
initial screening results and suggest that SHG is highly sensitive to 
even weak protein-ligand interactions.  
Next, we studied the consequences of BIOD303 binding on the 
conformational ensemble populated by a-synuclein in solution using 
PRE. The interaction between a specifically attached paramagnetic 
nitroxide radical and nearby protons (less than ≈  25 Å) causes 
broadening of their NMR signals because of an increase in transverse 
relaxation rate (19). This effect has an r -6 dependence on the 
electron-proton distance and thus allows the detection of long-range 
interactions in proteins. To observe transient long-range contacts 
within a-synuclein in the presence of BIOD303, we attached a 
paramagnetic MTSL label at position 90 in a-synuclein. A 
comparison of the PRE profiles of MTSL-A90C a-synuclein in the 
absence and presence of BIOD303 revealed decreased paramagnetic 
broadening at residues 40 – 46 and the C-terminal region covering 
residues 124 – 136 (Fig. 6C). Thus, BIOD303 binds to a similar site 
as spermine or to one with substantial overlap with it, and induces a 
conformational change by attenuating the long-range interactions in 
a-synuclein. 
 
Effect of BIOD303 on a-Synuclein Aggregation in Cells—  
Because both SHG and PRE data indicated that BIOD303 altered the 
conformation of monomeric a-synuclein in vitro, we investigated the 
effect of BIOD303 on a-synuclein aggregation in cells. To do so, we 
tested BIOD303 in an established human H4 neuronal cell model of 
a-synuclein aggregation and inclusion formation (45, 46). In this 
model, a C terminally modified version of a-synuclein (SynT) is co-
expressed with synphilin-1, resulting in the formation of LB-like, 
detergent-insoluble inclusions. The addition of 500 𝜇M BIOD303 to 
H4 cells significantly increased the percentage of cells without a-
synuclein inclusions (*, p= 0.0172, Student’s t test) as shown by the 
absence of a-synuclein inclusions compared with control cells (Fig. 
7). The effect on a-synuclein inclusion formation was dose dependent 
(data not shown). Analogs 1 and 2 also reduced inclusion formation 
(*, p 0.0203, 0.0477 respectively, Student’s t test), although to a 
lesser extent than BIOD303, consistent with the SHG and NMR data. 




























































































FIGURE 7. BIOD303 inhibits -synuclein inclusion formation in an H4 neuronal cell model. A, representative images of transfected H4 cells 
treated with 500 𝜇M of each compound. The staining for a-synuclein or the merge of a-synuclein and DNA (Hoechst) are indicated above the 
image. The compound addition is shown to the left of each image row. Scale bar 20 𝜇M. B, bar graph showing the percentage of H4 cells with no 




















































FIGURE 8. BIOD303 does not significantly alter proteasome 
activity in H4 cells. H4 cells expressing SynT+ synphilin were 
transfected with a plasmid encoding GFP-u, a reporter of proteasome 
activity. Twenty-four hours after transfection, cells were treated with 
different concentrations of BIOD303. No significant differences could 
be detected between treated and untreated cells. Error bars= S.E. n=2. 
 
tion (p value 0.7365, Student’s t test). These results demon-strate that 
BIOD303 and analogs 1 and 2 directly target a-synuclein and reduce 
inclusion formation in a cellular context. 
 
Because inclusion formation is a complex, multistep process we 
further investigated the mechanism by which BIOD303 reduced a-
synuclein inclusion formation. We began by deter-mining whether 
BIOD303 affected proteasome activity, which in turn could affect a-
synuclein inclusion formation. To address this we used an unstable 
version of GFP (GFPu) that is targeted for proteasomal degradation 
(47). If proteasome activity is compromised, GFP-u accumulates in 
the cell, leading to an increase in fluorescence signal. In our 
experiments, we 
 
found no significant difference in the GFP signal of control cells 
compared with cells treated with different concentrations of 
BIOD303, suggesting that proteasome activity was not significantly 
affected (Fig. 8).  
To assess whether the observed effect on inclusion formation was 
indeed due to a change in the biochemical state of a-synuclein, we 
performed Triton X -100 solubility assays. We found that BIOD303 
reduced the amount of detergent-insoluble a-synuclein compared 
with control cells (*, p 0.0424, Student’s t test) (Fig. 9, A and B), 
without changing the total levels of a-synuclein expression (Fig. 9, C 
and D), as assessed in a model where SynT and synphilin-1 are 
expressed in a 1:1 ratio (hence the slight difference in the apparent 
size on the SDS- PAGE when compared with the detergent solubility 
assay) . This result, in combination with the in vitro biochemical and 
SHG experiments, indicates that BIOD303 reduces a-synuclein 
inclusion formation in cells, by binding to and directly modulating 




Here we present an SHG-based approach to study and identify 
protein-small molecule conformational changes. Our goal was to test 
the hypothesis that modulating the monomeric a-synuclein 
conformation can affect aggregation of the protein in cells. SHG has 
previously been used to study the natural polarizability of biological 
materials such as collagen. In the pioneering studies by Freund et al. 
(52), SHG was used to demonstrate the highly ordered, anisotropic 
organization of collagen fibers in rat tail tendon. The intrinsic SHG 
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FIGURE 9. BIOD303 reduces the level of insoluble -synuclein in H4 cells. A, a representative Western blot of the Triton X-100 solubility assay 
comparing the soluble and insoluble fractions of a-synuclein upon BIOD303 treatment. Cells treated with 500 𝜇M BIOD303 show a significant 
reduction in the amount of a-synuclein in the insoluble (Insol) fraction. B, bar graph quantifying the ratio of insoluble a-synuclein to total a-synuclein 
from the Triton X-100 solubility assay. H4 cells treated with different concentrations of BIOD303 show a dose-dependent reduction in the amount 
of a-synuclein in the insoluble (Insol) fraction. Student’s t test; *, <p 0.05. n=3. C, representative immunoblot; and D, quantification showing that 































logical materials has also been demonstrated in other biological 
samples including tetra fish keratocytes and the nematode 
Caenorhabditis elegans (53, 54). Other applications of SHG include 
study of the cell membrane potential through the exogenous 
incorporation of organic second-harmonic active membrane dyes 
(55). The technique presented here renders a protein second-
harmonic active by coupling a second-harmonic active dye to it via 
standard chemistries. Conjugation with an second-harmonic active 
probe offers the key advantage that the target protein can be modified 
either randomly at lysine residues using amine labeling or site 
specifically at either naturally occurring or engineered cysteine 
residues via maleimide labeling. In addition, attaching the protein 
directly to a surface ensures that the requirement for 
noncentrosymmetric orientation of the dye, necessary for SHG, is 
met. Taken together, the approach described here should allow the 
study of virtually any biological target via SHG. 
To probe the role of conformation in a-synuclein aggregation and 
PD pathogenesis, we used SHG to identify a single compound, 
BIOD303, as a potent conformational modulator of the protein in 
vitro. The fragment appears to bind to a conformation of monomeric 
a-synuclein distinct from that bound by spermine, and it significantly 
reduces a-synuclein aggregation in a neuronal cell model. BIOD303 
is distinct from other previ-ously identified a-synuclein aggregation 
inhibitors such as cur-curmin, epigallocatechin gallate, and 
hydroxyquinolines, which are known pan-assay interference 
compounds (26, 29, 56 –58) in that it specifically binds to monomeric 
a-synuclein. In addition, BIOD303 has drug-like properties and 
appears to be an excellent starting point for medicinal chemistry 
efforts. The ability of SHG to identify BIOD303 and distinguish it 
from closely related analogs that bind to an IDP target that is chal-
lenging to screen against, for which few specific ligands are known, 
illustrates the sensitivity of the technique. As the magnitude and sign 
of the measured SHG change depend on the 
 
specific conformation and therefore the tilt angle of the label 
produced by binding each ligand, the technique can also classify 
ligands by the different conformations to which they bind. Pro-teins 
exist in an ensemble of conformations, particularly in the case of 
IDPs such as a-synuclein. Many of these conformations are short-
lived and represent only minor populations in the total ensemble, yet 
they may nonetheless be crucially important to the function of a 
protein and also unique across a protein family. Therefore, a key 
potential advantage of conformational modulators as therapeutics is 
that they can target specific, conserved con-formations and thereby 
act more selectively (1, 59 – 61). In summary, our results indicate 
that the conformation of monomeric a-synuclein plays an important, 
possibly decisive, role in the aggregation of the protein, and 
presumably PD pathogenesis. As shown here, small molecules that 
modulate a-synuclein conformation can be identified rapidly by 
SHG. By modulating the con-formation of the monomeric protein, 
selective therapeutics directed to suppressing protein aggregation and 
PD pathogenesis at the earliest stage could be developed. 
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α-synuclein (aSyn) is associated with both sporadic and familial forms of Parkinson’s disease (PD), the second most 
common neurodegenerative disorder after Alzheimer’s disease. In particular, multiplications and point mutations in 
the gene encoding for aSyn cause familial forms of PD. Moreover, the accumulation of aSyn in Lewy Bodies and 
Lewy neurites in disorders such as PD, dementia with Lewy bodies, or multiple system atrophy, suggests aSyn 
misfolding and aggregation plays an important role in these disorders, collectively known as synucleinopathies. The 
exact function of aSyn remains unclear, but it is known to be associated with vesicles and membranes, and to have 
an impact on important cellular functions such as intracellular trafficking and protein degradation systems, leading 
to cellular pathologies that can be readily studied in cell-based models. Thus, understanding the molecular effects 
of aSyn point mutations may provide important insight into the molecular mechanisms underlying disease onset. 
We investigated the effect of the recently identified A53E aSyn mutation. Combining in vitro studies with studies in 
cell models, we found that this mutation reduces aSyn aggregation and increases proteasome activity, altering 
normal proteostasis. 
We observed that, in our experimental paradigms, the A53E mutation affects specific steps of the aggregation 
process of aSyn and different cellular processes, providing novel ideas about the molecular mechanisms involved in 
synucleinopathies. 
 
Keywords: Alpha-synuclein, Parkinson’s disease, Oligomerization, Aggregation, Neurodegeneration 
 
Introduction 
Parkinson’s disease (PD) is a highly debilitating and pro- 
gressive neurodegenerative disorder affecting around seven 
million people worldwide. PD is typically known as a 
movement disorder, due to the characteristic motor 
manifestations associated with the loss of dopaminergic 
neurons from the substantia nigra, although it also affects 
other areas of the brain. PD and other neurodegenerative 
disorders, such as demential with Lewy bodies, and 
multiple system atrophy, are also characterized by the 
accumulation of aggregated alpha-synuclein  (aSyn) in 
proteinaceous inclusions known as Lewy bodies (LBs) or 
Lewy  neurites   [54].  Together, these diseases are known 
as synucleinopathies [17, 55]. However, it is still unclear 
whether LBs are themselves toxic or protective [7, 43], 
with smaller oligomeric species of aSyn being the culprits 
as recent studies suggest [31, 45, 58, 63]. aSyn is a  
disordered  and abundant  neuronal protein whose normal  
function is still elusive. Familial forms of PD associated 
with duplication and triplication of the SNCA gene [53], 
along with studies of aSyn overexpression, in cellular 
and animal models, suggest the protein
                                                                                                         may acquire  a toxic function. The cellular pathologies
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associated with increased levels and accumulation  of aSyn 
include disruption of vesicular transport [6, 42], 
mitochondrial  dysfunction,   impairment  of autophagy 
and proteasome, and oxidative stress [2, 21], suggesting 
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to its intrinsically disordered nature. Under physiological 
conditions, aSyn is considered to be a pre-synaptic protein 
[37] that associates with vesicles and membranes [11]. 
According to the “Braak hypothesis”, PD pathology is 
thought to start from the periphery (gut or nose), and   
progress until it reaches the brain [4, 5, 49], spreading in a 
prion-like manner [20, 29, 36]. However, this hypothesis is 
still controversial, and the molecular mechanisms 
underlying this phenomenon are not fully understood [25]. 
The vast majority of PD cases are sporadic but single 
point mutations in the gene encoding for aSyn (SNCA) 
cause familial forms of the disease [10]. The most recently 
identified aSyn mutation causes the substitution of alanine 
at position 53 by a glutamate residue (A53E), identified in a 
36 year-old Finnish patient with atypical PD. The patient 
displayed a dense accumulation of SNCA inclusions in the 
striatum and a severe cortical pathology, affecting both the 
superficial and deep laminae [3]. In vitro, the A53E 
mutation was shown to reduce aSyn aggregation and fi- 
bril formation without changing the secondary structure 
content of the protein, when compared to WT aSyn [15]. 
These data suggest that the negatively charged glutamate 
residue may affect the folding and, consequently, the ag- 
gregation process of the protein. 
In our study, we conducted a detailed study of the ef- 
fects of the A53E mutation on aSyn using a combination 
of in vitro and cellular models of aSyn oligomerization and 
aggregation [40, 45]. Our results showed that the A53E 
mutation modulates aSyn aggregation in vitro and in vivo 
and impacts  on distinct  cellular pathways. 
Altogether, the study of specific aSyn mutants provides 
novel insight into the spectrum of functions and cellular 
pathologies  associated,  opening  novel  avenues  for the 
design of therapeutic strategies for PD and other 
synucleinopathies. 
 
Materials and methods 
Protein  expression and  purification 
pET21a  vectors  (Novagen)  encoding  for WT  aSyn and 
the  A53E  mutant were  transformed into  E. coli BL21 
(DE3)  cells.  For  protein   expression,   10  ml  overnight 
culture  of transformed cells was used  to  inoculate  1 L 
of LB medium  with  100  μg/mL  ampicillin,  which  was 
further  incubated  at  37 °C and  250 rpm.  At an  OD600 
0.6,  protein   expression   was  induced   with  1  mM   of 
isopropyl-1-thio-β-D-galactopyranoside  (IPTG)  for  4 h 
at 37 °C. Afterwards,  the  cultures  were centrifuged  and 
the cell pellet frozen at −80 °C. 
For  cell  lysis, pellets  were  resuspended in  15  mL  of 
lysis buffer (50 mM  Tris · HCl, 150 mM  NaCl, 1 μg/mL 
Pepstatin   A, 20  μg/ml  Aprotinin,   1  mM  Benzamidine, 
1 mM  PMSF and  1 mM  EDTA)  and  sonicated  on  ice. 
The  lysate was boiled  for 10 min  at  95 °C and  soluble 
and  insoluble fractions  were separated by centrifugation at  
48,384 × g, for  15 min. 136 μL/mL of 10% strepto- 
mycin sulfate  and  228 μL/mL  of glacial acetic  acid was 
added to the supernatant. The resulting solution was 
centrifuged for 5 min at 48,384 × g, and the supernatant 
was collected and precipitated with saturated   ammo- 
nium  sulphate  at 4 °C in a ratio 1:1 (v/v) with the super- 
natant.  The pellets were washed with a 1:1 (v/v) solution 
of ammonium sulphate and  water. The  pellets  were re- 
suspended in 900 μL of ammonium acetate  100 mM and 
the same volume  of 100% ethanol  was added  to precipi- 
tated  aSyn. 
Purification protocol  was as adapted  from [59]. Briefly, 
ethanol precipitated aSyn was resuspended in starting 
buffer (25 mM Tris · HCl at pH 8.0) and filtered through 
a Millex-HP filter syringe-driven  filter unit (0.45 μm, 
Millipore). Anion exchange high-performance liquid- 
chromatography was carried out on an AKTA-FPLC (GE 
Healthcare).   The  sample  was  loaded,  bounded   to  Hi- 
Trap  column  (GE Healthcare) and  eluted  with  a NaCl 
linear  gradient  of  elution  buffer  (25  mM  Tris · HCl  at 
pH  8.0, 1 M NaCl). The  fractions  containing  aSyn were 
collected  and  buffer  was exchanged  for 20 mM  ammo- 
nium  acetate.  The  identity,  and  purity  of the  recombin- 
ant  proteins   was  assessed  by  Mass  Spectrometry and 




The  protein   stocks  were  prepared   by resuspending  ly- 
ophilized  protein  in native buffer (10 mM sodium  phos- 
phate  at  pH  7.0)  to  a  concentration  of  approximately 
100 μM. Then,  the  protein  stocks  were filtered  through 
0.22 μm filter unit.  The  integrity  of the  protein  and  the 
absence  of soluble oligomers  at the  beginning  of the re- 
action  was  confirmed   by gel filtration  chromatography 
in a Superdex 75 10/300 column (GE Healthcare Life 
Sciences).  Three   aliquots  of  300  μL  of  aSyn  WT  and 
A53E mutant were prepared  from  the  protein  stocks, in 
native buffer to a final concentration of 60 μM. Samples 
were incubated  in an Eppendorf  Thermomixer Comfort 
(Eppendorf,  USA) with  0.02% sodium  azide at 600 rpm 
and 37 °C. 
 
 
Light scattering spectroscopy 
The  transition of aSyn from  initial  soluble  monomeric 
form  to  aggregated  state  was determined by measuring 
light scattering  in a Jasco FP-8200 spectrofluorometer 
(Jasco  Inc, MD, USA) with  an  excitation  wavelength  of 
330 nm and emission range from 320 to 340 nm at 25 °C. 
Final protein  concentration was 10 μM  in native  buffer. 
Solutions  without  protein  were used as negative controls. 





Thioflavin T binding assay 
Th-T   binding  to  amyloid  fibrils  was  recorded   using  a 
JASCO  FP-8200   spectrofluorometer  (Jasco  Inc,   MD, 
USA)  with  an  excitation   wavelength   of  445  nm   and 
emission range from 460 to 600 nm at 25 °C, using a slit 
width of 5 nm for excitation and emission. The final 
concentration of Th-T  was 25 μM and final protein  con- 
centration was 10 μM in native buffer. Solutions  without 
protein  were used  as negative  controls.  All experiments 
were carried  out in triplicates. 
 
Congo  red  binding assay 
CR binding  to  amyloid  fibrils was tested  using  a Cary- 
400  Varian  spectrophotometer  (Varian  Inc.,  Palo  Alto, 
CA, USA) by recording  the absorbance  spectra  from 375 
to 675 nm, at 25 °C. A final concentration of 10 μM CR 
was added  to  10  μM  protein  samples  in  native  buffer. 
Protein   solutions   in  the  presence   and  absence  of  CR 
were used to calculate the differential CR spectra. All ex- 
periments were carried out in triplicates. 
 
Transmission electron microscopy (TEM) assays 
For negative staining,  incubated samples  were diluted  in 
Mili-Q  water  to 10 μM and  10 μL were then  placed  on 
carbon-coated copper  grids, and  left to stand  for 5 min. 
The  grids  were  washed  with  distilled  water  and  stained 
with 2% (w/v) uranyl acetate  for 1 min. The morphology 
of aggregates  of WT and A53E aSyn was observed  using 
a  JEOL  JEM  1400  transmission  electron   microscope 
(JEOL, USA) at  an  accelerating  voltage of 120 kV. The 
width  of fibrils for WT and  necklace-like  structures  for 
A53E was measured  using  ImageJ (250 measurements). 
Results are provided  as Mean ± SE. 
 
ATR-FTIR spectroscopy 
Attenuated total reflectance Fourier transform infrared 
spectroscopy  (ATR FT-IR) analysis of amyloid fibrils was 
performed using a Bruker Tensor  27 FTIR Spectrometer 
(Bruker Optics Inc.) with a Golden Gate MKII ATR 
accessory. Incubated samples were centrifuged and the 
insoluble fraction was resuspended in water. Each spectrum 
consists  of 16 independent scans,  measured at  a spectral 
resolution of 4 cm−1    within  the  1800–1500  cm−1  range. 
Second  derivatives  of the  spectra  were used  to determine 
the frequencies  at which the different spectral  components 
were  located.   FTIR  spectra   were  fitted   to  overlapping 




Aggregation  of aSyn, departing  from soluble monomeric 
form,  was monitored by measuring  the  transition from 
non-aggregated to aggregated  state according  to the Th-T 
fluorescence  at  486 nm  on  a 96-wells  microplate  reader 
for 72 h at 37 °C (Victor Microplate  reader, Perkin Elmer, 
USA). The reactions  were carried  out with 70 μM soluble 
purified WT and A53E aSyn in native buffer. Experiments 




aSyn aggregation  was measured  by sedimentation using 
centrifugation. The  incubated  samples  of WT and  A53E 
mutant were  centrifuged  at 48,384 × g for 30 min,  and 
the supernatants were carefully removed.  The amount  of 
soluble  aSyn  was  measured   by  absorbance   at  280  nm 





before  and  after  centrifugation. All measurements  were 
carried out in triplicates. 
 
 
Primer  design 
The primers  were designed  according  with the manufac- 
turer’s instructions (Table 1). 
 
 
Generation of A53E aSyn constructs for expression in 
mammalian cells 
A53E  was  inserted   in  the  Venus-BiFC  system  [45]  or 
SynT [40] by site-directed mutagenesis  (QuickChange II 
Site-Directed  Mutagenesis  Kit, Agilent  Technologies,  SC, 
USA) following the  manufacturer’s instructions. All con- 




Human  Embryonic  Kidney 293 (HEK) cells were grown 
in Dulbecco’s Modified Eagle Medium (DMEM, Life 
Technologies- Invitrogen,  Carlsbad,  CA, USA), and  hu- 
man  neuroglioma cells (H4) in Opti-MEM I with Gluta- 
max  (Life  Technologies-  Gibco,  Carlsbad,   CA,  USA), 
both  supplemented with  10% Fetal Bovine Serum  Gold 
(PAA, Cölbe, Germany)  and  1% Penicillin-Streptomycin 
(PAN, Aidenbach,  Germany).  Cells were grown at 37 °C, 





The day before transfection, 100 000 cells were plated  in 
12-well  plates  (Costar,  Corning,  New  York,  USA).  The 
cells were transfected with equimolar  amounts of the plas- 
mids using Metafectene (Biotex, Munich, Germany)  as 
specified  by the  manufacturer. After  twenty-four hours, 
the cells were collected or stained for further  analysis. 
 
 
Table 1 Primers used to perform site-directed mutagenesis and 
generate the A53E mutant 
A53E forward     5′ GAGTGGTGCATGGTGTGGAAACAGTGGCTGAGAAGAC 3′ 






Eighty thousand cells were plated in 12-well plates (Costar, 
Corning, New York, USA). After 24 h, equal amount of 
SynT and Synphilin-1 were transfected using  FuGENE6 
Transfection Reagent (Promega, Madison, USA) in a ratio 
of 1:3 according  to  the  manufacturer’s recommendation. 
Forty-eight hours after transfection, the cells were proc- 
essed for different assays. 
 
Immunocytochemistry 
After transfection, cells were  fixed with  4% paraformal- 
dehyde at room temperature (RT), followed by a 
permeabilization with 0.5% Triton  X-100 (SigmaAldrich, 
St.  Louis,  MO,  USA). The  cells  were  blocked  in  1.5% 
normal    goat   serum    (PAA,   Cölbe,   Germany)/1xPBS 
(1.37 M NaCl, 27 mM  KCl, 101.4 mM  Na2HPO47
.
H2O, 
16.7 mM KH2PO4), and then incubated  with primary 
antibody.  Primary  antibodies   used  in  this  study  were: 
mouse  Syn1 (1:1000, BD Transduction Laboratory,  New 
Jersey, USA) or rabbit  anti-aSyn  (1:1000, Abcam, Boston, 
USA), anti-Giantin (1:1000, Abcam, Boston, USA), aSyn- 
S129  1:1000  (Wako   Chemicals   USA,  Inc.,  Richmond, 
USA)  overnight,  and  secondary   antibody   (Alexa  Fluor 
488 donkey anti-mouse IgG and/or Alexa Fluor 555 goat 
anti rabbit  IgG, (Life Technologies- Invitrogen,  Carlsbad, 
CA, USA)) for 2 h at RT. Cells were finally stained  with 
Hoechst  33258 (Life Technologies- Invitrogen,  Carlsbad, 
CA, USA) (1:5000 in DPBS) for 5 min,  and  maintained 
in 1xPBS for imaging. 
 
Yeast transformation and  plasmids 
The   p426GAL-aSyn-GFP   plasmid   carries   the   human 
gene of aSyn with a C-terminal fusion to GFP, under  the 
regulation  of GAL1 inducible  promoter [44]. This  plas- 
mid was used to generate  aSyn A53E by site directed 
mutagenesis.   The  yeast  cells  W303-1A   (MATa;  can1- 
100; his3-11,15; leu2-3,112; trp1-1; ura3-1; ade2-1)  were 
transformed with  the  indicated   plasmids  using  lithium 
acetate  standard method  [16]. 
 
Yeast growth 
For all experiments,  an inoculum  was prepared  to obtain 
cells in log growth  phase, using synthetic  complete  (SC) 
medium  [0.67% (w/v) yeast nitrogen  base without  amino 
acids (Difco), 1% (w/v) raffinose and 0.79 g.L−1  complete 
supplement mixture  (CSM) (QBiogene)], 200 rpm,  30 °C, 
as we described  [57]. To induce aSyn expression,  in liquid 
medium,  cells were grown (OD600  nm   0.2) in SC selective 
medium  1% (w/v) galactose  (aSyn ON)  for 7 h at 30 °C, 
200 rpm.  aSyn cytotoxicity  was evaluated  by spotting  as- 
says. OD600 nm  was set to 0.1 ± 0.005 and 1:10 serially dilu- 
tions  of each  sample  were  prepared  [57]. Then,  4 μL of 
each  dilution  was spotted  in  solid  SC selective  medium 
containing  2% glucose  (aSyn OFF) or 1% (w/v)  galactose 
(aSyn ON)  and  incubated  at  30 °C for 36–42  h. Images 
were acquired  using ChemiDoc Touch (Bio-Rad). 
 
Fluorescence microscopy 
HEK cells expressing the aSyn Venus-BiFC assay were 
visualized   using   the   Olympus   IX81-ZDC   microscope 
system, with a 20× objective. One hundred images were 
randomly   taken out of four independent experiments. 
Total intensity was measured using the Olympus Scan^R 
Image Analysis Software. 
In order   to determine the percentage of  yeast  cells 
with   aSyn  inclusions,   cells  were  grown   as  described 
above and  GFP fluorescence  was visualized with a Zeiss 
Z2 Widefield  Fluorescence  microscope.  The  percentage 
of cells presenting aSyn inclusions  was then  determined 
by counting  at  least  300 cells for each  treatment  using 
ImageJ software. 
 
Quantification of aSyn inclusions 
Cells expressing aSyn were scored according with the 
presence   or  absence  of  inclusion   on  transfected   cells. 
Three   independent  experiments  were  performed,   and 
the results  were expressed  as the percentage of the total 
number of transfected  cells. 
 
Thioflavin S staining 
Freshly prepared,  0.5% of Thio-S (Sigma-Aldrich,  St. Louis, 
MO, USA) was incubated within  the  cells for 5 min. The 
cells were washed three times with 80% ethanol, and main- 
tained in 1xPBS for fluorescence microscopy. 
 
Quantification of Golgi fragmentation 
Golgi morphology  was assessed  in transfected HEK and 
H4, and scored into three groups, was we previously 
published  [32] (normal,  diffused and fragmented).  Three 
independent experiments were performed. 
 
Western  blot  analysis 
HEK and  H4  cells were  lysed with  Radio-Immunopre- 
cipitation  Assay (RIPA) lysis buffer (50 mM  Tris  pH 8.0, 
0.15    M    NaCl,    0.1%   SDS,   1%   NP40,    0.5%   Na- 
Deoxycholate),   2  mM  EDTA  and  a  Protease   Inhibitor 
Cocktail (1 tablet/10  mL) (Roche Diagnostics,  Mannheim, 
Germany). Protein  concentration was determined by 
Bradford assay (BioRad Laboratories,  Hercules, CA, USA), 
and the sample  were denaturation for 5 min at 100 °C in 
protein  sample  buffer (125 mM of 1 M Tris HCl pH 6.8, 
4% SDS  0,5% Bromophenol  blue,  4  mM  EDTA,  20% 
Glycerol, 10% b-Mercapto ethanol).  The  gels were loaded 
with  80  μg  protein,  and  the  samples  separated   on  12% 
SDS-polyacrylamide   gels.  The  gel  was  transferred  to  a 
PVDF membrane using a Trans-Blot  Turbo transfer system 
(BioRad), according  to the manufacturer’s instructions. 





Sigma-Aldrich  St. Louis, MO,  USA), and  incubated  with 
Syn1 (1:1000, BD Biosciences, San  Jose, CA, USA), and 
1:2000 anti-b-actin (Sigma-Aldrich, St. Louis, MO,  USA) 
overnight  at 4 °C. After washing,  the  membranes were 
incubated for 1 h with secondary  antibody,  anti-mouse 
IgG, or anti-rabbit IgG, horseradish peroxidase  labeled 
secondary   antibody   (GE  Healthcare,   Bucks,  UK)  at 
1:10,000. Proteins  were detected  by ECL chemiluminescent 
detection  system (Millipore, Billerica, MA, USA) in Fusion 
FX (Vilber  Lourmat).   The  band  intensity  was  estimated 
using the ImageJ software (NIH, Bethesda, MD, USA) and 
normalized against b-actin. 
For  aSyn quantification total  yeast  protein  extraction 
and western  blot was performed following standard pro- 
cedures  as described  before  [57]. Antibodies  used: aSyn 
(BD Transduction Laboratories,  San Jose, CA, USA), 
pS129-aSyn (Wako  Chemicals  USA, Inc., Richmond  VA, 
USA) PGK (Life Technologies,  PaisleyUK). Triton  soluble 
and insoluble fractions were processed and analyzed as de- 
scribed before [56]. 
 
Native PAGE 
For native PAGE, HEK cells were lysed in 1xPBS pH 7.4 
with  Protease  Inhibitor  Cocktail  tablet  and  separated  in 
4–16% gradient  Native pre-cast  gel (SERVA Electrophor- 
esis GmbH,  Heidelberg,  Germany).  Gels were run accord- 
ing to the  manufacturer’s instructions, and  transferred as 
previously described. 
 
Proteinase K digestion 
H4   cells  samples   were   digested   with   Proteinase   K 
(2.5 μg/mL)  (Roth,  Carlsbad,  Germany)  for  1, 3, and 
5 min at 37 °C. The enzyme reaction  was stopped  with 
protein  sample  buffer, and  the  samples  were separated 
in a SDS-page gel, as described  above. 
 
Flow cytometry (FCM) 
FCM was performed in a BD FACSCanto  II. To analyze 
cell viability yeast  cells  transformed with  the  indicated 
plasmids  were incubated with 5 μg.mL
−1   
PI, for 15 min 
at 30 °C, 200 rpm  and  protected from  light. Cells were 
then  washed with PBS and used to FCM. A minimum of 
10,000  events  were  collected  for  each  experiment.  Re- 
sults  were  expressed   as  median   fluorescence   intensity 
(MFI) of a molecule. 
 
Measurement of 26S Proteasome Catalytic Activity 
The  chymotrypsin-like  activity  of  the  26S  proteasome 
was  determined  has  previously  described   [27].  Briefly, 
after 48 h transfected  cells were collected  in lysis buffer 
(50 mM  Tris,  pH  7.5, 250 mM  Sucrose,  5 mM  MgCl2, 
1 mM  DTT,  0.5 mM  EDTA,  0.025% Digitonin,  2 mM 
ATP). The reaction  was initiated  with 15 μg from the total 
protein  lysates, together  with the addition of reaction  buffer 
(50 mM Tris (pH 7.5), 40 mM KCl2, 5 mM MgCl2, 1 mM 
DTT,  0.5 mM  ATP, 100 μM Suc-LLVYAMC) were mix in 
100 μl fina volume. The fluorescence of AMC (380 nm ex- 
Citation and 460 nm emission)  was monitored in a micro- 
plate  fluorometer  (Infinite  M1000,  Tecan)  at  37  °C. As 
control, proteasome was  inhibited   with  20  μM  MG132 
(Sigma, Hamburg,  Germany) prior to the measurements. 
 
Statistical analyses 
Data were analyzed using GraphPad Prism 6 (San Diego 
California, USA) software and  were  expressed   as  the 
mean + − SD. Statistical  differences  from  WT aSyn were 
calculated using unpaired Student t-test and one-way 
ANOVA with post-hoc  Tukey’s test. Significance was 
assessed for, where  * corresponds to  p < 0.05, **  corre- 
sponds  to p < 0.01 and *** corresponds to p < 0.001. 
 
Results 
A53E mutant forms protofibrils by reducing 
aSyn fibrilization 
To understand the effect of the A53E substitution in the 
aggregation  process  of  aSyn  (Fig. 1a),  we  assembled  a 
pipeline  of both  in  in vitro  and  cellular  studies,  in  hu- 
man and yeast cells (Fig. 1b), and conducted a battery  of 
experiments to characterize the behavior  of this recently 
identified aSyn mutant form. 
We  started  to compare  the  in vitro aggregation  prop- 
erties of WT and A53E aSyn using synchronous light 
scattering,  sedimentation and binding  to amyloid-binding 
dyes. For these  assays, the soluble forms of both  proteins 
were incubated  at 60 μM under  agitation  at 37 °C for two 
weeks.  The  light  scattering  signal  was 6-fold  higher  for 
WT  aSyn than  for  the  A53E mutant,   suggesting  differ- 
ences in aggregation  process  (Fig. 2a). Using spectropho- 
tometry,  we quantified  the levels of aggregated  protein  in 
both  solutions  after separating  aSyn in two fractions  (sol- 
uble and insoluble), by centrifugation. The amount of pro- 
tein in the insoluble  fraction  in the WT aSyn preparation 
was two times higher than with A53E (*p < 0.05, Fig. 2b). 
The presence  of amyloid fibrils can be detected  in vitro 
using Thioflavin T (Th-T),  a dye that  specifically binds to 
amyloid fibrils [35, 51]. In agreement with light scattering 
and  sedimentation data, we found  that  the Th-T  fluores- 
cence  signal was 10 times  lower  for A53E than  for WT 
aSyn (Fig. 2c). The presence  of amyloid fibrils can be fur- 
ther  detected  by monitoring the  increase  of the  absorb- 
ance of Congo Red (CR) and the red shift of the dye 
absorbance  maximum  [28]. The  binding  of A53E to  CR 
was negligible, since the  peak of absorbance  in the  pres- 
ence of A53E aSyn was similar to that of free CR (Fig. 2d). 
In contrast,  we observed a dramatic  spectral change in CR 
for WT aSyn (Fig. 2d). To confirm the different amyloido- 
genic propensities of WT and A53E aSyn, we analyzed the 







































Fig. 1 Aggregation process and study design. a aSyn aggregation process in cell models. b Experimental design used in the study. In vitro 
studies and studies in cell models were used to assess the effect of the A53E mutation on aSyn 
 
transmission electron microscopy (TEM). Although we 
detected  the  presence  of higher  order  complexes  in both 
preparations, their size and morphology  was different. For 
WT aSyn, we observed  the  typical long and  unbranched 
amyloid  fibrils (Fig. 2e), 11.6 ± 0.4 nm  with  a width  of 
11.6 ± 0.4  nm   (Fig.  2e).  In   contrast,    the   structures 
formed by A53E aSyn exhibited a protofibrillar  appearance, 
with small round  oligomeric  structures that  seemed  to be 
linked in a necklace fashion, with a width of 28.5 ± 0.7 nm 
(Fig. 2f-g). 
To  assess  the  secondary  structure content of the  as- 
semblies formed  by WT and A53E aSyn, we analyzed the 
amide I region of the FTIR spectrum (1700–1600  cm
−1
). 
This region  of the  spectrum corresponds to the  absorp- 
tion  of  the  carbonyl  peptide  bond  of  the  main  amino 
acid  chain  of the  protein,  and  is a  sensitive  marker  of 
the  protein  secondary  structure. After  deconvolution of 
the  FTIR spectra  of the  aSyn solutions,  we were able to 
assign  the  individual  secondary  structure elements  and 
their  relative contribution to the main  absorbance  signal 
at the end of the aggregation  reaction  (Fig. 2g and h and 
Table 2). The absorbance  spectra  were radically different 
for WT and A53E aSyn. While the spectrum of WT aSyn 
was dominated by a peak  at  1625 cm−1,  attributable to 
the presence of amyloid-like inter-molecular β–sheet 
structure (Fig. 2g),  the  spectrum  of  the  A53E  mutant 
was dominated by a peak at 1649 cm
−1  
corresponding to 
disordered/random coil conformation (Fig. 2h). 
Next,  we  monitored  how  the  mutation impacted   on 
the  aggregation  kinetics  of aSyn by continuously moni- 
toring  the  changes  in  Th-T  binding  over  time  for  WT 
and A53E variants.  The  kinetics  of amyloid fibril forma- 
tion usually follows a sigmoidal curve that reflects a 
nucleation-dependent growth  mechanism.  The  aggrega- 
tion  of both  proteins  followed this  pattern,  with  an  ap- 
parent  lag phase of 8 h (Fig. 2i). After this lag phase, the 
two aggregation  reactions  diverged  significantly, with an 
exponential   increase   for  WT  aSyn  that   plateaued   at 
around  55 h, and a steady and much  slower increase  for 
A53E aSyn, reaching  a 3.5-times  lower  fluorescence  in- 
tensity. Altogether,  our data demonstrates that  the A53E 
mutation reduces  aSyn amyloid formation  in vitro. 
 
The A53E mutation decreases aSyn oligomerization in 
cellular models 
We  next  investigated  the  effects  of the  A53E mutation 
on  the  behavior  of aSyn in the  context  of living human 






































































(See figure on previous page.) 
Fig. 2 Aggregation properties of WT and A53E aSyn variants. aSyn WT and A53E mutant, prepared at 60 μM in 10 mM sodium phosphate, 
pH 7.0, were incubated for 2 weeks under agitation at 37 °C. a Static light scattering of 10 μM aSyn in 10 mM sodium phosphate, WT (solid line) 
and A53E mutant (dashed line). b Distribution of aSyn between the soluble and insoluble fractions. c Fluorescence emission spectra of Th-T upon 
incubation with 10 μM aSyn WT (solid line) and A53E mutant (dashed line). Free Th-T emission spectrum is represented in grey. d CR absorbance 
spectra in the presence of 10 μM aSyn WT (solid  line) and A53E mutant (dashed line). Free CR absorbance spectrum is represented in grey. 
f-g Morphology of WT and A53E aSyn aggregates TEM micrographs. Negatively stained aggregates formed by aSyn WT (left panel) and A53E 
mutant (right panel) incubated for two weeks. h-i Secondary structure of WT and A53E aSyn aggregates. Secondary structure content of the aSyn 
WT and A53E mutant after two weeks incubation. ATR-FTIR absorbance spectra in the amide I region was acquired (thick line) and the fitted 
individual bands after Gaussian deconvolution are shown (thin lines). i Aggregation kinetics of WT and A53E aSyn. Aggregation kinetics of aSyn 
were monitored by following the changes in relative ThioT fluorescence emission. Concentration of protein was 70 μM WT aSyn (crosses) and 
A53E mutant (dots) in a final volume of 150 μL. The evolution of Th-T fluorescence in the absence of protein is represented in grey, n = 3  
 
Complementation (BiFC) assay to monitor aSyn 
oligomerization, as we previously  described  [45]. Briefly, 
non-fluorescence Venus fragments  are fused to either  the 
N- or C-terminus of aSyn and, upon dimerization/ 
oligomerization of the protein, the fluorophore is reconsti- 
tuted  resulting  in fluorescence  signal. While this assay in- 
volves the  tagging  of aSyn with fragments  of fluorescent 
proteins,  it constitutes a powerful paradigm  to assess aSyn 
oligomerization. We observed  that  A53E aSyn, similarly 
to  WT,  formed   dimers/oligomers  (Fig.  3a).  However, 
the  fluorescence   signal  was  lower  than  that  observed 
with WT aSyn, suggesting differences in the dimerization/ 
oligomerization  process   (**p < 0.01)  (Fig.  3b),  since  the 
levels of expression  of WT and A53E aSyn were identical 
(Fig. 3c and d, Additional  file 1: Figure S2.1 and Additional 
file 1: Figure S2.2). We also found  that  the A53E mutant 
produced high  molecular  weight  species,  similar  to  WT 
aSyn (Fig. 3e). Thus,  we refer  to  the  species  formed  as 
oligomers, for simplicity. 
 
The A53E mutation alters  the  biochemical properties 
of aSyn inclusions 
Next,  we investigated  if the  later  stages  of the  aSyn ag- 
gregation   process  were  altered  by  the  A53E  mutation. 
For that,  we used  a well-established  cell-based  aggrega- 
tion  model  that  consists  in  the  co-expression  of SynT 
(C-terminally  modified  aSyn) and Synphilin-1  [40], since 
expression  of aSyn alone  does not  result  in inclusion  for- 
mation.  In  this  aSyn aggregation  model,  aSyn inclusions 
are  readily detected  by immunocytochemistry using  anti- 
bodies against aSyn, allowing the characterization of differ- 
ent  types of inclusions  [32], and  screening  modulators of 
aSyn aggregation  [41]. 48 h after transfection, we analyzed
inclusion formation  in the cells (Fig. 4a), and observed that 
the A53E mutation did not alter inclusion  formation  when 
compared to WT aSyn (Fig. 4b). Again, no differences  in 
the  levels of aSyn or  Synphilin-1  were  detected  between 
WT and A53E mutant aSyn (Fig. 4c-e). 
aSyn is phosphorylated on  Serine  129 (pS129) in LBs 
found in the brains of PD patients, linking this post- 
translational modification  with disease [14, 52]. We pre- 
viously showed  that  specific aSyn mutations, such as the 
E46K, can alter pS129 on aSyn [39]. Thus  we investigated 
the effect of the A53E mutation on S129 phosphorylation. 
We found  that  both  WT and  A53E aSyn inclusions  were 
positive for pS129 (Fig. 4f ). 
To further investigate the biochemical nature  of the 
inclusions  formed  by the A53E aSyn mutant, we stained 
the cells with Thioflavin  S (Th-S), a dye that  binds  to β- 
sheet rich amyloid structures [33]. We observed  that  the 
larger  inclusions  formed  by WT and  A53E aSyn stained 
positive for Th-S (Fig. 4g). In addition,  we also used pro- 
teinase  K (PK) resistance  as a marker  of aggregate  for- 
mation,  as protein  inclusions  tend  to be more  resistance 
to  PK digestion.  Interestingly,  we found  that  the  A53E 
mutant was less resistant  when  compared to  WT  aSyn 
(Fig. 4h and  i), suggesting  the  inclusions  formed  by the 
A53E  mutant  have  a  less-compact  nature   than   those 
formed  by the WT protein. 
The  ubiquitin-proteasome system  (UPS) is the  major 
non-lysosomal pathway for selective protein  degradation. 
In  cell models,  it has  been  shown  that  aSyn accumula- 
tion  can  affect  the  activity  of the  UPS  system  [61]. In 
our  experimental conditions,  we observed  that  cells ex- 
pressing A53E aSyn mutant display increased  proteolytic 
activity of the proteasome (Fig. 4j and k).
 
Table 2 Assignment of secondary structure components of aSyn variants in the amide I region of the FTIR spectra 
 
 WT    A53E  
Band (cm−1) Area (%) Structure  Band (cm
−1) Area (%) Structure 
1 1625 40 β -sheet (inter)  1628 24 β -sheet (inter) 
2 1645 22   1649 38  
3 1663 25 Loop/β-turn/bend/α-helix  1666 25 Loop/β-turn/bend/α-helix 











































Fig. 3 A53E reduces aSyn oligomerization. a Fluorescent cells, expressing VN-aSyn and aSyn-VC constructs, as a result of the aSyn interaction. 
Scale bar: 30 μm. b Mean fluorescence intensity of cells were assessed 24 h post-transfection using an Olympus  IX81-ZDC microscope. For each 
condition, 100 pictures were acquire in 4 independent  experiments were conducted. Student’s t test (**p < 0.01). c-d aSyn protein levels were 
assessed by immunoblot analysis and were found to similar between WT aSyn and the A53E mutant. n = 3. e Native-PAGE gel showed that the 
A53E mutant forms high molecular weight species similar to WT aSyn 
 
aSyn aggregation leads  to Golgi fragmentation 
aSyn induces  several cellular  pathologies  that  have been 
documented over the  years and  are routinely  used  to as- 
sess the effect of specific mutations or genetic interactors 
[60]. One  particular  type of cellular  pathology  associated 
with aSyn toxicity is the fragmentation of the Golgi appar- 
atus [13]. This is also evident  in other  neurodegenerative 
diseases  [18], suggesting  it might  be  a more  general  re- 
sponse  to the  proteotoxicity associated  with protein  mis- 
folding and  aggregation.  To assess whether  expression  of 
A53E mutant aSyn affected the integrity  of the Golgi, we 
analyzed  the  morphology   of  this  organelle  in  both  the 
aSyn oligomerization and aggregation  models (Fig. 5a and 
c). We classified the morphology  of the Golgi as normal, 
diffuse and fragmented,  as we previously described [32]. 
In  the  oligomerization model,  we  observed  that  WT 
aSyn reduced  the  percentage of cells exhibiting  normal 
Golgi morphology  (~40%, ***p < 0.001 Fig. 5a and  b and 
Additional   file  1:  Figure  S3.1–3.3),  as  we  previously 
reported   [32].  However,  in  cells  expressing   the  A53E 
mutant  the  effects  were  not   as  pronounced  as  with 
WT,  and  the  phenotype   was  more  similar  to  that  of 
cells  carrying  an  empty  vector  (~70% and  80% of the 
transfected  cells displayed  normal  Golgi morphology  for 
A53E, and  empty  vector,  respectively)  (*p < 0.05) (Fig. 5b 
and Additional  file 1: Figure S3.1). 
In  the  aSyn aggregation  model,  we observed  the  op- 
posite  effect.  Around   50% of  the  cells  expressing  the 
A53E SynT displayed normal  Golgi morphology  whereas 
around  70% of the  cells expressing  WT  SynT displayed 
normal  Golgi (Fig. 5c and d and Additional  file 1: Figure 
S2.4–2.6; ***p < 0.001 and *p < 0.01 for empty vector, and 
WT,  respectively).  This  suggests  that  the  aggregation  of 
A53E aSyn induces  Golgi alterations. 
 
A53E aSyn behaves identically to WT aSyn in yeast cells 
Yeast cells have been  extremely  useful to assess cellular 


























   





































(See figure on previous page.) 
Fig. 4 A53E does not change the inclusion pattern. a-b At least 50 cells per condition were classified according to the pattern formed. We 
observed that A53E did not change the number of inclusions per cells. n = 3. Scale bar: 30 μm. c-e Immunoblot analysis of the aSyn and 
Synphilin-1 levels showed no significant differences in expression of WT or A53E aSyn. n = 3 (f) Inclusions  formed by WT and A53E are positive for 
pS129. Positive inclusions are indicated with white arrows. Scale bar: 30 μm. g Inclusions were stained with Th-S and analyzed via fluorescence 
microscopy.  As indicated with arrow heads, we observed that some inclusions displayed amyloid-like properties, by staining positive with Th-S. 
Scale bar: 30 μm. h-i WT and A53E aSyn protein lysates were digested with PD for different times (1, 3 and 5 min). After normalization of the 
values to the undigested condition, we observed that A53E inclusions  are less resistant to PK-digestion. n = 2. j-k 48 h post-transfection the cells 
were collected and we assessed the activity of the proteasome. We observed that cells expressing A53E mutant increased proteolytic activity of 
the proteasome in comparison with WT. n = 3. Student’s t test (*p < 0.05, **p < 0.01) 
in order to assess if the A53E mutation alters the cytotox- 
icity and aggregation  of aSyn, we expressed  this mutant in 
S. cerevisiae and  monitored phenotypes  previously  estab- 
lished [44]. We expressed WT or mutant A53E aSyn fused 
to  eGFP using  multi-copy  (2 μ) plasmids  and  under  the 
regulation  of a galactose-inducible promoter (GAL1). aSyn 
cytotoxicity  was first  evaluated  by a spotting  assay. The 
growth  of the  cells expressing  A53E aSyn was compared 
to that of cells expressing WT aSyn (Fig. 6a). As described 
before, expression  of WT aSyn is toxic and  results  in re- 
duced cell growth (Fig. 6a). We found that cells expressing 
A53E aSyn display  a  similar  phenotype,   suggesting  that 
this  familial  mutation does  not  significantly  affect  aSyn 
toxicity in yeast (Fig. 6a). To further  dissect  the  cytotox- 
icity of the A53E mutant,  we performed  propidium iodide 
(PI)  staining  and  flow  cytometry  analysis,  a  readout   of 
plasma  membrane integrity  (Fig. 6b). We  observed  that, 
7 h after induction of aSyn expression,  no significant  dif- 
ferences  were  observed  between  cells  expressing  either 
WT or the A53E aSyn (Fig. 6b). 
Next,  we evaluated  the  subcellular  distribution of the 
A53E mutant aSyn, using  fluorescence  microscopy.  7 h 
after induction of aSyn expression  we assessed inclusion 
formation  in the  cells (Fig. 6c). The  expression  of A53E 
aSyn resulted  in the formation  of cytoplasmic  inclusions 
that  looked  similar  to  those  formed  in  cells expressing 
aSyn WT (Fig. 6c). In addition,  no significant differences 
were observed  in the  percentage of cells with inclusions 
between  WT and  the  A53E (Fig. 6c). We  also evaluated 
the  levels  of  aSyn  expression   by  immunoblot analyses 
and  found  that  both  proteins  were  expressed  at  similar 
levels (Fig. 6d). The  levels of phosphorylation on  serine 
129 were  also indistinguishable between  WT  and  A53E 
mutant aSyn (Fig. 6d). 
 
Discussion 
aSyn plays a major  role in the  pathological  processes  in- 
volved in neurodegenerative diseases, like PD or Dementia 
with  Lewy Bodies [26]. When  overexpressed  in  cells, to 
mimic familial forms of PD associated with multiplications 
of  the  aSyn  gene,  aSyn  can  promote   cytotoxicity  and 
impair  vital processes,  thereby  contributing to cell death 
[9, 38, 44]. However,  the  precise  molecular  mechanisms 
underlying  aSyn toxicity  are  still  unclear,  compromising 
our  ability  to  intervene   therapeutically.   Both  mutations 
and multiplications of the SNCA gene cause familial forms 
of PD  [8, 22, 64]. Currently,  six missense  mutations in 
aSyn  have  been   associated   with   autosomal   dominant 
forms of parkinsonism (A30P, E46K, H50Q, G51D, A53E, 
A53T)  [1, 30, 34, 46–48,  65]. Of  these,  the  A53E was 
the  last  one  to  be  identified  and,  therefore,  has  been 
less investigated. 
In this study, we aimed  to investigate  the effect of the 
substitution of the  alanine  at position  53 by a glutamic 
acid residue  that  introduces an additional  negative charge 
in  the  protein.  For  this  purpose,  we used  in  vitro  tech- 
niques to characterize the biophysical effects of the muta- 
tion, and exploited  cell-based  models  to assess the effects 
of the expression  of the A53E mutant on the distribution, 
aggregation, and toxicity of the protein. 
In vitro, we observed that A53E attenuates aSyn aggre- 
gation  and  reduces  amyloid  fibril formation  when  com- 
pared to WT aSyn. In fact, the formation  of amyloid 
structures by the  A53E mutant is marginal,  since  A53E 
is unable  to bind  CR. Overall,  these  observations  are in 
line with a previous  report  showing that  the presence  of 
a negatively-charged residue  can reduce  the intrinsic  ag- 
gregation  propensity  of aSyn [15]. Nevertheless,  because 
the  change  in net  charge  in  aSyn is small, −9 and  −10 
for  the  WT  and  A53E proteins,  respectively,  the  effect 
this mutation has on aggregation  has more  likely a local 
origin. We used the Amylpred2 consensus aggregation 
predictor  to analyze if the A53E mutation might have an 
impact   in  the  intrinsic   aggregation   propensity   of  the 
aSyn sequence.  Amylpred2  identifies a hot spot of aggre- 
gation corresponding to the 49–55 sequence stretch 
(VHGVATV),   including   Ala53.   The   A53E   mutation 
shortens  the aggregation  region now including  only resi- 
dues 49–53  (VHGVE). The AGGRESCAN algorithm  en- 
ables  the  comparison  of  the  aggregation  propensity   of 
the  two  regions,  showing  that  it  is 2.1 lower  for  A53E 
than  for WT aSyn. 
In  the  context  of a cell, the  behavior  of a protein  is 
subjected  not  only to the crowded  environment but also 
to  the  action  of various  protein  quality  control  mecha- 
nisms. In human  cells, we observed that  the A53E muta- 
tion  reduces  aSyn oligomerization without  changing  the 























































Fig. 5 Golgi morphology in the oligomerization and aggregation models. a-b Representative pictures of transfected cells with the BiFC system. 
We analyzed and categorized transfected cells in different categories. Scale bar: 30 μm. b WT aSyn resulted in an increased percentage of cells 
with fragmented Golgi morphology when compared with the empty vector and with cells expressing the A53E mutant. c-d Representative 
pictures of transfected cells with SynT + Synphilin-1. Scale bar: 30 μm. d In the presence of A53E SynT, the Golgi is more diffuse when compared 
with the control and with WT SynT. n = 3  
 
by A53E aSyn are  more  sensitive  to  PK digestion  than 
those formed  by WT aSyn, suggesting that  the inclusions 
formed  are less compact  or, possibly, more  immature. The 
negative  charge  introduced by the  glutamate  residue  can 
perhaps  alter the intermolecular interactions between  aSyn 
molecules,  and prevent  the formation  of tighter  inclusions. 
This may also correlate  with the increase in proteasome ac- 
tivity that  we observed,  since this is an important degrad- 
ation system to eliminate soluble proteins and smaller 
assemblies that are not degraded by autophagy. 
In our previous studies, we did not observe major differ- 











































Fig. 6 Phenotypic characterization of yeast cells expressing the A53E aSyn mutant. a Cytotoxicity of WT and A53E aSyn in yeast cells compared to 
the empty vector, assessed by spotting assay. Photos were taken 3 days after incubation at 30 °C. b Frequency of PI positive cells assessed by flow 
cytometry, after 7 h of induction of expression of WT and A53E aSyn. c Fluorescence microscopy visualization  (left panel) and percentage of cells 
with WT and A53E aSyn inclusions (right panel). d Expression levels of WT and A53E aSyn-GFP in yeast cells assessed by western blot analysis of 
total protein extracts. Results shown are from one representative experiment from at least three independent  experiments.  Values represent 
the mean ± SD of at least three independent  measurements 
 
 
at position 53 (A53T) with WT protein.  We found that the 
aggregation  of A53T aSyn was identical to that of WT aSyn 
[32], suggesting again that the change in charge at position 
53 may influence the initial steps of the aggregation  process 
(dimerization/oligomerization)  of aSyn, and  not  the  later 
steps that  culminate  with the formation  of the mature  in- 
clusions.  Also,  the  differences  might  result  by difference 
spatial sequestration of aSyn. Misfolded proteins  can be tar- 
getted  to specific compartments, like aggresomes,  to facili- 
tate  their  degradation [23, 24, 62].  These  compartments 
rely on filament  network  proteins  like vimentin,  actin, and 
tubulin,  or proteins  that  can assist in the transportation of 
misfolded  proteins  through the microtubule network,  such 
as p62 (24843142, 12093283, 14623963, 24086678). For ex- 
ample, Tubulin  Polymerization Promoting Protein  (TPPP/ 
p25), belongs  to  the  microtubule network,  and  associates 
with  aSyn  in  pathological   conditions,   possibly  affecting 
aSyn aggregation (17123092). 
The  Golgi  apparatus plays  a  determinant role  in  the 
intracellular flow of several endogenous proteins  and ex- 
ogenous   macromolecules,  regulating   the  trafficking  to 
their  final destination inside  or  outside  cells [12]. Frag- 
mentation of the  Golgi apparatus is a characteristic  fea- 
ture  in several neurodegenerative diseases, including  PD 
[13, 18, 19]. Interestingly,  in our  cell-based  aggregation 
models,  we observed  a striking  loss of the  typical Golgi 
morphology   in  cells  expressing   A53E  aSyn.  Previous 
studies  about   the  effect  of  this  recently  identified  PD 
mutation in aSyn showed  that  A53E is as toxic  as WT 
aSyn [15, 50]. While this was also the trend  we observed 
in our cellular models, our findings suggest that the A53E 











Overall, our study demonstrates that the A53E aSyn mu- 
tation  influences  the ability of aSyn to aggregate in vitro 
and  in  vivo, and  that  it  may  induce  different  cellular 
pathologies that should be further investigated in vivo. 
Ultimately,  a deeper  understanding of the  effect of aSyn 
mutations on  the  behavior  of the  protein  will enable 
the   design  of  novel  models   to  assess  the   potential 






Additional file 1: Figure  S1.1. Biochemical characterization of WT and 
A53E recombinant aSyn. Analysis of purified WT and A53E aSyn variants 
by SDS-PAGE (18%) stained with Coomassie Brilliant Blue. S1.2. MALDI-TOF 
mass spectrometry analysis of purified WT (up) and A53E (down) aSyn 
variants.  A MW of 14462.98 Da was obtained for WT (theoretical of 
14460.16 da) and of 14519.47 Da for A53E (theoretical of 14518.19 Da) 
aSyn variants. The peaks of 7231.82 and 7260.97 Da correspond to the 
M
+2 
ions of WT and A53E aSyn, respectively.  Figure S2.1 and  S2.2. 
Immunoblot quantifications. Levels of VN-aSyn (S2.1) and aSyn-VC 
(S2.1). n=3. Figure S3.1-S3.3. Morphological analysis of Golgi apparatus 
in the aSyn BiFC system. The morphology of the Golgi was analyzed as 
normal (S3.1), diffuse (S3.2) and fragmented (S3.3). One-way ANOVA 
with post-hoc Tukey’s test (*p<0.05, **p<0.01, ***p<0.001). n=3. Figure 
S3.4-3.6 Morphological analysis of Golgi apparatus in the aSyn 
aggregation model. Transfected cells were analyzed according to the 
morphology of the Golgi: normal (S3.4), diffuse (S3.5) and fragmented 
(S3.6) One-way ANOVA with post-hoc Tukey’s test (*p<0.05, **p<0.01, 




A53E: Substitution of alanine at position 53 by a glutamate residue; aSyn: 
alpha-synuclein; ATR FT-IR: Attenuated total reflectance Fourier transform 
infrared spectroscopy; BiFC: Bimolecular fluorescence complementation assay; CR: 
Congo red; H4: Human Neuroglioma cells; HEK: Human embryonic kidney cells; 
IPTG: isopropyl-1-thio-β-D-galactopyranoside; LBs: Lewy  bodies; 
PD: Parkinson’s disease; PI: Propidium iodide; PK: Proteinase K; RT: Room 
temperature; SC: synthetic complete medium; TEM: Transmission electron 
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4.1. The urgency for standardization of models and observations  
Many neurodegeneration disorders are associated with the misfolding and 
aggregation of proteins. However, the molecular events that underlie the aggregation 
process and that specifically dictate neuronal cell death in each disease are still 
unclear. Over the years, different in vitro and in vivo models were established and 
enabled tremendous progress in the field. However, due to the complexity of each 
disorder, we still lack a clear and fundamental understanding of the underpinning 
molecular mechanisms and cellular pathways. This is also due to the complexity and 
specificity of each model system, and our limited success in transposing findings 
across the various models.  
The present study aimed at shedding light into the cellular pathologies 
associated with aSyn aggregation. To do this, we exploited two cell-based models of 
aSyn aggregation in order to compare the effect of genetic alterations in aSyn on its 
aggregation. For the first time, all reported familial and artificial mutations were 
systematically compared in well-established cell models. Our goal was to create a 
comprehensive and pivotal knowledge that can then be explored to screen and 
optimize novel compounds that interfere with pathological forms of aSyn. In addition, 
we tested the effect of small molecules selected based on in vitro assays, and found 
protective effects in the cell models. 
 
4.2. Distinguishing aSyn species and their cellular effects 
Artificial mutants of aSyn are useful tools to probe the behavior of the protein, 
since they can trap aSyn in specific conformations, therefore allowing us to assess 
their effects in different environments. The E35K and E57K aSyn mutants were 
specifically designed to form oligomers, by disrupting aSyn salt bridges. In vitro 
studies confirmed that they form ring/pore-like structures and not amyloid fibers (as 
the A30P, E46K and A53T aSyn mutants do). In vivo, E35K and E57K aSyn cause a 
stronger reduction in DA cells in the rat SN (Winner et al. 2011). Furthermore, those 
toxic oligomer-forming mutants display a higher affinity to bind to membranes in 
comparison with WT aSyn. The E46K mutant was been described to fibrillize more 
4. Discussion 
89 
rapidly than WT aSyn (Greenbaum et al. 2005; Ono et al. 2011), and the fibrils 
formed have a distinct twisted appearance (Choi et al. 2004), maybe because of the 
long-range interactions of the C-terminus with the N-terminus and NAC regions, 
producing more compact structures (Wise-Scira et al. 2013). Although this mutant 
occurs in PD patients, it was found to cause reduced cell death, and reduced calcium 
influx when compared with the artificial E35K and E57K mutants (Winner et al. 
2011).   
In our aSyn-aggregation cell model, we observed that E46K, E35K and E57K 
produce inclusions that are morphologically different (Fig.3B- Lázaro DF et al., PLoS 
Genet. 2014). The inclusions produced by E35K and E57K were smaller, appearing as 
puncta (Fig.3C- Lázaro DF et al., PLoS Genet. 2014), and were ThioS negative 
(Fig.6C- Lázaro DF et al., PLoS Genet. 2014). Furthermore, these two mutations 
increased aSyn oligomerization, as measured by the fluorescence intensity 
complementation of the BiFC assay, in line with what was reported in previous 
studies (Fig.1C- Lázaro DF et al., PLoS Genet. 2014). On the other hand, the E46K 
produces enlarged cytoplasmic inclusions enriched in amyloid structure, as indicated 
by the positive staining with ThioS (Fig.6C- Lázaro DF et al., PLoS Genet. 2014). A 
possible explanation for the formation of these large structures can be an inefficient 
clearance of aSyn by autophagy. E46K aSyn inactivates JNK1 by decreasing its 
phosphorylation, resulting in impairment of autophagy (Yan et al. 2014). Importantly, 
these three lysine substitution mutants produced the most extreme increase in aSyn 
inclusion formation from the whole panel tested. 
The Golgi apparatus is an important organelle for transporting, processing, 
and targeting synthesized proteins, from the ER to their final destination in the cell 
(Nakagomi et al. 2008). However, different cellular insults can induce its 
fragmentation, leading to dysfunctional machinery and protein accumulation in the 
cytoplasm, or even to cell death (Nakagomi et al. 2008). It is now normally accepted 
in the field that oligomerized aSyn is more toxic to the cell, and our results strengthen 
this idea, since the aSyn E35K and E57K mutants promote fragmentation of the Golgi 
apparatus (Fig.10A and Fig S2A. Lázaro DF et al., PLoS Genet. 2014). These 
observations are important because they allow us to hypothesize additional scenarios 
that can be tested experimentally in future studies. For example, the ER is closely 
associated with several other organelles in the cell, especially with the Golgi. If the 
ER is afflicted by certain types of stress (such as glucose starvation, hypoxia, calcium 
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homeostasis disruption, oxidative stress (Omura et al. 2013)), or increased aSyn 
expression (Colla et al. 2012) it can result in Golgi fragmentation (Nakagomi et al. 
2008) and, consequently, to cell death (Gonatas et al. 2006; Fan et al. 2008; Fujita et 
al. 2006).  
Our results provide a simple readout to test new agents that may reduce ER 
damage, or that may even directly affect the Golgi apparatus. As proof of concept, 
Salubrinal could be tested, as it was shown to act as an anti-ER stress agent that 
attenuates A53T aSyn-mediated effects in mice and in a rat adeno-associated virus 
model (Colla et al. 2012). 
 
4.3. Modulation of aSyn aggregation by proline residues 
The aa proline is a potent breaker of both α-helical and -sheet structures in 
soluble proteins (Li et al. 1996). Thus, a series of aSyn proline mutants (familial-
A30P, and artificial- A56P, A75P, A56P/A75P-DP, A30P/A56P/A75P-TP) was 
designed based on the flexibility of the backbone in monomeric state (Bertoncini et al. 
2005). Interestingly, the proline mutations slowed down fibril and -sheet structure 
formation in vitro and in vivo (Karpinar et al. 2009; Taschenberger et al. 2012). 
Consistently, it was not entirely surprising that we observed similar effects in our cell-
based aSyn aggregation models. All proline mutations reduce/abolish the propensity 
of aSyn to form inclusions (Fig.3B and C, Fig.5B and C- Lázaro DF et al., PLoS 
Genet. 2014). This was further validated by super resolution microscopy (STED), and 
biochemically, using Triton X-100 solubility assays (Fig.6B and E- Lázaro DF et al., 
PLoS Genet. 2014). Additionally, we observed a prominent increase in aSyn 
oligomerization for A56P and TP aSyn (Fig.2C- Lázaro DF et al., PLoS Genet.).  
The TP mutant showed, so far, to be the most effective in promoting the 
accumulation of pre-fibrillar species of aSyn (Karpinar et al. 2009). Despite the 
impairment in amyloid fibril formation in vitro, it increases neurotoxicity in primary 
neurons, worms, and flies (Karpinar et al. 2009; Gajula Balija et al. 2011), reinforcing 
the idea that soluble aSyn oligomers have detrimental effects. However, in yeast the 
behavior of this mutant seems to be different. We and others (Petroi et al. 2012) 
observed that the TP aSyn mutant is not toxic in yeast cells (Fig.5A and C- Lázaro DF 
et al. PLoS Genet), suggesting that yeast cells may have a different strategy to deal 
with oligomeric aSyn species. Furthermore, the TP mutant can increase the number of 
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vacuoles, the compartments that are equivalent to lysosomes in yeast. The vacuoles 
are the major contributors to aggregate clearance in yeast and the TP induces the 
formation of tube-like structures that resemble autophagic tubes (Petroi et al. 2012), 
and are characteristic of yeast microautophagy (Muller et al. 2000). Thus, it is 
possible that the increase of these acidic structures assists the degradation machinery 
to eliminate the toxic forms of aSyn.  
In vitro, A30P aSyn promotes the formation of non-fibrillar protofibrils 
(Conway et al. 2000), and its seeds accelerate WT fibrillization more effectively than 
WT seeds (Yonetani et al. 2009). Moreover, A30P disrupts α-helix formation, 
essential for lipid binding (Jo et al. 2002), and significantly reduces presynaptic 
targeting of aSyn (Burre et al. 2012), which might compromise SNARE-complex 
assembly. Thus, one can speculate that the A30P aSyn mutant disrupts the normal 
function of the protein, which is then no longer in its stable form, causing its 
accumulation. In turn, this accumulation will act as a positive loop that potentiates 
even more aSyn seeding, causing deposition of harmful protofibrillar species and 
cellular damage.   
 
4.4. Position 53: the effect of the charge 
Recently, a new point mutation in aSyn (A53E) was associated with familial 
forms of PD (Pasanen et al. 2014). The A53E was initially reported to attenuate aSyn 
aggregation, slow fibrillization and oligomerization, and to exhibit reduced membrane 
binding affinity when compared to WT aSyn (Ghosh et al. 2014). In addition, it was 
found to enhance toxicity upon mitochondrial stress (Rutherford et al. 2015).  
Combining in vitro studies with recombinant aSyn and studies in cellular 
models, we showed that A53E forms higher order complexes (Fig.2f and Fig.3a, b 
and e- Lázaro DF et al. Acta Neuropathol Commun. 2016), displaying protofibrillar 
appearance (small round oligomers) (Fig.2f- Lázaro DF et al. Acta Neuropathol 
Commun. 2016). We also found that A53E aSyn inclusions are less compact or more 
immature than those formed by WT aSyn, since they are less resistant to PK digestion 
(Fig.4h and i- Lázaro DF et al. Acta Neuropathol Commun. 2016). This can explain 
the increase in proteasomal activity induced by A53E aSyn (Fig.4j- Lázaro DF et al. 
Acta Neuropathol Commun. 2016), since this degradation system eliminates mostly 
soluble proteins. These results were very interesting, since in our previous report, 
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A53T did not induce significant differences in terms of oligomerization (Fig.2C- 
Lázaro DF et al. Acta Neuropathol Commun. 2016) or aggregation (Fig.3C- Lázaro 
DF et al. Acta Neuropathol Commun. 2016). The negatively charged glutamate 
residue might disrupt the α-helical structure, similarly to the effect of the A30P 
mutation, resulting in altered fibrillation kinetics. Substitution for a positively charged 
aa, such as a lysine, induces a similar behavior in aSyn, delaying aggregation (Ghosh 
et al. 2014). Thus, one possibility is that the neutral side chain of threonine, in the 
A53T mutant aSyn, may facilitate hydrophobic interactions, with the -OH group 
participating in favoring fibril formation (Ghosh et al. 2014). 
 
4.5. Phosphorylation and other PTMs: the need for additional in 
depth studies 
 Of all PTMs studied thus far, phosphorylation is perhaps the most widely 
investigated, since the majority of aSyn in LBs is thought to be phosphorylated on 
serine 129 (Fujiwara et al. 2002). Most of the known aSyn PTMs are located in the C-
terminal region of the protein: phosphorylation (S87, Y125, S129, Y133 and Y136), 
truncation (D115, D119, P120, E130 and D135), ubiquitination (K96), or sumoylation 
(k96 and K102) (Schmid et al. 2009; Oueslati et al. 2010).  
In PD patients, the levels of aSyn phosphorylation on S129 rise from 5% to 
30%-100% (depending on the brain region and the severity of the pathology) (Zhou et 
al. 2011), and are thought to be useful for distinguishing between different 
synucleinopathies (Foulds et al. 2012; Swirski et al. 2014). However, in PD models 
there is a lot of controversy, due to conflicting data. This is partly due to the fact that 
artificial aSyn mutants are often used to mimic the phosphorylated state (S129D/E), 
and the dephosphorylated state of aSyn (S129A/G), but these fail to fully replicate the 
real phosphorylation of aSyn (Paleologou et al. 2008). This is also true for other 
phosphorylation sites (S87, or Y125, for example), or even other PTMs, such as 
sumoylation.  
In our study, we did not observe major differences between mimicking or 
blocking aSyn phosphorylation on S129 (Fig. 2C and Fig.3C9- Lázaro DF et al. PLoS 
Genet. 2014 Nov). This suggests that different model systems likely handle the 
proteins slightly differently, and that other mechanisms may be involved in 
modulating the behavior of these mutant forms of aSyn.  
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 Strikingly, despite all studies performed, whether aSyn phosphorylation is the 
cause or a consequence of PD is still unclear. To understand the relevance of 
phosphorylation it is important to determine the origins of its increases and the 
consequences it may have on cell function and survival. Three important aspects seem 
to be correlated with aSyn phosphorylation: (i) aSyn turnover, (ii) protein-protein 
interactions, and (iii) its subcellular localization. We can speculate that the 
accumulation of aSyn pS129 is an attempt of the cell to sequester toxic forms of aSyn 
when proteasome and the autophagy-lysosome pathway are compromised (Chau et al. 
2009; Machiya et al. 2010). Furthermore, non-phosphorylated aSyn mainly interacts 
with proteins related to mitochondrial electron transport but when it is phosphorylated 
it has more affinity to specific cytoskeletal proteins and presynaptic proteins 
(McFarland et al. 2008). This can indicate that phosphorylation can participate in 
regulating the movement of in the cell, and also in synaptic transmission and vesicle 
trafficking. These are two major cellular aspects associated in PD, not only because 
different types of compartments have different fates (section 1.2.4) but also because 
aSyn pathology can be transmitted from neuron-to-neuron, afflicting surrounding 
cells. 
  Changes in the phosphorylation status of aSyn could also represent a response 
to other biochemical events. Several studies report the detection of aSyn in the 
nucleus of mammalian cell lines (Mbefo et al. 2010; Lee et al. 2013), primary 
neuronal cultures (McLean et al. 2000; Seo et al. 2002), tg mice (Goers et al. 2003; 
Schell et al. 2009), adeno-associated-based rat model of PD (Azeredo da Silveira et 
al. 2009), or in drosophila models (Takahashi et al. 2003). Our group showed that 
there is a continuous trafficking of aSyn between the cytoplasm and nucleus that is 
partially regulated by phosphorylation. Blocking phosphorylation of aSyn (S129A) 
significantly reduces aSyn translocation to the nuclear compartment (Goncalves et al. 
2013). Thus, additional studies will be necessary to further dissect the effects of 
phosphorylation in the cell and on PD. 
 
4.6. Better treatments for a brighter future 
PD, as well as all the other synucleinopathies, is devastating disorders that 
cannot currently be prevented or reverted. Thus, seeking for better treatments that 
interfere with, or ultimately stop the progression of such complex disorders is 
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essential. For that, it is pivotal to study how drugs/compounds/small molecules affect 
aSyn aggregation and biology. 
  Using SHG-based approach, we identified a small molecule (BIOD303) that 
affects aSyn aggregation (Moree B, Yin G, Lázaro DF et al. J Biol Chem. 2015). 
BIOD303 is a potent conformational modulator of aSyn, by binding to monomeric 
aSyn (Fig.3 Moree B, Yin G, Lázaro DF et al. J Biol Chem. 2015), and strongly 
reducing aSyn aggregation in our cell model (Fig.7 Moree B, Yin G, Lázaro DF et al. 
J Biol Chem. 2015). Not only percentage of cells with inclusions diminished by 
BIOD303, but also the amount of insoluble aSyn is reduced in a dose dependent 
manner (Fig.9A and B Moree B, Yin G, Lázaro DF et al. J Biol Chem. 2015). These 
results indicate that the conformation of aSyn is highly associated with its 
aggregation, and suggest that it may be possible to develop novel therapeutic 










Protein misfolding and aggregation are linked to many neurodegenerative 
disorders but the precise molecular events that dictate the selective neuronal cell death 
in each disease are unclear. PD is a common and complex neurological disorder 
associated with the misfolding and aggregation of the protein aSyn, that was first 
described two centuries ago. It is a slowly progressive neurodegenerative disorder that 
begins years before the onset of motor symptoms. This complicates clinical diagnosis, 
especially at early stages of the disease. Currently, only symptomatic treatments are 
available, and these only aid with motor symptoms. Thus, there is a tremendous need 
for both a deeper understanding of the underlying causes of the disease, and for the 
development of novel and more effective therapeutic approaches.  
Although cell-based models are minimalistic, and do not fully recapitulate the 
complexity of a complete living organism, they enable us to eliminate sources of 
variability that compromise our understanding of basic molecular mechanisms 
underlying protein aggregation. Therefore, these models can serve as first line of 
investigation, prior to in vivo studies (worms, flies, mice, or non-human primates), 
thereby accelerating drug discovery efforts.  
Our studies establish, for the first time a common basis for the comparison of 
the effects of mutations on the aggregation behavior and on the biology of aSyn in 
cells. For this, we exploited two cellular models that model aSyn oligomerization 
(BiFC) and aggregation (SynT+Sph1).  
The aggregation of aSyn is considered one of the key steps for the 
development of PD. Until recently, directly visualization of aSyn interactions in living 
cells was not possible. The BiFC assay, despite its limitations, affords a unique 
opportunity to visualize aSyn interactions and where these interactions take place (for 
example in the nucleus versus the cytoplasm). In the future, using techniques such as 
Fluorescence Recovery After Photobleaching (FRAP) or Fluorescence Loss in 
Photobleaching (FLIP) will enable additional questions to be addressed. For example, 
do different familial aSyn mutants have different mobilities in the cell? Or, does the 
increase of oligomerization affect the movement from one compartment to another? 
Tracking the movement of soluble aSyn oligomers, and how fast these processes 
occur is just one more aspect that can be investigated. 
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With few exceptions, the tested mutants promote the accumulation of a variety 
of cytoplasmic inclusions. However, conventional light microscopy has limit of 
resolution that does not allow to reliably distinguish structures smaller that this limit.  
Emerging super-resolution microscopy techniques, such expansion microscopy, 
promise to lead to new findings in the field by enabling the visualization of species 
that could not be previously resolved without an electron microscope, which is of 
course powerful, but has its own limitations, such as a much more cumbersome 
sample preparation. Thus, the use of these novel imaging techniques, in combination 
with the SynT + Sph1 model might enable a better characterization of the protein 
inclusions formed (e.g. in terms of size, volume, or intracellular localization).  
In conclusion, I am confident we are living exciting moments in science. 
Every day there are reports of new findings or new tools that can be used in the field 
of neurodegeneration. Our findings add to our understanding of the molecular basis of 
devastating maladies and, ultimately, may enable the identification of molecules that 
could form the basis for future therapeutic strategies for synucleinopathies and other 







6. Annex  
6.1. Supporting Information   
Lázaro DF. et al. Plos Genetics 2014 
 
Figure S1 Statistical analysis of ASYN inclusion formation. 
 
 




























































































































































































































































































































































Figure S3 Phosphorylation state of ASYN on S129.  
 
 























Forward: 5' GTGGCAACAGTGGCTAAGAAGACCAAAGAGC 3' 











































6.2. Additional file 
Lázaro DF. et al Acta Neuropathol Commun. 2016 
 
Figure S1.1. Biochemical characterization of WT and A53E recombinant aSyn. 
 
 
S1.2. MALDI-TOF mass spectrometry analysis of purified WT (up) and A53E 





Figure S2.1 and S2.2. Immunoblot quantifications.  
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